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Abstract
The cell biology of Prion formation and transfer is not well understood. In order 
to further elucidate the dynamics of PrPc and PrPsc in a cellular context, fusions 
between Green Fluorescent Protein (GFP) and PrP were constructed and 
infected/uninfected cell line pairs expressing these constructs were created. 
Biochemical analysis indicated that the C-terminal PrPc portion of the fusion 
protein successfully converted to PrPsc. However, further studies demonstrated 
that proteolysis occurs between GFP and PrP and therefore the fusion protein 
cannot be employed as a direct reporter for PrPsc.
A Time-Lapse microscopy system was set up and studies were undertaken with 
infected and uninfected cell lines expressing the fusion construct or cytoplasmic 
markers to observe events that may be related to transfer of infectivity. Although 
no exchange of fusion protein is observed, cytoplasmic material is released 
from both infected and uninfected cell lines.
Fluorescence recovery after photobleaching (FRAP) was carried out to 
establish a system for further investigation of PrP dynamics in the plane of the 
membrane.  Early experiments indicate the possibility of a difference in the 
diffusion of PrP between infected and uninfected contexts.
It is not currently known how Prion glycoform profile is transmitted and 
maintained following a new infection. The glycoform profile of PrPscwas 
perturbed in order to investigate the causal role of PrPsc glycotypes in 
transmission and maintanence of Prion glycoform profile. The results indicate 
that perturbation of PrPsc glycoform profile in an infectious source does not lead 
to a correlated perturbation of glycoform profile in the newly established 
infection. Therefore the glycosylation of PrPsc in an infectious source is not a 
required source of information for establishing the glycoform profile of a Prion 
infection.4
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1.1.  Introduction overview
The Transmissible Spongiform Encephalopathies (TSE’s) are a group of 
neurodegenerative diseases now thought to be associated with a novel form of 
infectious agent called a prion. An aberrant conformer, PrPsc,  of a normal 
cellular protein, PrPc  is thought to propagate by co-opting normal protein into its 
conformation by an as yet undiscovered mechanism.  The introduction below 
reviews the group of diseases associated with the Prion phenomenon and then 
discusses the Prion hypothesis in more detail.  In the context of models of the 
diseases, some of the key issues of the field are highlighted and discussed 
including the basis for strain variation, the transfer of a Prion infection, and the 
cell biology of the normal and abnormal forms of the Prion protein (PrPc and 
Prpse respectively).  Finally, potential therapeutics are considered for a group of 
diseases which have so far proved untreatable.
1.2.  Animal TSE’s
Table1.1  Summary of Animal TSE’s 
adapted from (Aguzzi and Sigurdaon 2004)
.Disaaso Natural host 
species
Transmission route OtherSusceptible 
species
Scrapie Sheep and Goats Horizontal/Vertical Primates, hamsters, 
wild-type mice, ovine 
PRNP-transgenlc mice
Chronic wasting disease Mule deer, white-tailed 
deer and Rocky mountain 
elk
Horizontal/Vertical Ferrets
Bovine spongiform 
encephalopathy
Cattle Ingestion of BSE- 
contaminated feed
Primates, wild-type mice, 
bovine/human Pmp- 
transgenic mice
Spongiform 
encephalopathy of zoo 
animals
Zoological bovids and 
primates
Ingestion of BSE- 
contaminated feed
Wild-type mice
Feline spongiform 
encephalopathy
Zoological and domestic 
feiids
Ingestion of BSE- 
contaminated feed
Wild-type mice
Transmissible mink 
encephalopathy
Mink Ingestion, origin of 
epidemic unclear
Wild-type mice
Scrapie is a naturally occurring disease of sheep and goats which is endemic in 
Europe, and was first identified over 200 years ago. Surprisingly, little is known16
about the key mode of transmission of Scrapie although it is thought to be both 
horizontal, (Pattison, Hoare et al. 1972) and vertical  (Elsen, Amigues et al. 
1999).There is no epidemiological evidence for a connection between Scrapie 
and Creutzfeldt-Jakob disease (CJD), a human prion-associated disease 
(Brown, Cathala et al. 1987). A wide variety of Scrapie strains exist as defined 
by vacuolation profile in the CNS (central nervous system), incubation time in 
animal models, and these strains are associated with a wide range of PrPsc 
glycosylation profiles (Somerville, Chong et al. 1997).  A number of studies 
have indicated that the natural incidence of Scrapie in a flock is dependent on 
the genetic background and the allelic variation amongst sheep. Three 
polymorphisms in the PrP gene are particularly linked with the occurrence of 
Scrapie: A136V, R154H, Q171R/H. The alleles ARQ, ARH, VRQ are commonly 
associated with susceptibility to disease in contrast to ARR and AHQ which are 
associated with resistance (Spraker, Miller et al. 1997; Baylis and Goldmann 
2004). This finding has led to a European wide initiative to select ARR/ARR 
sheep in favour of other allelic variants in order to breed out Scrapie.  It is 
noteworthy however, in the light of the BSE (Bovine spongiform 
encephalopathy) epidemic, that ARR/ARR sheep are susceptible to BSE (Kao, 
Gravenor et al. 2002; Kao, Houston et al. 2003).
Other animal TSEs (summarised in Table 1.1) include Transmissible Mink 
Encephalopathy (TME) (Bessen and Marsh 1992; Marsh and Hadlow 1992) and 
Chronic wasting disease (CWD) of mule deer and elk,  a common condition in 
wild deer and elk in Colorado (Spraker, Miller et al. 1997; Miller and Williams 
2004). Of particular interest to Prion theory is the existence of two distinct TME 
strains which were identified after passage to hamster and named hyper and 
drowsy for their distinct clinical presentations  (Bessen and Marsh 1992; Bessen 
and Marsh 1992). These strains, after passage through hamsters, demonstrate 
different vacuolation profiles, incubation periods and different sensitivity to 
Proteinase K digestion. The latter property has been taken as one possible 
indication of conformational differences which might underlie the difference in 
strain properties.17
In 1986 a new Prion disease BSE was identified at the start of what was to 
become an epidemic which led to an estimated total number of 1   million 
infected animals in the U.K.  (Wilesmith, Ryan et al. 1991; Anderson, Donnelly 
et al. 1996).  Epidemics of smaller size were also reported in a number of other 
European countries (Collinge 2001). Hypotheses for the cause of the disease 
initially included  transmission of Scrapie to cattle but it is more likely that rare 
sporadic cases of cattle disease entered into the food chain. The change in the 
1970s in the rendering process of the protein supplement, meat and bone meal 
that is fed to the animals may have led to an increased Prion content and a 
resultant increase in exposure (Collinge 2001).
Many other species of Bovidae and Felidae, probably fed with the same 
rendered meat and bone meal, have since been identified as having contracted 
the disease (Bruce, Chree et al.  1994; Collinge, Sidle et al.  1996). The range of 
species is particularly noteworthy when comparing BSE with natural Scrapie 
because these reports of BSE crossing the species barrier have highlighted the 
difference in host range of the new disease.
1.3.  Human Prion Disease
Table1.2  Human prion diseases summary
adapted from (Aguzzi and Sigurdson 2004)
Disease Natural host 
species
Transmission
route
Other Susceptible species
Creutzfeldt-Jakob
disease
Humans Familial (PRNP germ 
line mutation), sporadic, 
or iatrogenic
Primates, hamsters, wild-type mice, 
Human PRNP-transgenic mice
Variant Creutzfeldt- 
Jakob disease
Humans Ingestion of BSE- 
contaminated food
Wild-type mice, Human PRNP- 
transgenic mice
Kuru Humans Ingestion or ritualistic 
cannibalism
Primates
Fatal familial 
insomnia
Humans Familial (PRNP germ 
line mutation)
Wild-type mice
Gertstmann- 
Straussler- 
Scheinker 
syndrome (GSS)
Humans Familial (PRNP germ 
line mutation)
Primates and mutated PRNP- 
transgenic mice
The human TSE’s (summarised in table 5.2) were originally identified through 
their symptomatic and then pathological profiles, with Creutzfeldt-Jakob disease18
(CJD) the first to be described in 1926. They present as infectious (acquired), 
genetic and sporadic conditions (Ironside 1998). The extent of shared aetiology 
between these types of Prion disease remains to be determined.
1.3.1.  Sporadic Prion disease
The annual incidence of CJD has been established at an average of 1   case per 
million of the population and sporadic CJD accounts for 85 % of all CJD cases 
(Brown, Preece et al. 1992; Will 1998). The disease is characterised by a 
stereotyped, rapidly progressive clinical course with median duration of 4 
months and occurring in the 45-75  age range, with mean age 66 (Collinge 
2001). There is no predictable geographic clustering (Will, Matthews et al. 1986) 
and no established common environmental risk factor (Wientjens, Davanipour 
et al. 1996).  A genetic risk factor has been identified in relation to codon 129 
(M129V) polymorphism of the PrP gene (Palmer, Dryden et al.  1991). The brain 
pathology associated with CJD includes spongiform degeneration,  exhibiting a 
wide variety of intensities and distributions from case to case, and reactive 
astrocytic gliosis (DeArmond 2004).
1.3.2.  Acquired human Prion disease
Kuru was first recorded as an acquired human Prion disease, when an epidemic 
occurred in the Fore people of Papua New Guinea. The central clinical feature 
is progressive cerebellar ataxia. In sharp contrast to CJD dementia is often 
absent.  It was transmitted through the cannibalistic rituals associated with 
consumption rites for deceased relatives and community members(Alpers 
1987). The epidemic is thought to have originated following the consumption of 
a community member that had died from CJD of sporadic origin. Although the 
cannibalism ceased in the late 1950’s, cases of Kuru still occur in the region 
suggesting incubation periods of up to 40 years.  The incidence in children 
indicates that incubation period can be as short as 4 years (Alpers 1987).
Iatrogenic transmission has been suggested in numerous surgical interventions. 
In 1974 transmission of CJD was found in a patient who had received a comeal19
implant from a donor that had died of CJD (Duffy, Wolf et al. 1974). It has also 
been suggestedihat transmission of CJD has occurred through the use of 
depth electrodes and cases have been reported of transmission through dura 
matter grafts (Thadani, Penar et al. 1988). Transmission of CJD through growth 
pituitary derived growth hormone and gonadotrophin have also been reported 
(Koch, Berg et al. 1985).
All of these transmissions have involved cross contamination with material from 
the brain, where the expected titre of infection is presumed to be high, and have 
involved parenteral inoculation through surgery or intramuscular injection. 
Interestingly, cases resulting from intracerebral or optic inoculation manifest as 
conditions similar to classical CJD, with a rapidly progressive dementia. In 
contrast, cases resulting from peripheral inoculation often present with 
progressive cerebellar ataxia, a presentation more reminiscent of Kuru (Collinge 
2001).
It is still unclear if Prion transmission is possible through other infected tissues 
such as the blood. Laboratory studies have shown both the presence of 
infectivity and the development of disease in animal models (Diringer 1984; 
Casaccia, Ladogana et al. 1989).  Case control studies have not identified 
increased risk in haemophiliacs of CJD (Wientjens, Davanipour et al. 1996)  and 
claims of transfusion related patient cases of CJD have not been substantiated 
(Klein and Dumble 1993).
The evidence indicates that transmission of CJD via the blood route is unlikely. 
However, this does not necessarily apply to New Variant CJD  (vCJD) 
transmission and the finding that BSE infection via  blood , from sheep to 
sheep, is  reasonably efficacious is of particular concern (Houston, Foster et al. 
2000; Hunter, Foster et al. 2002). A recent case of a blood transfusion recipient 
who contracted vCJD has highlighted the possibility of its transmission via the 
blood (Aguzzi and Glatzel 2004).
Following the BSE epidemic, surveillance of CJD in the UK was instituted in 
1990 to assess the possibility of transmission to humans. By 1995 a number of20
cases of CJD with distinct clinical presentation and pathology had emerged. 
Presentation of Hlness was identified with a mean age of onset of 29 years in 
comparison to 66 years for sporadic CJD and with 14 months illness duration 
compared to 4.5 months. The clinical presentation was unusually uniform  and 
the pathological profile distinct (Will, Ironside et al. 1996).
The case for a causal link between BSE and vCJD has been argued 
epidemiologically and through reference to pathology, biochemistry and findings 
using animal models. To date there have been less than 150 cases of vCJD 
identified world wide with the majority in the U.K. The geographical clustering 
and the relative timing of the majority of these vCJD and BSE cases in the U.K., 
has indicated BSE as a novel risk factor (Will and Kimberlin 1998).The 
neuropathological features of vCJD have been reproduced by macaque 
monkeys inoculated with BSE (Lasmezas, Deslys et al. 1996) and the existence 
of similar Prion glycoform patterns has been argued as evidence of common 
strain (Collinge, Sidle et al. 1996). Of particular note, given the reproducibility of 
incubation time with strain type, BSE and vCJD inoculation into mouse models 
has demonstrated similar incubation period and vacuolation profile, features 
that would ordinarily indicate a common strain of Prion (Bruce, Will et al. 1997; 
Hill, Desbruslais et al. 1997).
One risk factor that has emerged consistently is the genetic background of the 
patients.  In all cases of vCJD infection to date the patients are homozygous for 
methionine at Pmp codon 129  (Zeidlerand Ironside 2000).
Epidemiologists have struggled with the paucity of data available to formulate 
consistent estimates for the final numbers of  people that will suffer from vCJD 
as a result of the BSE epidemic, and predictions vary widely from a few hundred 
people to tens of thousands (Cousens, Vynnycky et al. 1997; Ghani, Ferguson 
et al. 2000; d'Aignaux, Cousens et al. 2001; Ghani 2002; Ghani, Ferguson et al. 
2003).21
1.3.3.  Genetic Prion Disease
Inherited Prion disorders account for around 10 percent of human Prion 
diseases and are all autosomal dominant conditions (Cohen 1994).  Currently 
55 pathogenic mutations and 16 polymorphisms have been identified in the 
Prnp gene. These are described by either point mutations in the gene, which 
result in an amino acid substitution/stop codon, or insertions/deletions in the 
octapeptide repeat region (Fig 1.1)
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Figure 1.1.  Diagram of mutations in Prnp known to cause pathogenesis.
p-sheet is indicated by arrows and alpha helix (H) in the light red shade.
‘CHO’ and ‘S-S’ indicates glycosylation and disulphide bond respectively.
Octapeptide repeat region is indicated in the blue shaded region.  Disease association is stated 
(CJD.FFI, GSS), otherwise a variable phenotype is associated with the mutation, as with the 
octapeptide repeat insertions/deletions.
(Figure adapted from Kong et al 2004)22
Models have suggested that mutations may favour spontaneous conversion to 
the Prion state by lowering the activation energy barrier for conversion from 
PrPc to PrPsc (Cohen 1994). However, the  aetiological background shared by 
exogenous infections and heritable Prion disease remains unclear (Mallucci and 
Collinge 2004). Familial Prion diseases have been demonstrated to be 
infectious as evidenced by transmission of CJD and  GSS (Gertstmann- 
Straussler-Scheinker syndrome) to nonhuman primates (Prusiner 1998).
Classification of inherited Prion disease is often associated with phenotype 
rather than haplotype. (Medori, Montagna et al.  1992; Monari, Chen et al.
1994).  Disease related changes in the PrP gene have three phenotypic 
outcomes resulting in 1) CJD, FFI (Fatal Familial Insomnia) or GSS,  2) 
mixtures of features of GSS and CJD, or  3) Variable histopathological 
features/variable phenotype (Gambetti, Kong et al. 2003).
Distinct sizes of Prion fragments found after Proteinase K digestion and western 
blotting procedures supports the supposition that distinct disease types underlie 
the differences in phenotypes. There is also a consistent difference in glycoform 
ratio between Prion from FFI and CJD diseased brains (Medori, Montagna et al. 
1992; Monari, Chen etal. 1994).
Clinical and pathological phenotype can be affected by polymorphisms. In FFI 
and one form of familial CJD there is an identical PrP D178N mutation although 
FFI is associated with Methionine at codon129 and CJD with Valine at codon 
129. Phenotypic variation in age of onset and duration have also been shown to 
be affected by the E219K polymorphism. It is therefore important to describe the 
full haplotype when considering the inherited Prion diseases. (Ironside 1996; 
Ironside 1998).
GSS  was first recognised as being linked with the P102L mutation (Hsiao,
Baker et al. 1989) and is now recognised as being linked with many others 
including a Y145 stop mutation which results in truncated PrP protein (Ghetti, 
Dlouhy et al. 1995).23
Variable phenotypes, have been associated with the insertion of 1-2 and 4-9 
repeats in the octapeptide region of the gene and with deletions of 1  or 2 
repeats in this region (Ironside 1998). Patients with five, six, seven, eight, and 
nine extra octapeptide repeats show an autosomal dominant pattern of 
inheritance and features of CJD, GSS, or atypical dementia, patients with one, 
two, or four extra repeats have typical CJD (Rossi, Giaccone et al. 2000).
1.4.  The Prion concept
Following the recognition that Scrapie and Kuru showed similarities in 
pathology, the transmissibility of Kuru was established by intracerebral 
inoculation of chimpanzees (Gajdusek, Gibbs et al. 1966). CJD was later shown 
to be transmissible to animals and to result in a spongiform condition (Gibbs, 
Gajdusek et al. 1968). On this basis a group of transmissible diseases was 
identified which resulted in a spongiform encephalopathy prior to death, and 
included familial as well as classically infectious cases.
The Prion concept was initially postulated by Griffith in 1967 along with other 
concepts for replication in biological systems.  Later it was taken up by Prusiner 
to explain a series of findings associated with the Scrapie agent. Prusiner 
defines a Prion as ‘a proteinaceous infectious particle that lacks nucleic acid’. 
One might represent the implicit assumptions that comprise the modern Prion 
theory by the following statements:
1) A Prion is a protein that is able to replicate without the intervention of nucleic 
acid
2a) Replication refers to a property of the protein and not just a material copy 
2b) In the case of the Scrapie Prion, the property that is replicated is 
responsible for the transmission of disease and or pathogenesis.
2c) the property is an alternate conformation of the protein.
Before the impact of transgenic mice on the field, theories concerning the 
nature of the agent abounded.  It was argued by Stanley Prusiner that the agent 
could not be a carbohydrate, lipid, or nucleic acid based infectious agent and 
that the agent was a protein (Bolton, McKinley et al. 1982; Prusiner 1982;24
Prusiner, Bolton et al. 1982).  The Scrapie agent is unusually resistant to 
attempted inactivation by U.V. and ionising radiation in comparison to virus 
related material.  (Alper, Haig et al.  1966; Alper, Cramp et al. 1967; Latarjet, 
Muel et al.  1970). The implication of these results is that a traditional nucleic 
acid is unlikely to be part of the active virus and in search for a Scrapie specific 
nucleic acid associated with a viral like particle, many experiments have been 
performed which demonstrate that it would have to be smaller than 50-100 
bases (Prusiner 1998).
Radiation inactivation studies also indicated that the infectious agent itself 
would have to be limited to a minimum size of 55 kda  (Alper, Haig et al.  1966; 
Prusiner, Hadlowet al. 1978; Bellinger-Kawahara, Kempneretal. 1988) 
which on a protein only model implies a PrP dimer as the minimum size of the 
infectious particle.
Viral related theories have responded to these results, which inveigh heavily 
against the involvement of nucleic acid, by postulating that the viral DNA might 
have coat proteins that were highly homologous to PrP or protected by PrPsc, 
and/or that PrPc functioned as a viral receptor.  The explanatory strength of viral 
theories has been an implicit model for the infectious process and an imagined 
clearer view of strain variation. However adaptations of previous versions of 
viral agent hypotheses suffered the charge of poor explanatory benefit and ad 
hoc adjustments to fit other data.
Work in transgenic mice has reinforced the hypothesis that a protein might be 
responsible for infectious propagation. Numerous experiments have confirmed 
the findings that PrPc is necessary for propagation of infectivity, because 
knockout out mice do not support disease infection, and that the efficacy  of 
disease has been shown to be correlated with levels of expression of the PrP 
gene (Prusiner 1998).  Although these experiments indicate the necessity of 
PrP for infection, the data is still compatible with a theory that might include viral 
transmission. The final test of the theory will be provided by confirmation of the 
in vitro production of Prion (see below).25
Originally, studies on the sedimentation properties of Scrapie using sucrose 
gradients demonstrated that infectivity was poly-dispersed, making standard 
purification procedures difficult (Prusiner, Hadlow et al.  1977; Prusiner, Hadlow 
et al.  1978). A critical limit to research progression had been the length of time 
and number of animals necessary to assay for infectivity, despite the passage 
of Scrapie material within mouse models which decreased incubation times.
The development of an assay which reduced incubation time and increased 
Prion titres in Syrian Hamsters by a factor of 5,  (Marsh and Kimberlin 1975) 
permitted quantitative assessment of  fractions enriched for infectivity and led to 
the now characteristic biochemical assay for PrPsc: A procedure including 
detergent extraction, protease digestion, and differential centrifugation was 
employed to purify infectious material and in turn led to sequencing of the 
protease resistant core of PrPsc  (Bolton, McKinley et al.  1984) and later the 
cloning of Prnp (Basler, Oesch et al.  1986).
The resistant core is now associated with a cleaved product of PrP named 
PrP27-30 and it is understood that only part of the molecule acquires this 
resistance on conversion (see Figure 1.2).
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Figure 1.2.  Diagram of PrP before and after cleavage with Proteinase K
Full length PrP polypeptide, PrP species following removal of N-terminal signal peptide, and the 
142 amino acid protease resistant core of PrP8 0  following Proteinase K digestion (Adapted from 
Prusiner 1998)26
The  ratio of infectious units to PrPsc molecules is 1:105   and one interpretation 
of this is that only a small number of the PrPsc related molecules in an infectious 
sample, as defined by protease resistance and detergent insolubility, are 
actually responsible for infection (Bolton, Rudelli et al. 1991). This has prompted 
theories that a particular  species might be responsible for infection other than 
the traditionally defined PrPsc (Weissmann 1991).
The most difficult aspect of the Prion hypothesis remains the explanation of the 
variety of TSE strains that exist.  The simple solution has been to posit the 
existence of multiple, corresponding conformations. Although there is some 
evidence for association of strain with conformation (see 1.9.4) there is little 
evidence for the general scope of this hypothesis.
The idea that information is transferred by a Prion mechanism took a long time 
to be absorbed into the main stream because viral theories embodied the 
paradigm for envisaging how replication/transmission of information was 
thought to occur in disease. The discovery of DNA had set down a dogma in 
general for replication in biological systems. Now that the theory has been 
widely accepted there seem to be many additions to what was a straightforward 
protein only theory 20 years ago. Amongst these is the suggestion that 
accessory molecules are necessary for the conversion process and ironically, 
as reviewed elsewhere in this introduction, it has also been suggested that 
these accessory molecules may include nucleic acids.
1.4.1.  Mechanisms of Prion replication
At present there is little evidence in favour of any particular model of conversion 
from PrPc to PrPsc. This is because there is no structural data from NMR or X- 
ray crystallography on PrPsc and it is has not been established which, if any, of 
the species produced from in vitro reactions are pertinent to actual physiological 
infection. Nevertheless, two basic models (see Figure 1.3) have been 
suggested for conversion of PrPc to PrPsc, a template-directed refolding model 
and a nucleation-dependent polymerisation model (Jarrett and Lansbury 1993; 
Lansbury and Caughey 1995; Weissmann 1996; Harrison, Chan et al. 1999).27
The template assisted refolding model in its basic form posits a high activation 
energy barrier which under ordinary circumstances prevents the spontaneous 
conversion of PrPc to PrPsc.  Templating of PrPc with PrPsc  promotes 
conversion by lowering the barrier and shifting the equilibrium towards the PrPsc 
form, a process which may include an unfolding step for PrPc prior to a refolding 
step. The process then becomes self fuelling leading to an effective chain 
reaction in producing more PrPsc to elicit more conversion of the cellular pool of 
PrPc (Weissmann 1991; Weissmann 1996). On this model inherited Prion 
disease would be explained by alteration of the initial energy barrier due to an 
alteration in kinetics of protein folding caused by the mutation. However, this 
does not explain why the familial Prion diseases take many years before onset, 
despite expression of mutant genes.  A more involved version of this model 
introduces a chaperone or protein X that is necessary for conversion (Telling, 
Scott et al.  1995). Here protein X binds to PrPc and forms a complex that is able 
to convert when further templating with PrPsc.  The complex has been denoted 
PrP*/protein X, to imply the difference in nature of the associated PrP species 
from the point of view of conversion potential.
The nucleation-dependent polymerisation process model, much along the lines 
suggested in work on yeast Prion, posits the slow formation of an infectious 
seed: a rate limiting step (Jarrett and Lansbury 1993). The seed then acts to 
promote further conversion, perhaps by stabiliising PrPsc, taking it out of a weak 
equilibrium with PrPc.  Predictions which distinguish this model from the 
template assisted refolding theory include the existence of a threshold 
concentration at which seed formation will occur, and the existence of a lag 
phase up to the point where seeding begins to take root.  Evidence for this 
model has been found from in vitro studies (Kocisko, Come et al.  1994; Bessen, 
Kocisko et al. 1995; Kocisko, Priola et al. 1995; Kocisko, Lansbury et al. 1996)
In the case of infectious disease, the model posits that exogenous seed like 
material is introduced to catalyse further conversion.
The two models are not necessarily mutually exclusive and it is possible that 
components of each may play a role in the production of infectious Prion. It is28
also conceivable that protein X like phenomena could be explained in the 
context of a nucleation-dependent polymerisation.
1.4.2.  Yeast and Other Prions
There is an open question as to how ubiquitous the Prion phenomenon is in the 
biological world which is of particular interest because Prion offers a distinct 
form of heritable information transfer.
Two non-Mendelian cytoplasmically inherited traits in Sacharomyces cerevisiae 
were explained by the [PSI+] and [URE3] associated Prion states (Wickner 
1994; Wickner, Masison et al. 1995).
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Figure 1.3.  Schema for conversion of PrPc  to PrPsc
Template directed refolding model: Templating of PrPc with PrP8 0  elicits conversion in an 
otherwise thermodynamically unstable reaction.
Seeding model: The conformational change occurs independently of a templating step but is 
stabilised by formation of a seed, the rate limiting step, and then further formation of larger 
aggregates. (Adapted from Weissmann 1996)29
The existence of the Prions underlying these states explained a) that for 
propagation the expression of the SUP35 and URE2 genes were necessary, b) 
that growth on guanidine hydrochloride returns the yeast to their original states, 
and c) that overexpression of URE2 and Sup35p increased the frequency of the 
novel states.  More Prion related states in yeast and other systems have since 
been discovered including [Het-S] [RNQ+], [NU+] (Osherovich and Weissman 
2002; Uptain and Lindquist 2002).  Of particular interest is the fact that these 
non-mammalian Prions are often associated with either gain or loss of function 
as a result of conversion to the Prion form.
Sup35, a normal yeast gene, has been implicated in the process of translational 
termination (Chernoff, Uptain et al. 2002).  In [PSI+] cells, the Prion state, 
nonsense suppression occurs because the usual function of Sup35  is lost upon 
conversion to its Prion form.  This is most clearly evidenced by observing yeast 
which contain ade1-14 alleles in which the open reading frame of the ADE1 
gene is interrupted by a UGA mutation. These yeast do not grow on medium 
without adenine and accumulate a red pigment on complete medium. However 
in the [PSI+] cells, read through proceeds and restoring growth on media 
without adenine, and leading to formation of white colonies in complete media. 
The Sup35 protein contains 3 domains: the C-proximal domain is necessary 
and sufficient for the translational termination activity, the N-proximal region is 
the Prion forming domain and finally there is a non-functional middle region. 
When the Prion forming domain is fused to other proteins, like GFP (green 
fluorescent protein), it converts the protein into an aggregated state on 
expression in the [PSI+] cells (Patino, Liu et al. 1996).
Increased levels of HSP104 have been shown to affect PSI+ propagation in 
yeast  (Chernoff, Lindquist et al. 1995). Overproduction of HSP104 in yeast 
cells leads to curing of [PSI+].  However, deletion of HSP-104 also results in the 
loss of the [PSI+] and reversion to [PSI-]. The apparent contradiction has been 
partially resolved by work which demonstrates a subtle disaggregating role for 
the chaperone in cooperation with other chaperone protein (Sanchez, Taulien et 
al. 1992; Glover and Lindquist 1998).  Models suggest that the function of HSP- 
104 is to disaggregate, which leads to curing of the Prion state.  However,30
disaggregation of Prion by HSP-104, is also necessary for maintenance of 
seeds of the right size in order to continue the process of conversion. In favour 
of the latter part of the model, GFP-Sup35 fusion proteins rapidly accumulate 
and form large GFP-Sup35 aggregates on loss of HSP104 activity (Wegrzyn, 
Bapat et al. 2001).  It is an interesting model that might have some relevance in 
the mammalian system, although this remains to be tested in the light of future 
advances in antibody technologies.  Other chaperones, including Hsp70 and 
Hsp40, have also been implicated in yeast Prion propagation (Glover and 
Lindquist 1998; Allen, Wegrzyn et al. 2004).
In some ways the yeast system is the envy and goal of present studies in 
mammalian systems. For example, two aspects of Prion theory have been 
clearly demonstrated, enabling models for further research into the molecular 
basis of Prion phenomena in yeast. Firstly, in vitro forms of Prion can be 
prepared which demonstrate activity in vivo: Induction of [PSI+]  could be 
achieved by the introduction of recombinant fragments of Sup35 into [PSI-] cells 
(Sparrer, Santoso et al. 2000). Secondly, distinct strain types can be produced 
in vitro which are associated with conformational differences, and are 
propagated faithfully in vivo.  In vitro Prion was formed by protocols at different 
temperatures resulting in different conformations of the recombinant amino- 
terminal fragments. Different Prion strains were then generated and faithfully 
propagated following introduction of the in vitro formed conformers into [PSI-] 
cells (Tanaka, Chien et al. 2004).
It may also be the case that alternative Prions exist in mammals. A role for 
mRNA at the synapse has been postulated in the formation of long term 
potentiation and a leading candidate for regulation of mRNA translation in this 
regard has been cytoplasmic polyadenylation element binding protein 
(CPEB)(Richter 2001; Huang, Carson et al. 2003).  CPEB activates 
translationally dormant mRNA in Xenopus ooccytes by binding to 
polyadenylation binding elements (CPE) within the 3’UTR  following synaptic 
stimulation (Richter 2001; Huang, Carson et al. 2003). In Aplysia ApCREB has 
an N-terminal motif with multiple Glutamine/Asparagine repeats, reminiscent of 
the yeast Prion domains. Following overexpression CPEB demonstrates the31
ability to bind to CPE’s and activate translation. It also demonstrates Proteinase 
K resistance and the ability, in vitro, to confer this property on newly formed 
protein. The system therefore indicates a potential switch for LTP (long term 
potentiation): overexpression of CPEB, caused by dendritic stimulation, and 
subsequent conversion to the Prion state, produces an effectively maintained 
‘ON’ state, in which CPEB can bind and activate translation of mRNA (Si, 
Giustetto et al. 2003; Si, Lindquist et al. 2003).
1.5.  PrP gene structure and expression
All known mammalian and avian PrP gene coding regions reside within a single 
exon (Prusiner and Scott 1997). One implication of this is that differences in 
protein structure associated with PrPsc, or cellular properties of PrP, cannot be 
attributed to gene splicing.  PrP protein is encoded by the gene locus Prnp, 
which is now thought to be proximal to a second locus, 19kb downstream, 
termed Pmd, which encodes the Doppel (Dpi) gene (Moore, Lee et al. 1999). 
The Prnd locus has 24% coding sequence identity with the Prnp locus.
Sequencing of PrP from multiple species has demonstrated that there is a high 
degree of conservation between the mammalian and avian PrP genes (Schatzl, 
Da Costa et al. 1995). The chicken sequence is more divergent from the human 
gene than the others (Gabriel, Oesch et al. 1992).  There is a high degree of 
conservation of the P(H/Q)GGG(G)WGQ sequence found repeated in the 
octapeptide repeat region (Goldmann, Hunter et al. 1991; Prusiner, Fuzi et al. 
1993) and a conserved Alanine-Glycine rich region found from A113 to Y128, 
the C-terminal end of the octapeptide repeat region  (Hsiao, Cass et al. 1991).
Prnp haplotype diversity and coding allele frequencies suggest that strong 
balancing selection has occurred during the evolution of modern humans, and 
indicates possible selection for disease resistance. The implication is that Prion 
disease has had some influence on the gene’s structure (Mead, Stumpf et al. 
2003).32
Studies have suggested that prp message is expressed in the adult brain of 
animals in neurons, and to varying extents in glia (Chesebro, Race et al.  1985; 
Oesch, Westaway et al.  1985; Ford, Burton et al. 2002) and that it is highly 
regulated during development (Mobley, Neve et al. 1988). Epression of PrP has 
also been detected in heart, lung, spleen, skeletal muscle and testis (Oesch, 
Westaway et al.  1985; Bendheim, Brown et al. 1992). By contrast,  Dpi is 
expressed  at low levels in the CNS and very high levels in testis (Moore, Lee et 
al.  1999).
1.6.  Prion protein Structure
The key event underlying the Prion phenomenon is the molecular switch 
between PrPc and its abnormal conformer PrPsc.  In terms of pure folding theory 
this should provide an unusual insight into how two stable forms of a protein can 
exist and effect a transition between conformational states.  However, it has 
proven impossible to form crystals from PrPsc because it is too insoluble, either 
as full length protein or PrP27-30.  Electron micrographs of PrP27-30 have 
revealed fibrillar structures which appear as visible rod like entities which, after 
staining with congo red, demonstrate birefringence common to amyloids 
(Prusiner, McKinley et al. 1983). In vivo, Prion is found in the form of diffuse 
deposits, amyloid fibres, condensed and florid plaques (Prusiner 1998).
The difference in solubility of PrPsc and PrPc is likely to be a consequence of the 
secondary and tertiary structures of the molecules.  Large differences in 
secondary structure are apparent from studies using circular dichroism and infra 
red spectroscopy which demonstrate that PrPsc is a mix of roughly equal alpha 
helix and beta sheet in contrast to PrPc which is almost entirely alpha helix in 
content and less than 5% beta sheet.  (Caughey, Dong et al.  1991; Safar,
Roller et al. 1993).
NMR studies of PrPc have been undertaken on recombinant protein fragments 
(Riek, Hornemann et al. 1996; Donne, Viles et al. 1997; Zahn, Liu et al. 2000) 
and more recently x-ray crystal structures have been solved for sheep PrP 
(Haire, Whyte et al. 2004) and for a truncated mutant of human PrP (Knaus,33
Morillas et al. 2001). PrP for mouse, human, and sheep (Zahn, Liu et al. 2000) 
share the structure of 3 alpha helices  (amino acids 114-154, 175-193, 200-219) 
and a small antiparallel beta sheet (amino acids 128-131 and 161-64) and are 
structurally speaking  homologous.  NMR studies of the full length protein (23- 
231) demonstrated that the C-terminal portion (126-231) comprised the entire 
globular domain and reveals that the N-terminus was in fact largely unstructured 
(Riek, Hornemann et al. 1997).  A disulphide bridge connects helix 2 and 3 
between amino acids 166 and 171
Helix B
Figure 1.4.  NMR structure of human PrP
Structure of Human PrP highlighting positions of those residues corresponding to the protein X 
binding site in mouse PrP. Adapted from (Zahn, Liu et al. 2000)
It is presumed that the carbohydrate residues, which were not present in these 
studies, do not affect the overall conformation of the backbone and it is unclear 
whether the addition of copper ions might bind and contribute to the structuring 
of the N-terminus.  The contribution to structure as a whole of GPI anchorage to 
the membrane surface remains to be determined.
Helix A34
Local intra-species differences between the beta sheet and helix 2 (amino acids 
166-171) and helix 3 are of particular interest. Differences in structure of mouse 
and hamster PrP as compared with bovine and human PrP are restricted to that 
part of the molecule (Lopez Garcia, Zahn et al. 2000; Zahn, Liu et al. 2000).
This putative region has been argued to be the region for protein X binding 
which in turn has been argued is a determinant of the species barrier and an 
important part of Prion replication in vivo (see Fig 1.4).
Studies have indicated that PrP can exists as a dimer under conditions which 
are reasonably physiological (Meyer, Lustig et al. 2000; Jansen, Schafer et al.
2001). A further study has indicated that a dimer is formed by domain swapping 
and the formation of intermolecular disulphide bridges through a reorganisation 
of tertiary structure (Knaus, Morillas et al. 2001).
It is unclear whether this covalently linked dimer is in fact an artefact of long­
term crystallisation conditions or a biologically relevant structure. However, it is 
suggestive of a model for the subsequent formation of beta sheet in transit to 
PrPsc because a central feature of the dimer is the formation of an inter-chain 
beta sheet which can then act as a surface for oligomerisation.
1.7.  PrP biogenesis and trafficking
The biosynthesis of PrP is similar to that of other membrane and secreted 
proteins. A summary of modifications to PrP during biosynthesis is represented 
in Figure1.5.  During synthesis PrPc is translocated into the Endoplasmic 
Reticulum (ER) where its N-terminal signal peptide is cleaved and, following 
cleavage of its c-terminal Glycosyl-phosphatidyl-inosotol (GPI) signal, it  is 
derivatised with a GPI anchor (Stahl, Borchelt et al. 1987). It also undergoes 
non-obligatory glycosylation at asparagines, N180 and N196 (Endo, Groth et al. 
1989) and a disulphide bond is formed (Turk, Teplow et al. 1988). The N-linked 
oligosaccharides are of high mannose content and are sensitive to 
endoglycosidase H (endoH) digestion. When progressing to the Golgi PrPc 
oligosaccharides are modified to complex type chains containing sialic acid and 
are no longer resistant to endoH.35
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Figure 1.5.  Diagram of PrP modifications in the ER following synthesis of the 
polypeptide
Following synthesis of the polypeptide, the signal peptide is cleaved N-terminally and a GPI 
anchor is added (A), tethering the protein to the membrane surface. The hydrophobic region 
implicated in the alternative transmembrane form of PrP is also indicated (B).  A disulphide bond 
is formed and oligosaccharide chains are added to two potential sites.
1.7.1.  Endocytic trafficking of PrPc
Following transit down the secretory pathway and subsequent tethering to the 
plasma membrane by the GPI anchor, some PrPc constitutively cycles between 
the membrane and an endocytic compartment (Shyng, Huber et al. 1993). 
Figure 1.6 represents a summary of the trafficking of PrPc.  The cycle time of 
approximately 60 minutes has been demonstrated during kinetic studies which 
also indicate that 5% of the PrP molecules undergo proteolytic cleavage near 
residue 110 (Harris, Huber et al. 1993).  A PrP-GFP fusion has also been 
shown to co-localise with Transferrin and FM4-64, indicating an endosomal 
recycling location (Borchelt, Taraboulos et al. 1992; Magalhaes, Silva et al.
2002)36
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Figure 1.6.  Diagram illustrating the two potential routes of PrP endocytosis
A) PrP is endocytosed directly by caveolae (indicated in the figure) or by caveolae like domains.
B) PrP finds its way to clathrin coated pits which are subsequently endocytosed
Experiments localising PrPc through immunogold labelling and electron 
microscopy have indicated that clathrin coated pits appear to be associated with 
PrP uptake (Shyng, Heuser et al. 1994; Madore, Smith et al. 1999) and 
incubation with hypertonic sucrose, which disrupts clathrin lattices, abolishes 
internalisation of PrP (Shyng, Heuser et al. 1994). Expression of a dominant 
negative mutant of dynamin I prohibits invagination of clathrin coated pits from 
the membrane, and leads to accumulation of PrPc containing structures beneath 
the membrane which co-localise with endocytic markers. (Shyng, Moulder et al. 
1995; Magalhaes, Silva et al. 2002)
It is not clear how endocytosis of PrP is able to proceed via clathrin coated pits 
because PrPc is in its majority not transmembrane and therefore does not 
present a c-terminal domain for cytoplasmic interaction with adaptor proteins 
and clathrin. It has been hypothesised that a PrP receptor, a transmembrane 
protein, must exist which has the necessary clathrin coated pit localisation 
signal and has a PrP binding site in its N-terminus (Harris, Gorodinsky et al.37
1996). A number of candidates have been suggested as potential partners for 
this interaction but the existence of a PrP receptor to mediate endocytosis 
through clathrin coated pits remains to be established (Gauczynski, Peyrin et al. 
2001; Zanata, Lopes et al. 2002). A precedent does exist for such a model in 
the form of the interaction between urokinase receptor (a GPI anchored protein) 
and the low-density lipoprotein receptor related protein, a transmembrane 
protein (Czekay, Kuemmel et al. 2001).
1.7.2.  Lipid rafts and internalisation
The majority of PrP protein in neuronal and non-neuronal cells is found in 
detergent resistant raft domains on the plasma membrane (Gorodinsky and 
Harris 1995; Vey, Pilkuhn et al. 1996; Naslavsky, Stein et al. 1997). The raft 
domains are composed of sphingolipids and cholesterol and represent an 
ordered lipid environment (Simons and Ikonen 1997). This environment is 
enriched with other GPI anchored proteins and protein tyrosine kinases but 
excludes most transmembrane proteins.  Rafts have been suggested as 
potentially important sites for signalling (Anderson 1998) and in the case of PrP 
resident in raft domains, signal transduction via fyn kinase has been suggested 
(Mouillet-Richard, Ermonval et al. 2000).  The rafts are defined biochemically 
but also ultrastrucuturally and PrP containing invaginations are apparent on the 
surface of culture cells which are reminiscent of caveolae -  rafts containing 
caveolin famiy proteins. Many cultured cell lines, including N2a cells, lack 
caveolin and therefore these domains have been nominated caveolae-like 
domains. PrP-containing rafts are a distinct subset from rafts containing other 
GPI anchored proteins; a significant proportion of PrP is fully soluble in non­
ionic detergents, indicating an additional presence in non raft domains (Madore, 
Smith et al. 1999). An  N-terminal motif of basic residues may be a  necessary 
feature for the internalisation of PrP and is sufficient for the re-localisation of 
Thy-1 to distinctive PrP containing rafts (Sunyach, Jen et al. 2003). 
Internalisation of PrP may also occur via non clathrin coated pit mechanisms. 
Perturbation of PrP trafficking following various changes in cholesterol 
metabolism, along with the raft localisation of PrP are suggestive of38
internalisation by clathrin independent means such as caveolae (Kaneko, Vey 
et al. 1997; Marella, Lehmann et al. 2002).
In summary, PrPc is found to be abundant in raft domains but also to exist 
outside of raft domains on the cell surface. It is unclear whether its 
internalisation occurs principally through clathrin-mediated means or through 
the raft domain itself.  It is difficult at present to see how a clear conclusion can 
be drawn on the issue of non-clathrin mediated endocytosis because 
perturbation of cholesterol, the main tool for assessment of raft mediated 
trafficking, has ramifications for cell trafficking in general.
1.7.3.  PrP8 C  localisation and site of conversion
Work in the area of Prion cell biology has been hampered by the lack of a 
reagent which enables specific detection of the Scrapie form of PrP in a cyto- 
chemical context.  Nevertheless techniques have been employed as surrogates 
for the absence of such a marker which usually rely on the differential 
biochemical properties of PrPsc from its normal cellular counterpart: for example 
the use of Proteinase K followed by centrifugation in non-ionic detergents. 
Immunofluorescence studies in Scrapie infected N2a cells have shown mixed 
distribution of PrPsc residing intracellularly and co-localising with the Golgi 
markers in some cases (Taraboulos, Serban et al. 1990).  Further studies in 
N2a cells and also brain sections have shown localisation of PrPsc with late 
endosomal and lysosomal markers (McKinley, Taraboulos et al. 1991; Arnold, 
Tipler et al. 1995). The cell surface has also been consistently implicated as a 
site of PrPsc accumulation through electron microscopy and the use of 
membrane-impermeable labelling reagents (Jeffrey, Goodsir et al.  1992; Shyng, 
Moulder et al. 1995; Vey, Pilkuhn et al. 1996).
It is perhaps even more difficult to establish the subcellular location of Prion 
conversion which is a crucial locus in understanding the cell biology of Prion 
disease. Evidence points to a site along the endocytic pathway, after passage 
down the secretory pathway to the plasma membrane.39
Treatment of cells with Brefeldin A, effectively dissolving the Golgi and blocking 
secretion, prevents the formation of PrPsc, implying a post Golgi conversion 
process (Taraboulos, Raeber et al. 1992).  Chasing PrP conversion by use of 
surface iodination of infected cells demonstrates incorporation of radiolabel into 
PrPsc (Caughey and Raymond 1991). Furthermore, treatment of infected cells 
with phosphatidylinositol-
specific phospholipase C ( PIPLC), inhibits the production  of PrPsc and implies 
the necessity of a PrP precursor which would otherwise be  available on the cell 
surface (Caughey and Raymond 1991; Borchelt, Taraboulos et al.  1992).
Further studies focussed on the issue of the presence of PrPsc in lipid rafts have 
more narrowly defined the locus of conversion. Depletion of cellular cholesterol 
which disrupts rafts also appears to inhibit PrPsc formation (Taraboulos, Scott et 
al. 1995).  However, as discussed above, cholesterol depletion as a 
manipulation has wide ranging effects on cellular metabolism. Furthermore, 
addition of trans-membrane domains in place of the GPI-anchor causes 
relocation to clathrin coated pits, and leads to the disruption of the conversion 
process (Kaneko, Vey et al. 1997). These studies have been taken as evidence 
for caveolae like domains (CLDs) as the likely locus for conversion.40
1.7.4.  Topological variants of PrP
Figure 1.7.  Topological variants of PrP
^PrP indicates the most abundant form of PrP which is transported down the secretory 
pathway and tethered at the plasma membrane; ctm PrP is a transmembrane form where PrP is 
tethered to the surface of the ER by a GPI anchor; ntm PrP is another transmembrane form but 
the N terminal of the molecule is luminal and it is not GPI anchored; Cytosolic PrP is indicated 
as a species unassociated with membrane and possibly formed by ERAD (Endoplasmic 
Reticulum-associated degradation).
Distinct PrP topologies were originally observed as outputs of in vitro translation 
studies ((Hegde, Mastrianni et al. 1998; Hegde, Voigt et al. 1998)). These 
include PrP, as described previously, which is anchored by its GPI anchor, a 
cytosolic PrP species, and two other species termed ntmPRP and ctmPRP 
which span the membrane bilayer via a hydrophobic region from amino  acids 
111-134. These species constitute less than 10 percent of normal PrP 
biosynthesis (Harris 2003).
Mutation in or near to the transmembrane region can however effect the 
production in favour of the membrane forms. For example, the mutation A117V 
and P105L, associated with GSS, increases the proportion of ctmPRP that is 
formed by up to 30 percent (Hegde, Mastrianni et al. 1998; Kim, Rahbar et al. 
2001). Competition at the translocon between the signal peptide, amino acids 1- 
22, and the hydrophobic residues 111-134, is responsible for either secPrP and 
NtmPrP on the one hand and ctmPrP on the other.41
Animals expressing A117V mutants which favour production of ctmPrP (Hegde, 
Mastrianni et al. 1998) develop a Scrapie like neurological disease without any 
detectable PrPsc. Interestingly the amount of ctmPrP increases when these 
animals are challenged with an inoculum containing PrPsc.
In order to further investigate the hypothesis that ctmPrP may be a key 
molecule in the pathogenesis of Prion disease, mutations were identified that 
led to the exclusive synthesis of the ctmPrP form. It was found that L9R 
mutation in the signal peptide with a 3AV mutation in the transmembrane 
domain led to a production of a pure ctmPrP form . L9R/3AV PrP, was found to 
be absent from the cell surface although an intact GPI anchor indicated an 
interesting topology of a species which is transmembrane and yet anchored to 
the ER membrane in which it is retained, as assessed by endoH 
resistance.(Stewart, Drisaldi et al. 2001).
On the basis of ER retention it has been hypothesised that ctmPrP may be toxic 
in virtue of its ability to activate an ER-stress response pathway leading to cell 
death.  Against the idea of ctmPrP as the primary toxic molecule in Prion 
disease is the finding that mutations associated with disease outside of the 
hydrophobic 111-134 segment do not lead to an increase in ctmPrP over 
normal levels and little ctmPrP has been identified in actual Prion disease 
(Stewart, Drisaldi et al. 2001; Stewart and Harris 2001)
In summary, the membrane form of PrP, ctmPrP has been shown to be an 
interesting potential molecule as a candidate for a toxic PrP species in culture 
studies. However, it remains to be clarified whether this has relevance to in vivo 
Prion disease and in particular a robust connection remains to be proven 
between infection and changes in the level of this membrane form of PrP.
1.7.5.  Proteasomal processing and ERAD (Endoplasmic Reticulum 
Associated Degradation)
ER associated degradation describes the control process of the ER in 
degrading  inappropriately folded or misprocessed proteins. Further export42
down the secretory pathway of these proteins is blocked and they are retro- 
translocated into the cytoplasm  where they are destined for degradation by the 
proteasome (Ellgaard, Molinari et al. 1999). It has been suggested that as part 
of normal PrP biosynthesis about 10 percent of the population undergoes 
ERAD, a small proportion of which are ubiquitinated (Yedidia, Horonchik et al. 
2001). In the presence of proteasomal inhibitors PrP accumulates in the cytosol 
where it forms aggregates of 26kda and a corresponding 19-kD protease 
resistant core (Ma and Lindquist 2001; Yedidia, Horonchik et al. 2001; Ma and 
Lindquist 2002).  This accumulation might provide evidence for the claim that 
PrP undergoes retrotranslocation from the ER.  Interestingly, following transient 
proteasomal inhibition and subsequent recovery of the proteasome an increase 
in the quantity of aggregated PrP is found which indicates that the conversion to 
a protease resistant form is self perpetuating (Ma and Lindquist 2002).  The role 
of the cytosolic PrP species in cytotoxicity has also been suggested  in N2a 
cells where PrP accumulation is cytotoxic in contrast to Presenilin-1, and in 
animal models where N and C terminal PrP deletion mutants, which do not 
enter the ER, are found to cause cytotoxicity (Ma, Wollmann et al. 2002).
The model emerging from the work described above suggests a convergence of 
explanation for both initial Prion formation and subsequent cytotoxicity.  At 
present it is unknown how sporadic CJD is initiated and this work may provide a 
key insight. However, it is notable that only an unglycosylated PrP is present in 
the cytosolic species which accumulates following proteasomal inhibition. This 
fact is consistent with work which has found that PrP accumulating in the 
presence of  proteasomal inhibition has an intact signal peptide and c-terminal 
GPI-anchor sequence (Drisaldi, Stewart et al. 2003). This work suggests that 
ERAD does not occur following proteasomal inhibition and consequently that 
there is no evidence for ERAD of normal PrP. In the same experiments it was 
found that proteasomal inhibition led to a sustained increase in PrP transcription 
which might explain the apparent self-perpetuating nature of the species 
formed. It might also offer an alternative explanation for the phenomenon of 
proteasomal targeting, given that overexpression can lead to saturation of 
translocational machinery and consequent proteasomal degradation (Drisaldi,43
Stewart et al. 2003).  The role of cytoplasmic forms of PrP as causes of 
cytotoxicity in ordinary disease remains to be established.
1.8.  Function of PrP
Although no clear phenotype has been found in knockout mice, some of the 
subtler findings like perturbed sleep (Tobler, Gaus et al. 1996) and loco-motor 
activity (Roesler, Walz et al. 1999) have been suggestive of minor neuronal 
deficits.  More in depth electrophysiological studies have indicated that GABA-A 
receptor mediated fast inhibition and long term potentiation are both impaired in 
the knockout mice (Collinge, Whittington et al. 1994). This work has been 
contradicted by other studies which demonstrate intact synaptic transmission in 
both the hippocampus (Lledo, Tremblay et al. 1996) and the cerebellum 
(Herms, Kretzchmar et al. 1995) of knockout mice.  In conditional knockouts, 
CA1 cells demonstrate some reduction in after hyperpolarisation potentials 
(Mallucci, Ratte et al. 2002), and in comparison high levels of PrPc mediate a 
more robust synaptic transmission in the hippocampus (Carleton, Tremblay et 
al. 2001).  The search for deficits in knockout mice has brought up a number of 
interesting issues connected with Prion protein and its cellular function, however 
the overall picture is that there is no clear function which can be attributed to 
PrPc at present.  Some of the putative roles are described below.
1.8.1.  Copper binding and SOD activity
PrPc binds copper with micromolar affinity (Brown, Qin et al.  1997) and also 
binds zinc and magnesium, although with lower affinity (Pan, Stahl et al. 1992; 
Jackson, Murray et al. 2001).  The N-terminus mediates binding at six 
conserved Histidine residues, four of which are situated within the octapeptide 
repeats (Jackson, Murray et al. 2001). Given the suggested role of the N- 
terminus in binding other ligands it is possible that copper binding has a role to 
play in PrP interactions.  Knockout mice demonstrate reduction of 50% copper 
concentration in synaptosomal fractions, indicating a possible role in reuptake of 
copper (Kretzschmar, Tings et al. 2000) and  copper addition to N2a cells 
stimulates PrP endocytosis (Pauly and Harris 1998). It has therefore been44
suggested that PrPc may play a role in copper metabolism as a transport 
mechanism across the cell membrane.
PrPc may also play a role as an antioxidant (Brown, Wong et al. 1999) and has 
some activity akin to that of a copper/zinc-dependent superoxide dismutase 
(SOD1). A decrease of SOD1 activity in the brains of knockout mice (Brown, 
Wong et al. 1999) and an increase in SOD1 activity and copper loading in 
transgenic mice over-expressing PrP (Brown and Besinger 1998) is consistent 
with this hypothesis.  However, these findings remain contentious and others 
have found little difference in copper concentrations in subcellular brain 
fractions from knockout mice and little difference in SOD1 activity (Waggoner, 
Drisaldi et al. 2000).
1.8.2.  PrP and Cell signalling
There is some evidence that PrP acts as a signalling molecule. Forcing 
dimerisation of PrPc in cell-culture models can activate the non-receptor 
tyrosine kinases (Mouillet-Richard, Ermonval et al. 2000). However, it is unclear 
whether the signal is mediated directly via PrPc. Mice suffer loss of 
hippocampal, cortical and cerebellar neurons following stereotactic injection of 
PrP specific monoclonal antibodies into the right hippocampus in contrast to 
knockout controls (Solforosi, Criado et al. 2004). This result might be taken to 
argue for a direct signalling role of PrP as a cause of neuronal apoptosis 
although it remains unclear whether a neuro-protective signal is abrogated or a 
direct apoptotic signal is initiated. It might be argued that this result taken in 
combination with the inducible PrP mouse models which do not show apoptosis 
on removal of PrP indicates a direct apoptotic signal mediated by the cross- 
linked PrP species.  It is difficult to assess signalling function by interventions 
like dimerisation because gross changes in membrane environment may 
themselves be responsible for the signalling changes.45
1.8.3.  PrP and cell survival
There have been conflicting reports of the contribution that PrP makes to cell 
survival. PrPccan bind Bcl-2 (Kurschner and Morgan 1995) and has been 
shown to protect neuroblasts and retinal rat explants from ansiomycin induced 
cell death (Chiarini, Freitas et al. 2002; Zanata, Lopes et al. 2002). Neurons 
taken from knockout mice have an increased  sensitivity to serum deprivation 
and over-expression of Bcl-2 re-establishes normal levels of resistance 
(Kuwahara, Takeuchi et al. 1999). Bax mediated cell death in primary neurons 
was abrogated by PrP overexpression  to the same levels as that of BCI-2 
overexpression (Bounhar, Zhang et al. 2001).
An alternative picture is delineated by the finding that over-expression of PrP 
can sensitise N2a cells to staurosporine induced apoptosis and lead to an 
increase in caspase 3 activity (Paitel, Alves da Costa et al. 2002).
Perhaps it is not surprising that a protein which is highly expressed in neuronal 
populations and connected with a disease that leads to neuronal death should 
be a focus of discussion as a candidate molecule with a role in cell survival. 
However, the evidence for the hypothesis that PrPc clearly mediates cell 
survival in some form remains to be firmly established.
1.8.4.  PrP binding molecules
Putative PrP-interacting molecules and receptors might shed some light on both 
the function of PrP and the necessary determinants for its normal cellular 
behaviour. Yeast two hybrid screens have been used to identify interacting 
proteins from  cDNA libraries and have led to the suggestions that potential 
interactors might include BCI-2 (Kurschner and Morgan 1995; Kurschner and 
Morgan 1996), the chaperones protein HSP60 (Edenhofer, Rieger et al. 1996), 
the laminin receptor precursor protein LRP or Laminin receptor LR (Rieger, 
Edenhofer et al.  1997)  and Grb2 (Spielhaupter and Schatzl 2001) amongst 
others. Immuno precipitation experiments have shown mutual pull down of PrP 
with antibodies to grp94, protein disulphide isomerase, calnexin and calreticulin 
(Capellari, Zaidi et al. 1999).46
The stress inducible protein 1   (ST 1-1), a cofactor for chaperones such as 
HSP70 and HSP90, has also been implicated as a binding partner and was 
identified through its complementary hydropathy profile in comparison with a 
PrP113-128 peptide (Zanata, Lopes et al. 2002). It is also a potential mediator 
of a PrPc neuroprotective signal through interaction at the cell surface with PrP.
Heparin sulphates have consistently been implicated in the cellular behaviour of 
PrP and also in the process of infection.  Heparin sulphates interact with a 
central binding domain in the N-terminal region of PrPc (Gabizon, Meiner et al. 
1993; Caughey, Brown et al. 1994; Brimacombe, Bennett et al. 1999).  There is 
a possibility that binding occurs to the octapeptide repeat itself, which is 
important given the potential copper binding to this region of PrP (Brimacombe, 
Bennett et al.  1999; Warner, Hundt et al. 2002).  PrP internalisation has also 
been shown to be affected by the presence of glycosaminoglycans (Shyng, 
Lehmann et al. 1995; Wong, Xiong et al. 2001), and sulphated glycans appear 
to stimulate cell-free conversion reactions (Snow, Wight et al. 1990; McBride, 
Wilson et al. 1998).
The laminin receptor precursor protein and the laminin receptor (LRP/LR) have 
been implicated in a number of studies as an important interacting protein. 
LRP/LR undergoes a complex maturation process involving acylation, and 
phosphorylation of the precursor of which several isoforms are present in the 
brain (Simoneau, Haik et al. 2003).
A role in the endocytic pathway of LR has been suggested given its 
demonstrated mediation in the binding and internalisation of PrPc to cells in 
culture models. It is also possible that LRP/LR might act as the cellular receptor 
for PrP molecules to interact with other cells for the purposes of signalling 
necessary for survival (Rieger, Edenhofer et al. 1997; Gauczynski, Peyrin et al. 
2001).
In culture models, knock down of LRP/LR using antisense and RNAi leads to a 
decrease in infectivity and hence LRP/LR may play an important role in the 
process of Prion conversion (Leucht, Simoneau et al. 2003).47
In summary, a large number of putative PrP binding proteins have been 
suggested. Of particular interest is the Laminin Receptor which has also been 
implicated in the conversion of PrP to Prion. However, it remains to be 
confirmed whether any of these molecules has any clear role to play in either 
the normal cellular metabolism of PrPc or in Prion infection.
1.9.  Animal models of Prion disease
Animal models have been seminal in securing the link between PrP expression 
and infection, demonstrating the necessity of PrP expression, gene dosage 
effects on incubation, the existence of a species barrier and the existence of 
distinct reproducible strains of Prion.
1.9.1.  PrP knockout mice
Two strategies have been employed for removal of PrP expression. The first 
involves disruption of the open reading frame of PrP (Bueler, Fischer et al.
1992; Manson, Clarke et al. 1994).  Both the Zurich I mouse and the Edinburgh 
knockout demonstrate disruption of PrP expression by this method. The animals 
develop normally, no obvious pathology is evident and they are resistant to 
Prion infection. Milder phenotypes described include disruption of circadian 
rhythms(Tobler, Gaus et al. 1996), changes in superoxide dismutase activity 
(Brown, Schulz-Schaeffer et al. 1997) and defects in copper metabolism 
(Brown, Qin et al. 1997). It is also noteworthy that some studies have suggested 
GABA-A receptor mediated fast inhibition and LTP  are impaired in hippocampal 
slices (Collinge, Whittington et al. 1994; Collinge, Sidle et al. 1996) although 
these studies have not been substantiated (Herms, Kretzchmar et al.  1995; 
Lledo, Tremblay et al. 1996).
The second strategy for knockout of PrP involved deletion of both the reading 
frame and flanking regions (Sakaguchi, Katamine et al. 1996).  In contrast to the 
first two knockout lines described these mice, Nagasaki and Zurich II, exhibit 
severe ataxia, and purkinje cell loss later in life (Sakaguchi, Katamine et al.
1996; Moore, Lee et al. 1999; Rossi, Cozzio et al. 2001). The disparity between48
the models has since been clarified with the discovery of a downstream gene 
locus Prpnd and the associated  Doppel (Dpi) gene. Ectopic brain expression of 
doppel in the PrP knockouts, as a result of the wider deletion strategy, leads to 
the toxic phenotypes (Moore, Lee et al. 1999).
Dpi is an N-glycosylated , GPI anchored protein expressed in many tissues but 
not in the brain. Dpi and PrP show about 25 percent homology (Moore, Lee et 
al. 1999; Silverman, Qin et al. 2000) and knockout leads to male sterility in mice 
(Behrens, Genoud et al. 2002).
1.9.2.  Transgenic models of human Prion diseases
The single base mutation P102L is directly linked to GSS with 100 percent 
penetrance (Hsiao, Baker et al. 1989). Transgenic mice with the equivalent 
mutation at amino acid 101  in murine PrP have been produced.  Mice with a 
high copy number of the Prnp P101L transgenes developed a 
neurodegenerative disorder, exhibiting spongiform change and PrP containing 
amyloid placques in the brain, in the apparent absence of PrPsc (Hsiao, Groth et 
al. 1994).  In low copy number mice, where transgene expression was only 
twice that of endogenous expression,  signs of CNS disorder were not apparent 
until 600 days and then only in a few mice (Kaneko, Ball et al. 2000). 
Nevertheless the high copy number disease could be transmitted to low copy 
number animals efficiently, but not to wild type mice (Telling, Parchi et al. 1996). 
This has been argued to provide evidence for a protein only hypothesis.
A second model introduced the 101L mutation through targeted means, thereby 
avoiding complications associated with overexpression. The finding in this 
model contrasted starkly with the overexpressed transgene described above, 
and did not evidence a spontaneously generated disease (Moore, Redhead et 
al. 1995; Manson, Jamieson et al. 1999).
Other models of disease have included the creation of mice expressing  PrP 
with nine octapeptide insertions , which demonstrate a slow progressive, 
neurological disorder (Chiesa, Piccardo et al. 1998). Mice homozygous for the49
transgene acquire ataxia at roughly 65 days compared to the hemizygous mice 
and partially Proteinase K resistant PrP species were found to accumulate in 
spinal cord , skeletal muscle and heart.(Chiesa, Pestronk et al. 2001).
Not all Prion diseases find analogues in mouse models. Transgenic mice 
overexpressing a mutant PrP gene, E200K , demonstrate the equivalent 
mutation to the E200K mutation found in one form of familial CJD. These 
animals did not display any sort of neurological disorder (Telling, Haga et al. 
1996).
1.9.3.  Transgenic studies of the species barrier
Prions are not always transferred efficiently between species, which constitutes 
a species barrier. In mice, abrogation of this barrier can often be attained by 
serial passage of infected materials from those mice that do come down with 
disease,  leading to a decreasing incubation time with passage until the barrier 
is overcome (Pattison 1965). The emerging model is that Prions which are 
synthesised in the new host species ultimately reflect the sequence of that 
species and not that of the PrPsc molecules in the initial inoculum (Bockman, 
Prusiner et al. 1987).
Expression of transgenes allows for efficient transfer across the species barrier 
without passaging.  One example of this is the introduction of a Syrian hamster 
PrP into mice rendering them susceptible to hamster Prion disease, and 
demonstrating gene dosage effects (Scott, Foster et al. 1989). When these 
transgenic mice were infected with mouse Prion they produced Prions 
pathogenic for normal mice, in contrast to inoculation with hamster Prion, which 
produced Prions that would only infect hamsters.  The results of this work 
indicated the importance of the primary structure of the PrP gene in determining 
the nature, and possibly the conformation of the Prion produced following 
infection (Prusiner, Scott et al. 1990).
Introducing a parallel transgene into a mouse model does not always overcome 
the problem of the species barrier. For example, transgenic mice expressing a50
Human PrP are not infected with CJD.  In contrast, expression of the same 
transgene on a knockout background permits infection. The implication here is 
that endogenous mouse PrP interferes in some way with the process of 
infection directed through the transgene.  When a chimera, MHu2M, of the 
human and mouse Prion is expressed on the normal background, infection is 
also able to proceed (Telling, Scott et al. 1995). The hypothesis from these 
experiments was that mouse and human PrP compete for a factor X which is 
necessary for conversion, and the mouse PrP has a significantly higher affinity 
for factor X. The chimera was converted because it was able to bind to this 
factor given the shared amino acid sequence at the N and C terminal portions 
PrP.
Scrapie infected N2a cells have been used to clarify the important binding 
residues to protein X. The side chains of residues 214 and 218 were delineated 
as part of a discontinuous epitope with residues 167 and 171  in an adjacent 
loop (Kaneko, Zulianello et al. 1997).
1.9.4.  Transgenic models of Prion strains
Different TSE isolates have different characteristics which are maintained 
following infectious transfer to another organism.  The different phenotypes 
resulting from TSE infection have been attributed to the existence of multiple 
strains.  The most studied system has been mice through which Scrapie, BSE 
or CJD from a range of isolates have been passaged. From these studies a 
number of criteria have emerged for distinguishing strains which include the 
pathological brain profile of an animal, the incubation time, and the biochemical 
characteristics of the Scrapie agent formed following infection. The incubation 
period for a given strain is highly replicable in mice studies given the same dose 
and genetic background and different strains show reproducibly different 
incubation periods (Bruce, McConnell et al. 1991). Pathology in TSEs varies 
according to vacuolation severity and area profile. ‘Lesion profile’ represents a 
score of these variables and appears to be reasonably characteristic for strains 
(Bruce, McConnell et al.  1991). Glycosylation profile of  brain PrPsc has been51
suggested as one possible marker of strain (Collinge, Sidle et al. 1996; 
Somerville, Chong et al. 1997). Conformational differences revealed by distinct 
Proteinase K digestion products (Telling, Parchi et al.  1996) and antibody 
binding propensities (Safar, Wille et al. 1998) have also been suggested as 
useful criteria.
The protein only hypothesis needs to account for the additional subtlety of 
information transfer that is associated with strain. Experiments indicating 
conformational variation as the molecular basis are therefore critical. Two 
strains of TME were found to produce distinct strain types as assayed by 
incubation period and clinical symptoms in hamsters.  Critically the two strains 
demonstrated differences in their Proteinase K cleavage sites (Bessen and 
Marsh 1992).
This provides some evidence for conformational distinctness underlying the 
difference in the two strains.  Further evidence for the conformational basis of 
strain has come from differences in Proteinase K cleavage site in Prion from 
sFFI (sporadic FFI) orfCJD (familial CJD) (E200K) patients (Telling, Parchi et 
al. 1996). The associated cleavage products of 19 and 21  kda for sFFI and 
fCJD respectively remain constant when the material is passaged through a 
transgenic mouse expressing a chimeric hamster-mouse transgene.
Studies comparing different sporadic and iatrogenic CJD cases with codon 129 
genotypes have also been shown to be typed according to PrPsc fragment sizes 
following Proteinase K digestion (Telling, Parchi etal. 1996).
Differential glycosylation has been taken as one indicator of strain and it 
remains to be established what the exact effects of PrPc glycosylation or PrPsc 
glycosylation are on the infectious process. This is discussed in the introduction 
and discussion of Chapter 3.52
1.10.  In vitro models of Prion disease
The first test for the protein only hypothesis came from the challenge to form 
PrPsc in vitro. PrPc was radiolabelled and incubated with unlabeled PrPsc which 
produced a small amount of Protease resistant, radiolabelled PrP species 
(Kocisko, Come et al. 1994). The newly formed material is here nominated PrP- 
res because it is not proven to have the infectious properties of PrPsc in vivo . 
Importantly, other amyloid related material, such as beta amyloid, could not act 
to convert PrPc in this assay.  Validation for in vitro models came from results 
indicating preservation of the species barrier (Kocisko, Priola et al. 1995; 
Raymond, Hope et al. 1997; Horiuchi, Priola et al. 2000), and of strain 
characteristics (Bessen and Marsh 1994).  However a key problem has been 
the demonstration of the in vivo efficacy of the newly produced PrP-res in 
propagating Prion infection and attempts to test infectivity produced by cell free 
reactions have not proven positive (Hill, Antoniou et al. 1999). One key issue 
has been the production of sufficient quantities of PrP-res and this is indicative 
of the fact that the conversion reaction is highly inefficient -  ratios of roughly 
50:1  in initial PrPsc to PrPc are necessary to run this reaction successfully 
(Supattapone 2004).
The reaction has been used to assess mechanistic aspects of conversion. The 
species that is associated with the converting activity appears not to be a 
monomer and is more likely a multimer or aggregate (Caughey, Kocisko et al. 
1995; Caughey, Raymond et al. 1997). Partial denaturation of PrPc or addition 
of chaperones like GroEL or hsp1054, can lead to enhancement of the 
conversion, perhaps indicating something about the need for refolding steps  in 
the conversion process (DebBurman, Raymond et al. 1997). A result consistent 
with a nucleated polymerisation model is the finding that PrPc substrate binds 
and remains bounds to PrPsc  during the process of the reaction (Bessen, 
Raymond et al. 1997; Horiuchi and Caughey 1999; Horiuchi and Caughey 1999; 
Horiuchi, Priola et al. 2000).
A conformational change occurs following binding of PrPc to PrPsc at the C- 
terminal end of the third helix and subsequently PrPc is more slowly converted53
to the high beta sheet containing state. It has been postulated that the breakage 
of the disulphide bond in PrPc (Welker, Wedemeyer et al. 2001) and formation 
of intermolecular disulphide bonds or domain swapped dimer (Knaus, Morillas 
et al. 2001) might be a necessary process.  However evidence suggests that 
this is not a necessary requirement in vitro (Welker, Raymond et al. 2002).
A more efficacious cell free conversion process protein misfolding cyclic 
amplification (PMCA) efficiently amplifies PrP-res in repeated cycles of 
sonication with the addition of the anionic detergent SDS  (sodium dodecyl 
sulphate) (Saborio, Permanne et al. 2001). PrPc conversion to PrP-res can be 
formed with an input PrPsc/ PrPc ratio of as little as 1:100 in molar terms 
compared to the 50:1  ratio of the original cell free system described above.  A 
modified procedure has been suggested which does not involve SDS and 
sonication although it produces only a 6-fold and not 30-fold 
amplification(Lucassen, Nishina et al. 2003).  Pancreatic RNAse T1 and RNAse 
A  were shown to inhibit PrPres amplification using PCMA in a dose dependent 
manner and addition of total RNA isolated from hamster brain was shown to 
stimulate amplification in a species specific manner (Deleault, Lucassen et al.
2003). No single RNA has been suggested as a binding candidate and it is 
therefore not known whether amplification occurs as a general property of RNA 
in Prion conversion. Of particular concern is the issue of whether the 
enhancement of Prion conversion in these experiments is specific to the cyclic 
amplification process.
Since the intial writing of this introduction, a study has been published which 
makes use of the enhanced efficiency of the PCMA process to produce 
PrPsc  in vitro from  a 263 K Prion strain template(Castilla, Saa et al. 2005). 
Adequate quantities were formed to effectively dilute out the original template to 
a level where it had no activity, whilst the newly formed Prion successfully 
brought about infection in mouse models. This is the first successful 
demonstration of its kind and is a promising step in the field.
A further important paper has recently provided the first published evidence of 
the formation of synthetic mammalian Prions. Previously attempts to54
demonstrate production of  infectivity by refolding wild-type PrPc into beta sheet 
rich isoforms have proved to be unsuccessful (Hill, Antoniou et al. 1999).  A 
mutant recombinant PrP (MorPrP 89-230) was expressed in E-coli and fibrils 
were produced by either a seeded or non seeded technique (Baskakov, 
Legname et al. 2002).  The resultant material was used as an inoculum in mice 
expressing MoPrP89-230 at 16 times the level of normal PrP. The results were 
a 382 day and 474 day incubation times for inoculums produced by the seeding 
and unseeded method respectively.  Brain pathology was assessed and found 
to be similar to that of infection of wild type mice with the RML strain of Prion. 
The Prion showed the classical criteria of PK resistance. One caveat with the 
experiment is the use an animal over-expressing a transgene at 16 times the 
level of normal PrP. Particularly the concern might be that both the biochemical 
properties and the pathology might have been a result of PrP aggregation rather 
than Prion formation. Nevertheless, the crucial result of Prion propagation in 
normal FVB mice with inoculums from the first passage transgenic mice brains 
was also demonstrated. Whether this is a special case based on the peculiar 
mutant PrP form remains to be determined.
It remains unclear whether these in vitro models reflect the possibility that 
conversion of PrPc to PrPsc may well occur in the context of a membrane. This 
may occur within a non fibrillar assembly of GPI-anchored PrPsc molecules in 
two dimensions (Wille, Michelitsch et al. 2002), or the membrane may 
thermodynamically permit the existence of monomeric  PrPsc which is not found 
in vitro.  When PrPc and PrPsc were attached to separate membrane vesicles 
conversion was not efficient as long as GPI anchorage obtained or until these 
separate vesicles were fused (Baron, Wehrly et al. 2002). The conclusion of this 
study is that conversion occurs only if PrPc and PrPsc can interact within the 
same membrane.
In summary, work in vitro has previously faced the difficult task of demonstrating 
the infectivity of Prion like species that have been produced, and it has 
therefore been of uncertain relevance to actual Prion formation. However, 
recent advances in formation of synthetic Prion and Prion by in vitro 
amplification methodologies, may represent a major step forward in this field if 
these results are found to be robust. Studies of the differences between models55
which have previously failed to produce infectivity in vitro and those which can 
produce infectivity may in the future reveal something critical about the 
molecular processes of Prion formation.
1.11.  Cell Culture Models
There are a number of reasons why cell culture remains a key strategic 
resource for the study of a Prion disease. Firstly, cell culture offers a means of 
assessing the in vivo requirement for Prion replication. This includes 
investigation of the physiological dynamics of replication and also a search for 
other molecules that contribute to physiological infection. Secondly, cell culture 
offers a key method for both the screening of potential therapeutic drugs and for 
the discovery of Prion specific markers which are crucial for study of the 
disease agent and enhanced diagnosis.
The use of cell lines in the cell biology of Prion has been limited by the fact that 
only some cell lines appear to be susceptible to infection (see Table 1.3 for 
summary of many of these lines). The cell lines which are susceptible are not 
necessarily restricted to lineages associated with the lymphoreticular system or 
the nervous system (Vorberg, Raines et al. 2004). Cell lines which are 
susceptible to infection are not necessarily susceptible to multiple strains of 
Prion from within the same species (Milhavet, McMahon et al. 2000; Birkett, 
Hennion et al. 2001; Vorberg, Raines et al. 2004).  It is also noteworthy that 
there has been little success in infecting primary neurons which would have 
been a key model for study of infectious process.56
1.11.1.  Cell culture models supporting Prion replication
Oil
designation
Species of 
origin
Tissues of origin 
or cell type
TSE strain Comments
Neural cell lines
N2a
c-1300
N1E-115
N2a#58
GT1
HaB
MSC-80
Schwann cell
DRG
Mouse
Mouse
Mouse
Mouse
Mouse
Hamster
Mouse
Mouse
Ovine PrP in 
transgenic mouse
Non-neural cell lines
SMB  Mouse
L ffcroblast
L 23 
NS1
PC12 
Glial cell 
RK-13
Mouse
Mouse
Mouse
Rat
Rat
Rabbit
Neuroblastoma
Neuroblastoma
Neuroblastoma
Neuroblastoma
Hypothalamic neural cell 
Hamster brain cell line 
Schwann cell 
Schwann cell 
Dorsal root ganglia
Brain cells from 
mesodermal origin
Fibroblast
Unspecified
Fusing spleen cell from 
scrapie-infected mice 
with NS1  cell
Pheochromocytoma
Chandler
Chandler
Chandler
22l/Chandler/139A
22L/Chandler/139A
Hamster strain
Chandler
Scrapie
Natural sheep 
scrapie
Chandler
Chandler
Compton or C-506 
Chandler
139A/ME7
Glial cell monolayers from  Chandler 
rat Gasserian ganglion
N2a overexpressing up to 
6-fold higher level of PrPc
T-antigen immortalised cells
Spontaneously immortalised cells
Cells present chromosome 
re-arrangement and change in 
chromosome morphology
Kidney epithelial Natural sheep 
scrapie
In presence of low concentrations 
of nerve growth factor
RK13 cells express the ovine PrP
Table1.3  Summary of cell types utilised for the study of prion infection
Source of cell type, strain type with which they have been infected are also indicated. 
Table adapted from (Solassol, Crozet et al. 2003)57
Infected cell lines are created either by addition of infectious homogenates, by 
Scrapie associated fibrils (Race, Fadness et al. 1987), by cell culture derived 
homogenates (Bosque and Prusiner 2000) or cell co-cultures (Kanu, Imokawa 
et al. 2002). It has been argued that efficacy of infection in these model systems 
depends on the mode of infectious presentation either through cell contact, 
addition of cell homogenates, brain homogenates or conditioned medium from 
infected cultures (Bosque and Prusiner 2000; Kanu, Imokawa et al. 2002).
The de novo synthesis of PrPsc has been shown in cell culture systems though 
metabolic labelling (Caughey, Race et al. 1989) and also the use of tagged PrP 
molecules (Vorberg, Buschmann et al. 1999). The presence of PrPsc is 
established through the standard biochemical procedure of SDS-PAGE 
following Proteinase K treatment and ultracentrifugation of detergent lysates 
(see Fig 1.8.  ScN2a +PK lane)
PK -  PK +
Figure 1.8.  Assay for PrPc and PrP# c
Western blot of infected or uninfected ScN2a cells post treatment with Proteinase K (PK+) or 
without Proteinase K (PK-).  Adapted from (Solassol, Crozet et al. 2003)
Another technique has involved blotting following denaturation and this has 
demonstrated enhanced sensitivity over traditional western blotting techniques 
(Bosque and Prusiner 2000). There is no clearly established procedure for 
assessing whether a single cell, as opposed to a colony or dish, is infected. 
This is of particular importance given the consideration that when N2a cells are58
subcloned, not all colonies recovered are infected (Race 1991; Bosque and 
Prusiner 2000; Nishida, Harris et al. 2000).
It is unclear whether infection has a direct effect on most cell lines.  In the case 
of infected N2a cells which support expression of RML strain of Prion, there are 
no obvious changes in the cytosol (Butler, Scott et al. 1988). There have been 
reports of morphological differences following infection of N2a cell lines 
(Markovits, Dautheville et al. 1983) but equally these have been disputed 
(Borchelt, Scott et al. 1990). It is difficult to reconcile such claims given the 
expected differences in cell behaviours attributable to clonal variation.
Improvement in the initial infection of N2a’s has been obtained by 
overexpressing mouse PrP and this has also facilitated infection with other 
mouse strains (Nishida, Harris et al. 2000).  Differences of initial propensity to 
infection have also been improved by subcloning N2a cells to produce highly 
susceptible lines which can then be infected (Bosque and Prusiner 2000). 
Diagnostic models for highly sensitive determination of Prion infectivity have 
been been proposed which make use of cell culture, and offer sensitivity by 
quantifying colonies of cells which have been infected following addition of the 
material to be diagnosed  (Klohn, Stoltze et al. 2003). One limitation of these 
models in practice has been the limitation of the cell lines to infection by a 
narrow range of strains.
Other cell lines produced include GT1  cells which are a well differentiated 
neuronal cell line. Interestingly they have also been shown to demonstrate 
some cytopathological effects following infection (Schatzl, Laszlo et al. 1997) 
and Prion infection can impair their cellular response to oxidative stress 
(Milhavet, McMahon et al. 2000)
Schwann cell lines have  been used as a model for Prion infection for the 
chandler strain of Scrapie, which is of particular note given the potential role for 
schwann cells in spread of infection (Follet, Lemaire-Vieille et al. 2002)59
The Scrapie Mouse Brain cell line (SMB), represents an alternative approach to 
derivation of infected, uninfected cell line pairs. It is derived from a mouse 
initially infected with the Chandler isolate of Scrapie (Clarke and Haig 1970;
Haig and Clarke 1971). An uninfected cell line was then derived from SMB by 
curing with pentosan sulphate on multiple passage (Birkett, Hennion et al.
2001). The resultant cells, PS cells, could be re-infected with multiple strains as 
demonstrated by pathology and incubation time when inoculated into mice. 
Unpublished observations, consistent with the original findings following 
derivation of the cell line, indicate that the SMB cell line is amongst the most 
stable in maintaining its infectivity on multiple passage.
1.11.2.  Mutant PrP molecules in cell culture
Mutant PrP models, analogous to human disease in terms of sequence, have 
been constructed in cell culture.  These models have delineated important steps 
in the cell biology of familial Prion disease but they may also bring insight to 
some issues that are more generally relevant to Prion infection.  Mutant PrPs 
expressed in Chinese Hamster Ovary (CHO) cells and pulse labelled, have 
been shown to demonstrate a stage wise process in the acquisition of 
properties reminiscent of PrPsc as they are processed by the cell (Daude, 
Lehmann et al. 1997).  The steps in this pathway which have been delineated 
are the acquisition of PIPLC resistance in the ER, the acquisition of detergent 
insolubility (maximal 1  hour post-chase), and the acquisition of partial protease 
resistance  (maximal several hours post-chase) which is demonstrated after 
arrival of the protein at the cell surface. The model posits that misfolding occurs 
in the ER, followed by initial oligomerisation and then further aggregation at or 
beyond the plasma membrane. Further support for the role of the ER has come 
from immunocytochemistry and EM - disease associated mutations (e.g. P101L, 
D177N/M128) expressed in CHO cells are found to accumulate in the ER and 
are more weakly represented at the plasma membrane in comparison with wild 
type PrP molecules (Petersen, Parchi et al. 1996; Jin, Gu et al. 2000; Ivanova, 
Barmada et al. 2001).60
Studies have also indicated a delayed maturation of mutant PrP molecules 
which leads to the delay in transiting the ER (Drisaldi, Stewart et al. 2003).
One upshot of this body of  work is the possibility that ER retention, as with 
some other human disorders, may be responsible for a component of toxicity in 
familial Prion disease (Aridor and Balch 1999).
1.11.3.  Insights into Prion transfer from culture models
The mechanism/s for transfer of Prion between infected and non infected cells 
remain undetermined although cell culture models have been employed in the 
assessment of mechanisms for intercellular transfer.  In the SMB/PS system 
described above one study (Kanu, Imokawa et al. 2002) has demonstrated that 
cell co-cultures can efficiently transfer infectivity and argues for the necessity of 
cell contact for Prion transfer. In support of this study, further elucidation of a 
possible transfer mechanisms has been indicated by work which demonstrates 
that PrP, like other GPI anchored proteins, may  be transferred by a ‘cell 
painting’ mechanism (Liu, Li et al. 2002). The transfer elicited required cell 
contact but efficient transfer also required prior treatment of cell donor or 
acceptor cells with Phorbol Myristate Acetate. These two studies contrasts with 
other systems such as GT 1  cells where cell culture medium has been found to 
contain infectivity (Schatzl, Laszlo et al. 1997) and studies in Scrapie infected 
rabbit epithelial cell lines (ROV) expressing ovine transgenes (Fevrier, Vilette et 
al. 2004).  Infectivity derived from media of infected cultured ROV cells can be 
found to co-purify through differential centrifugation, with membrane material 
along with exosomal markers.  The implication of this is that exosomal release 
of Prion may constitute one mechanism for infectious transfer and this work 
tallies with other recent studies on transfer of GPI anchored proteins which 
suggest vesicular release as a form of transport (Thery, Zitvogel et al. 2002). It 
is conceivable that multiple mechanisms for transfer exist both within one cell 
type and multiple but distinct mechanisms between cells types. Therefore the 
above studies may not be in contradiction with one another.
One potential means of transferring infectivity might be a templating that occurs 
across membranes between PrPsc molecules of an infected cell, and PrPc61
molecules of an uninfected cell. In vitro models utilising microsomal membranes 
which represent the opposition of the molecules at the cell surface demonstrate 
that templating does not occur and that fusion of membrane surfaces is needed 
in order for conversion to take place (Baron, Wehrly et al. 2002; Baron and 
Caughey 2003). These studies are however in artificial systems and it remains 
to be determined what relevance they have to the structure and dynamics of the 
membrane surfaces of cultured cells.
1.12.  Progression of Prion disease and Pathogenesis
In animal models infection in the fastest possible time is achieved via 
intracerebral inoculation with an infectious source of Prion. Other routes include 
feeding, intravenous and intraperitoneal injection, intra ocular injection and 
grafts. There is a long latency between peripheral infection and the clinical 
symptoms of Prion disease and a large proportion of the incubation period is 
taken up by the agent gaining access to the central nervous system from the 
periphery (Aguzzi 1997).
1.12.1.  Peripheral entry site for Prion
In the distal ileum there is an early rise in Prion infection following oral challenge 
in sheep and cows (Wells, Dawson et al. 1994; Terry, Marsh et al. 2003) and in 
particular Peyer’s patches accumulate Prion protein. This is also true in the 
case of mouse models of Scrapie infection. The hypothesis suggested is that 
Peyer’s patches are important sites in the transit of orally ingested Prion from 
the luminal side of the gastro-enteric tube to the CNS.
The identity of cells which might transport Prion from the intestinal mucosa to 
the Peyer’s patches remains unclear. One candidate cell type has been the 
Membranous epithelial cell (M-cell) which has been shown to be a key sites of 
entry for enteric pathogens via trans-epithelial transport (Neutra, Frey et al.
1996)  and M-cells were demonstrated to be sufficient for the passage of Prion 
across barriers in cell culture-models (Heppner, Christ et al. 2001).62
1.12.2.  Prions and Lymphocytes
Prion replication in lymphoid tissues may represent a necessary part of Prion 
pathogenesis and  studies interfering with lymphoid Prion replication have led to 
delay or prevention of disease (Aucouturier, Geissmann et al. 2001; Huang, 
Farquhar et al. 2002).  Peripheral pathogenesis of Prion disease is dependant 
on Lymphocytes in contrast to CNS progression which is not (Kitamoto, 
Muramoto et al. 1991; Lasmezas, Cesbron et al. 1996). Ablation of the T-cell 
compartment did not affect disease progression, whereas ablation of B-cells did 
affect progression (Klein, Frigg et al. 1997). However, Prion invasion occurs 
even when the B-cells have been transferred from PrP knockout mice to B-cell 
deficient mice (Klein, Frigg et al. 1998). The implication is that the presence of 
B-cells is a requirement for another cell-type to mediate infectious progression.
The leading candidate cell for mediation of the progression has been the 
follicular dendritic cell (FDC).  Lymphocytes do not appear to carry a large 
amount of Prion infectivity themselves and the infectivity in the spleen resides in 
a stromal fraction (Aguzzi 2003).  The contribution of  FDCs to Prion 
pathogenesis is to some extent difficult to understand fully because specific 
markers have not been clearly defined for these cells. Elegant experiments 
have made use of the gene deletion results in mice which demonstrate that B- 
cell signalling via Lymphotoxins is required for FDC maturation and 
maintenance. (Koni, Sacca et al. 1997; Endres, Alimzhanov et al. 1999). 
Signalling thorough the Lymphotoxin- a/p complexes which bind to the LT-a/p 
receptor activates the pathway for development of FDCs and maintenance of 
FDCs in a differentiated state requires continuous interaction with B- 
lymphocytes expressing surface LT- ap (Gonzalez, Mackay et al. 1998). 
Treatment of mice with LT- p receptor immunoglobulin fusion protein leads to 
the death of mature FDCs within a day in both the spleen and the lymph nodes 
(Crowe, VanArsdale et al. 1994; Mackay, Majeau et al. 1997; Mackay and 
Browning 1998). This effect was used in ablation experiments to asses the 
contribution of FDCs to pathogenesis in Prion disease. FDCs were depleted by 
administration of LT-p -Ig fusion protein. Following inoculation with Scrapie, the 
mice were free of any  PrPsc in the spleen up to 8 weeks later (Mabbott, Mackay63
et al. 2000; Mabbott, Young et al. 2003). Usually following peripheral inoculation 
the spleen demonstrates infectivity within a few days and peaks in a few weeks 
(Bruce 1985).  These experiments also demonstrate the potential for FDC 
depletion as a strategy in post-exposure prophylaxis of Prions for people 
working in fields with Prion material.
1.12.3.  Prion entry into the nervous system
One key model for Prion neuro-invasion delineates two stages involving 
infection of  Lymphatic systems followed by neuroinvasion (Aguzzi, Montrasio et 
al. 2001).  The autonomic nervous system may be responsible for transport of 
Prion from lymphoid tissues to the CNS and the innervation of lymphoid organs 
is mainly sympathetic (Felten and Felten 1988; Felten, Felten et al. 1988). 
Sympathectomy itself delays the transport of Prion from lymphatic organs to the 
thoracic spinal chord (Glatzel, Heppner et al. 2001) and transgenic mice, with 
hyperinnervated spleens, develop Scrapie significantly faster than controls 
(Glatzel, Heppner et al. 2001). It is interesting that the variation in proximity of 
FDCs to the  major splenic nerve alters the efficacy of Prion neuroinvasion 
although contact does not appear to be made between them (Prinz, 
Heikenwalder et al. 2003).
The velocity of Prion transport through peripheral nerves is slow (~1mm per 
day), and it is unclear how this transport occurs (Kimberlin, Hall et al. 1983). 
Spread may occur through axonal or non-axonal means of transport. It is 
however unlikely that fast-axonal transport is responsible for the spread given 
the kinetics and also the finding that in mice with a deficiency in fast axonal 
transport there is little perturbation in Prion infection (Kunzi, Glatzel et al. 2002).
One alternative model to axonal transport is a mechanism which involves 
conversion of PrPc by adjacent PrPsc molecules in a domino fashion along 
axons. The propensity of Schwann cells for infection might be suggestive of a 
domino like route for such transport in the PNS (peripheral nervous system) 
without reference to axons. This could be tested by reference to a mouse in 
which PrP knockout is specifically targeted in Schwann cells.64
1.12.4.  Spread of Prion within the CNS
The spread of Prion has been investigated in the CNS by means of Ocular 
injection of Prion which leaves the blood brain barrier intact. It was initially 
assumed that the spread along the retinal pathway following intra-ocular 
injection of Prion occurred via axonal transport (Fraser 1982). This was further 
explored with respect to PrPc dependence for transmission along this route. In 
one study PrP expressing neural grafts were used as indicators of Prion 
infectivity in the brain of a PrP knockout mice. Following intra ocular injection of 
PrPsc in PrPc deficient hosts no Scrapie was seen in neurons (Brandner, 
Isenmann et al. 1996). Therefore when the chain of PrP is interrupted it appears 
that intra-cerebral spread is not possible. It might be that PrPc is required more 
specifically for propagation between synapses  (Collinge, Whittington et al. 
1994); alternatively a clear path from PrPc molecule to PrPc molecule may be 
necessary to create a domino effect (Aguzzi, Blattler et al. 1997).
1.13.  Neuropathology
The cell types necessary for transmission and mediation of pathogenesis are 
unclear. In a mouse model in which  PrPc expression is restricted to Astrocytes 
(Raeber, Race et al. 1997), Prion disease progresses normally in the transgenic 
mice and this inveighs against the notion that neurons expressing PrPc are 
necessary for pathogenesis. Whether this implicates Glial cells as a central 
means of transmission in Prion disease in general is unclear because in 
neurons where depletion of PrPc is targeted following infection it is apparent that 
spongiform changes are reversible (Mallucci, Dickinson et al. 2003).
The necessity of PrPc in Prion disease is most clearly evidenced with reference 
to the PrP knockout mice which do not show neurotoxicity or any development 
of Prion disease following inoculation with Prion. One obvious hypothesis would 
be that  PrPsc is the toxic species which requires PrPc to replicate.  PrPsc toxicity 
has been assessed independently by introduction of neurografts which express 
prp, into knockout mice and then inoculating with Prion (Brandner, Isenmann et 
al. 1996). The grafts replicate and accumulate PrPsc and substantial quantities65
of PrPsc are also delivered into the host brain. In these cases clinical disease is 
not elicited and neuropathology is not present, indicating that PrPsc alone is 
unlikely to be the toxic species. Prion diseases where PrPsc is not readily 
detectable also present a challenge to the hypothesis that PrPsc is the key 
molecule in pathogenesis (Hegde, Mastrianni et al. 1998; Manson 1999)
The finding that PrPsc is cytotoxic only in the presence of PrPc has been 
supported in studies which demonstrate that a PrP peptide 106-126 which is 
toxic to cultured neurons from mouse brain is not toxic when the neurons do not 
express PrPc  (Forloni, Angeretti et al. 1993; Brown, Herms et al. 1994).
Hypotheses connected with mechanisms of cell death have focussed largely on 
issues concerning neuronal health.  Apoptotic cell death has been described in 
various cell culture systems (Kretzschmar, Giese et al. 1997) and in vivo 
(Giese, Groschup et al. 1995; Gray, Adle-Biassette et al. 1999). Hypotheses 
which have been suggested for apoptosis have included oxidative stress 
(Milhavet and Lehmann 2002) and microglial mediated damage (Betmouni, 
Perry et al. 1996).  One further hypothesis which has been discussed above, 
implicates a particular species, ctmPrP, in the process of disease. Although 
there is little evidence for ctmPrP as a significant species in normal disease, 
models of this sort are suggestive of the possibility of alternate PrP species 
which might be toxic and perhaps stimulated by PrPsc.
1.14.  Prion therapeutics
Prion has been cleared from cell culture models by polyionic compounds 
(Caughey and Raymond 1993) Congo red (Caughey and Raymond 1993), 
Amphotericin B (Mange, Nishida et al. 2000) Aporphyrins (Caughey, Raymond 
et al. 1998) and Quinacrine (Caughey, Raymond et al. 1998).  Most of these 
compounds have proven to have little effect on incubation period in vivo.
One means of preventing infection is the use of PrP antibodies in order to 
perturb new conversion of PrPc to PrPsc. In cell culture models several studies66
have demonstrated the ability of antibodies to clear infectivity. (Enari, Flechsig 
et al. 2001; Peretz, Williamson et al. 2001; Gilch, Wopfner et al. 2003). 
Transgenic mice which express anti-PrP mu chains are also protected against 
peripheral Prion infection. In another study mice previously infected with Prion 
were immunised with anit-PrP monoclonal antibodies. PrPsc levels in the 
spleens of  the mice were reduced significantly and animals remained healthy 
for long extended periods after controls had died from the disease (White, 
Enever et al. 2003). Attempts to extend this technique to the CNS have proven 
unsuccessful and intra-cerebral injection of anti PrP antibodies causes 
considerable neuronal apoptosis (Solforosi, Criado et al. 2004).  Active 
immunisation as an approach is at present also limited by the self-tolerance to 
PrP although some studies have shown modest effects (Sigurdsson, Brown et 
al. 2002; Schwarz, Kratke et al. 2003).
Work has already been described which provides biochemical means of 
blocking peripheral Prion replication and subsequent neuroinvasion. 
Administration of lymphtoxin receptor-IG fusion protein neutralises the 
lymphotox -B-receptor and thereby prevents FDC maturation.  This process 
prevents Scrapie neuroinvasion following intraperitoneal Scrapie infection but is 
not helpful in the case of intracerebral infection (Mabbott, Mackay et al. 2000; 
Montrasio, Frigg et al. 2000; Mabbott, Young et al. 2003).
One further possible intervention is the use of antibodies against PrPsc, which 
might halt the spread of disease by inhibiting further replication of Prion and 
allowing cell clearance of existing disease agent.  An antibody with specificity 
for PrPsc was formed by immunisation with  a Tyrosine-Tyrosine-Arginine 
containing PrP peptides in animals expressing endogenous PrP and clearance 
of PrPsc using these antibodies was demonstrated in a cell culture model 
(Paramithiotis, Pinard et al. 2003).67
1.15.  Rationale for experiments of this thesis
The subject matter for the thesis below falls broadly into two categories. The 
first, and the smaller body of work, represents an attempt to consider the effect 
of glycosylation on infection.  The identification of glycosylation with strain type 
has been a key argument in the identification and alignment of vCJD with BSE 
(Collinge, Sidle et al. 1996).  Work has been undertaken to assess the 
preservation of glycotype properties in culture as a key means of understanding 
how this feature of Prion disease is propagated and how the glycoform profile is 
determined (Birkett, Hennion et al. 2001; Vorberg and Priola 2002).
The agent tunicamycin has been employed as a means of perturbing the 
glycosylation profile of PrPc and consequently PrPsc in cells.  The purpose of 
these experiments is to ascertain to what extent glycosylation, particularly of 
PrPsc, directs the infectious process.  Two null hypotheses tested include a) that 
PrPsc synthesis is disproportionately determined by the abundance of the 
unglycosylated PrPc species and b) that PrPsc glycosylation is necessary for 
transmission and recovery of glycosylation profile.
The second part of the thesis is centred on the use of GFP fusion proteins, as a 
means of tracking the dynamics of both PrPc and, potentially, PrPsc. The rational 
thrust of these experiments issues from two sources: firstly, there is at present 
no single cell assay, and no subcellular assay, for Prion and secondly, very little 
is understood about the dynamics of the PrPc/ PrPsc cellular system.  The use of 
GFP fusion proteins over the time periods required for the studies described 
below is a risky and speculative process.  It pushes the limits of current 
technology in microscopy, a time and resource intensive endeavour requiring 
the creation and refinement of a new microscopy system. It also speculates on 
the potential observability of the relevant events at the required resolution and 
whether the C-terminal portion of the fusion proteins (PrPc) is converted to 
PrPsc. Clarification is provided for the merits of this approach to address issues 
of Prion infection and how such approaches might be improved in the future. In 
particular hypotheses relating to Prion biophysics are addressed which relate to 
the transfer of infectivity and diffusion of Prion protein in the plasma membrane.68
Chapter 2  Materials and Methods69
2.1.  Molecular Biology
2.1.1.  Standard protocols employed for molecular biology
2.1.1.1.  PCR (polymerase chain reaction)
0.5uM of each primer and 0.2mM dNTP mix were used unless otherwise stated. 
Magnesium was provided by the Taq PCR buffer and Taq enzyme was used 
following manufacturer’s instructions (Invitrogen).  Plasmid DNA was used as a 
template in a reaction following a standard PCR programme:
1)95°C  2 minutes
2) 95 °C  30  seconds
3) Annealing temperature  30  seconds
4) 72 °C  extension time
5) Go back to step 2, repeat 29 times
6) 72 °C  10  minutes
7) 10 °C  HOLD
The annealing temperature used was 1  °C lower than the lowest melting 
temperature of the primers.  Generally, 10ng of DNA template was used per 
PCR.  PCR products were checked by gel electrophoresis, purified using 
Qiaquick gel extraction kit (Qiagen) and sequenced (MWG Biotech).
2.1.1.2.  Restriction digestion and ligation of DNA
Unless otherwise stated, 1pg DNA was digested using 5 units of restriction 
enzyme (New England Biolabs) at 37°C for  2 hours. Digests were run on 
agarose gels and the DNA cleaned using Qiaquick gel extraction kit (Qiagen). 
Ligations were carried out using T4 DNA ligase (Invitrogen) according to 
manufacturer’s instructions.
2.1.1.3.  Preparation of DNA
Epicurian Coli, XL2 Blue Ultra competent cells (Stratagene) were used for 
transformation following manufacturer’s instructions). Approximately 50ng of 
DNA was used for each transformation  The PIAH vector was ampicillin70
resistant. All other vectors described in this thesis have a backbone including a 
kanamycin resistance gene.  The concentration of ampicillin used for agar 
plates was 50pg/ml and for kanamycin plates was 30pg/ml.
Maxi preps and mini preps were carried out according to manufacturer’s 
instructions (Qiagen). Briefly, alkali lysis of bacteria was followed by DNA 
separation using the column provided in the kit. Plasmid DNA was then eluted 
in salt buffer and precipitated using isopropanol.
DNA concentration and purity was determined by taking the A260/A280 ratio (a 
value of 1.8 was taken as ideal for the ratio).
2.1.2.  Generation of constructs: GFP in fusion with PrP, DsRedll in fusion 
with PrP and 3F4 mutant fusion
The fusion constructs were generated as two separate parts which were 
independently cloned into the vector providing the fluorescent tag.
The signal peptide of the mouse protein was indicated by the previous, 
successful design on which the construct is based (Lee, Magalhaes et al. 2001) 
and cross checked with reference to Signal IP, a bioinformatics online tool 
(http://www.cbs.dtu.dk/services/SignalP).
The signal peptide of mouse PrP (amino acids 1-22 inclusive) was generated by 
PCR from the plAH vector (a kind gift from Dr Chris Birkett, IAH) using forward 
(TCCACCGGTTCTGCCGCCACCATGGCGAACCT) and reverse 
(CAGACCGGTGCGCAGAGGCCGACATCAGTCC) primers.  The primers 
introduced an Agel site which was used to clone the signal peptide upstream of 
GFP in the pEGFPC3 vector (Clontech). The C-terminus of PrP was also 
generated by PCR from the PlAH vector using forward 
(GCCCTCGAGAAAAAGCGGCCAAAGCCT) and reverse 
(GCCCTCGAGTCATCCCACGATCAGGAA) primers which introduced an Xhol 
site at each end.  The fragment was cloned in-frame into pEGFPC3-Prp signal 
peptide using the Xhol site downstream of the GFP.71
The signal peptide for the DSRed fusion was similarly generated by PCR and 
cloned into the Agel site upstream of the DSRedll vector (Clontech).  DsRedll is 
a mutant of the original DsRed protein designed to decrease oligomerisation. 
The C-terminus of PrP was generated by PCR from the PlAH vector using 
forward (CGTGAATTCGAAAAAGCGGCCAAAGCCT) and reverse 
(CGTGGATCCTCATCCCACGATCAGGAA) primers which introduced an 
ECoRI and Bam HI site respectively.  These sites were used to clone the C- 
terminus into the DSred2-signal peptide vector downstream and in-frame with 
the DSRed.
2.1.3.  Site-directed mutagenesis to generate the 3F4 epitope
Leu1 08  and Val1 1 1  of mouse PrP were each mutated in the context of the GFP- 
PrP construct, to Methionine residues to generate the 3F4 epitope.  The Quick- 
Change Site-Directed Mutagenesis kit from Stratagene was used and 
manufacturer’s instructions were followed.  Briefly, forward 
(CCAAAAACCAACATGAAGCATATGGCAGGGGCTGCGGCA) and reverse 
(TGCCGCAGCCCCTGCCATATGCTTCATGTTGGTTTTTGG) primers each 
containing three point mutations (indicated in bold) were used in a circular PCR 
to generate a mutated plasmid with nicked staggered ends.  17 PCR cycles 
were performed, as recommended by the manufacturer.  Parental DNA was 
digested using Dpnl and the mutated, nicked plasmid transformed into XL-1 
blue super competent cells (Stratagene) which repair the nicks.
2.1.4.  Other vectors employed
GFP-GPI was kindly donated by Kai Simons. It contains an EGFP (Enahnced 
Green Fluorescent Protein) fused at the C-terminus to a GPI anchor sequence 
(of lymphocyte function associated antigen 3 (LFA-3)) and at the N-terminus to 
a signal sequence of lactase phlorizin hydrolase (Keller, Toomre et al. 2001).
CFP (cyan fluorescent protein) PrP was kindly donated by Nnenna Kanu.  This 
vector shares the same basic design with the GFP-PrP fusions, i.e. the signal72
peptide of PrP is placed N-terminally to CFP and the remainder of PrP is placed 
c-terminal to CFP.
It was employed to ensure that the specific linker added between the 
fluorescent protein and the PrP C-terminus was not responsible for cleavage. 
The difference in linker is illustrated in bold (KKRPK marks the start of the PrP 
c-terminal portion of the fusion proteins).
PrP-GFP junction (linker in bold):
K  YSDLEKKRPK
PrP-CFP junction (no linker):
K ---------------K K R P K
Zsgreen (Proteasome sensor vector: Clontech) is a vector which encodes a 
destabilized green fluorescent protein (ZSGREEN) in fusion with a degradation 
motif for removal by the 26S proteasome.
2.2.  Cell culture
2.2.1.  Cell transfection
Cells were plated onto 35mm dishes, 24 hours prior to transfection, at 
approximately 50% confluence.  Cells were transfected with cDNAs using Gene 
Juice (Novagen) following manufacturers specifications for all procedures. For 
each 35mm dish 1pg cDNA was used with 3pl of gene juice mixture. Media was 
changed 1  day post transfection.
2.2.2.  Cell lines and cell media
SMB cells were produced by culture of brains from mice infected with the 
Chandler scrapie isolate (Clarke and Haig 1970; Clarke and Haig 1971).
Scrapie mouse brain cells (SMB) cells and Pentosan sulphate (PS) cells were73
obtained from Dr C. Birkett, I.A.H. Compton.  PS cells were produced by curing 
of SMB cells with pentosan sulphate(Birkett, Hennion et al. 2001).  Cells were 
grown on plastic culture flasks for all passaging and experiments unless 
otherwise specified.  Media employed were M199 (M199 Gibco, BRL),  with 5% 
new Foetal calf serum (Firstlink Foetal calf serum)  and 10% New born calf 
serum  (GibcoBRL (Invitrogen post takeover), New born calf serum), penicillin 
50i.u./ml (Sigma), streptomycin 50pg/ml (Sigma).  Cells were grown in a 
humidified incubator at 37°C and 7.5% C02.  Cells, for the purpose of ordinary 
passage, were split with a ratio of 1:3 approximately every 7 days.
These media were employed for all experiments described in chapter 1. 
However, it was advised, (pers comm. Telling group, Kentucky) that problems in 
these cell lines with transfection efficiency and selection could be ameliorated 
by growth in DMEM (Dulbecco’s modified Eagle’s medium) rather than M199. 
Therefore cells described after chapter 1  are grown in the recommended 
medium: DMEM (DMEM Gibco BRL), with 10% new Foetal calf serum (Firstlink 
Foetal calf serum).
2.2.3.  Cell lines expressing fusion protein
Initial attempts at cloning cells met with failure. Even attempts to grow cells at 
low density, e.g. 1:50 split (not clonal dilutions) died. Higher ratios of split (e.g. 
1:10) produced groups of cells in relatively isolated clumps which could be 
taken with cloning rings, but it was clear that these cells did not themselves 
represent clones.  As described in chapter 4, attempts in the laboratory to 
overcome these difficulties including the use of conditioned media, transfection 
with large T antigen, and feeder layers have previously not been successful.
Therefore a recommended bulk selection procedure was employed.
To produce cell lines expressing fusion proteins, cDNA was transfected using 
the gene juice reagent as described (see below).  Media were changed the day 
after transfection and cells permitted to grow to confluence. Cells were then split 
at 50% confluence and 0.5mg/ml of neomycin was added to begin selection. 
Cells were kept in the selection media and split at 1:4 for the next passage.
Cells were split as normal thereafter but kept in selection medium for at least 374
weeks (from initial addition).  Cells froze and thawed with the same kind of 
efficiency as regular PS cells and therefore in general cells were frozen at low 
passage and not grown beyond p20 before revival of the lower passage cells.
2.2.4.  Preparation of culture materials by lysis
Cell were lysed in cell lysis buffer (see below) following removal of media and 
washing 2x in Hank’s balanced salt solution (HBSS : Invitrogen, Gibco BRL) or 
Phosphate buffered saline without calcium (Invitrogen, Gibco BRL) depending 
on whether the samples were cultured in M199 or DMEM respectively.  In 
general a 162 cm2 black cap flask was lysed in 1.5 ml of buffer.  Samples were 
then frozen at -20°C prior to analysis.
2.2.5.  Preparation and infection with dead cell freeze-thaw lysates
A confluent flask, 162 cm2 of the desired cells was washed in PBS (Gibco BRL) 
twice and subsequently, all liquid was carefully removed to ensure volume was 
minimised.  Cells were then lysed in a further 1ml of PBS by scraping the 
bottom of the flask.  The resulting cell mixture was then mixed thoroughly by 
vortexing and pipetting.  The material was passed 3 x through a 19 gauge 
syringe needle and was then put through 4 cycles of freezing in liquid nitrogen 
and thawing at 37°C.
Infection was carried out in 25 cm2 flasks, in which cells were grown to 50% 
confluence.  A third of the total homogenate produced from the SMB/PS culture 
was used for an infection to create the paired cell lines. (This was slightly 
different in the Tunicamycin treated cases as described below).  It was added to 
new media and pipetted thoroughly. The media containing the dispersed 
homogenate was then placed onto the cells and the cells left for 3 days.  Media 
were then changed and the cells were left for a further 1  day prior to splitting, 
and expansion, as normal.75
2.2.6.  Treatment with Tunicamcyin
Tunicamycin (Sigma) was prepared in 75% methanol and added to culture 
flasks after a change of media as the experiment required. Tunicamcyin was 
always added to confluent cells at 1  or 10pg / ml as specified. In general, after 
treatment for a period of 48 hours or greater, cells appeared refractory and 
some death occurred. Therefore careful handling of cultures for lysis was 
necessary to keep cells adherent to the flasks prior to lysis.
For the experiments which required production of freeze-thaw lysates from 
Tunicamcyin treated cells, 2 x 162 cm2  flasks were used. Samples were 
normalized for total protein using the BCA assay (Bicinchoninic acid protein 
assay; see below) and then were adjusted appropriately for comparison with the 
control samples prior to infection.
2.2.7.  Biotinylation protocol (Walmsley, Zeng et al. 2001)
Cells were incubated at confluence, with 0.5mg/ml of Sulpho-NHS biotin, for 30 
minutes at 0 degrees C.  Cells were then washed 3x in 50mM glycine to absorb 
unreacted biotin.  Cells were then lysed in cell lysis buffer and incubated with 
strepatavidin coated beads (Dynal Biotech -  dyna bead M280 streptavidin) 
according to the manufacturers specifications. Briefly:  Two black caps 
(162cm2) were used for each condition. 50 pi of bead suspension at (6.7  x108  
beads /ml)  was used per ml of lysate.  Following resuspension of  beads that 
had been incubated overnight with the samples,  10 % was removed for PrPc 
analysis (re-suspended in sample buffer, boiled, supernatant taken for western 
blotting) and 90% was re-suspended in lysis buffer and digested with 
Proteinase K, supernatant taken, and processed for PrPsc thereafter as normal.
2.2.8.  PIPLC treatment to cleave GPI anchored fusion protein
Cells were cultured on cover slips coated with laminin (sigma) at 20pg/ml until 
confluence was reached. They were washed in PBS and placed in L-15 medium 
without serum but containing PIPLC (ICN) at 2units /ml, for 1   hour at 4° C. 
Control cells had no PIPLC added over this period.76
2.2.9.  Preparation of cells for Microscopy
2.2.9.1.  Time-lapse
Glass bottom dishes (35mm dishes with 14mm glass insert Matek U.S.) were 
coated with laminin 20pg/ml (Sigma) for 1   hour. They were washed in PBS and 
finally in medium prior to addition of cells.
Depending on the configuration desired cells were split in different ways.
For example the configuration of cells depicted in results Chapter 5 Figures 5.3, 
cells were split  so that the majority cell line would be at 50 % confluence. The 
minority indicator cell line was split at 1:100.  Prior to plating, the cells were 
mixed by pipetting. For time-lapse on mobile cell populations cells were split at 
1:10 or 1:8 and mixed with their co-culture partner to a final confluency of 1:5 or 
1:4.  The cells were cultured in normal medium until the desired density and 
then removed to the time-lapse apparatus after changing into a non carbonate 
buffered medium Leibowitz  L-15 (Gibco), with the same constituents as the 
normal DMEM complete medium.
Initially cells were counted for the purposes of controlling for differences in 
density that might arise between experiments. However, it proved more 
accurate to split the cells from confluence to an appropriate density in order to 
arrive at the desired configuration for microscopy.
2.2.9.2.  Preparation of cells for Immunocytochemistry
Cells were split onto cover slips that were sterilised and pre-treated with laminin 
(20pg/ml; Sigma) in the same manner as the glass bottom dishes.  They were 
then placed in 4 well dishes and cultured in the usual manner until required for 
further analysis.
2.2.9.3.  Preparation of cells for Confocal microscopy
For use of an upright confocal, cells were grown on glass slides in wells defined 
by silicone gaskets (Multi-well system: Molecular Probes), which were coated77
with laminin 20pg/ml. The cells were washed and placed in L-15 media prior to 
microscopy and kept at 37°C.
For the confocal on the Zeiss LSM microscope, an inverted microscope, well 
glass bottom chambers (Nunclon) were coated with laminin and the cells 
cultured as normal until required. They were then transferred to L-15 media.78
2.3.  Microscopy
2.3.1.  Time-lapse microsocopy
camera
Heated lid (cells place under this)
Figure 2.1.  Time-lapse apparatus.
A)  The  time  lapse  set  up  is  indicated  in  broad  overview,  with  the  full  termperature 
controlled chamber in  place over the inverted  microscope. An anti-vibration table was 
added in order to help maintain focus.
B)  The motorised stage is visible from this angle more clearly. This was used primarily by 
the  newt  research  group  but  could  potentially  be  useful  for  studies  of  infected  cell 
behaviour at lower resolution. Note the circular heated lid (red wire is connected to it). 
Condenstation does not form and obstruct the camera path above the dish.  Cells are 
fixed into a metal ring with lens in place, and left to equilibrate for at least an hour to test 
whether focus is maintained before continuing with time-lapse observations.
(Digital Images kindly given by Amy Duckmanton)
Stage  Anti-Vibration
Table
Motorised Stage
xenon lamp
CCD camera 
control
CCD
stage control79
Over a 4 year period, a time-lapse system has been developed to permit the 
maintenance, in a controlled environment, of mammalian cells.  Fig 2.1 shows 
the Zeiss Axiovert S100 inverted microscope, with Orca ER, camera for 
acquisition and the surrounding temperature control environment. Also included 
in this picture is the motorised stage which was used extensively for 
regeneration studies. Motion of this stage caused a total loss of focus when 
used with an oil lens.
Most of the images described in chapter 5 were taken with a 40x neofluor oil 
lens, and cytoplasmic cells were imaged with a 20x apochromat lens.
The dish is secured at the centre of the stage. The securing ring contains a 
groove in which water is placed in order to ensure humidification. On top of this 
ring a heated lid is placed which ensures that condensation does not obscure 
the camera’s path and that drips of liquid do not affect the focus.  Fluorescent 
images were captured using the cooled digital cameral, Orca ER, 
(Hammamatsu).  The software employed for control of the microscope set up 
was Image Pro plus with the additional integrated AFA ( automatic fluorescence 
acquisition) module.  Images were captured every 15 minutes, using 2x binning 
setting in order to maximise the trade off between image quality and cell 
damage caused by exposure to U.V.  The U.V radiation was produced by a 
75W xenon lamp (Carl Zeiss). Originally a mercury lamp was employed but the 
xenon lamp provided a better trade off between image resolution and cell 
bleaching/survival because it produces a level intensity across the spectra 
rather than the higher peaks of intensity of the mercury emission spectrum. 
Filters were designed so that the emission signal was filtered to separate 
DsRed (Discosoma red) and GFP emissions: GFP filter (525/40nm Chroma 
technologies) and a DsRed filter  620/40mn (Chroma technologies)  A single 
exciter was used on the excitation filter wheel, and Images were acquired using 
different emission wheel positions (for the two filters) in 12 bit grey scale mode 
and then pseudo colour added during image processing to highlight the different 
channels.
Preparation for time-lapse included a process of equilibration; first,  equilibration 
of the  equipment at 37°C, and then the sample on the glass bottom dish which80
is ideally equilibrated overnight or for a minimum of 1   hour in order to ascertain 
whether focus drift is likely to occur.
2.3.2.  Microscopy for immunocytochemical studies
Imaging of cells following immunocytochemistry were taken on a Zeiss axioplan
2 upright microscope using a CCD camera (Axiocam HRC Zeiss), co-ordinated 
with the Zeiss Axiovision software.  For visualisation of the GFP signal the FITC 
(fluorescein isothiocyanate) filter set was used and for visualisation of the 
TRITC (tetramethyl rhodamine isothiocyanate) secondary antibody a Texas red 
filter set was employed.  Images were taken using a 63x oil objective.
2.3.3.  Use of confocal for FRAP (fluorescence recovery after 
photobleaching) measurements
2.3.3.1.  Experimental set 1
A Biorad radiance 2100, an upright confocal, was used at the Laboratory for 
Molecular Cell Biology, UCL.  Cells were prepared on multi-well chamber glass 
cover slides (for use with an oil lens) as described, or on glass bottom dishes 
(Matek) for use with a 40x water immersion lens. They were kept at 37°C by 
placing them on a heated tray with a glass base. The system suffered a lot of 
drift and the torsion was placed at maximum on the z-stage in order to minimise 
this effect.  Using the Laser sharp 2000 software package, cells were initially 
imaged at low intensity (4% of the maximum laser intensity) and a bleach box of
3 microns and a control box surrounding the cell were defined. The pin hole 
aperture was opened fully for FRAP measurement on this set up in order to 
minimise the effects of focus drift. Images were taken as 512x512 resolution. 3 
prescan images were taken at 4% laser intensity, 5s apart and then 15 bleach 
scans at 100% intensity, the pinhole was then opened fully and intensity 
changes measured at 4% laser intensity, scanning every 5 seconds. 
Experiments were ended when there appeared to be no more change in either 
the bleach box or the control box intensity values,  or when focus was lost.81
2.3.3.2.  Experimental set 2
Imaging was carried out using an inverted confocal microscope (LSM 510; Carl 
Zeiss Inc) at the London School for Hygiene and Tropical Medicine 
Fluorescence excitation was achieved for GFP using the 488 nm laser line.
Cells prepared on 6 well glass slide chambers (Nunclon) and were placed in a 
temperature controlled environment surrounding the microscope set up at 37°C. 
Images were taken using a 40x plan neofluar objective  (1.3NA).  The confocal 
pinhole was set at 1  Airy unit.
Bleach and control  boxes were defined as described above but the width set to 
1pM for the bleach region. 3 prescans were taken, at low laser intensity. 
Photobleaching was achieved with 10 scans at full power.  Recovery was 
measured every 0.4s.
2.3.3.3.  Data analysis of FRAP experiments
Data was transferred to excel spreadsheet format.  A programme was written in 
Matlab in order to a) normalise the data  and b) find the diffusion coefficient. 
The steps in the programme (see appendix) to process the data from the bleach 
strip in which recovery occurred were as follows:
Input the data from each spread sheet into the programme vector 
representations ->  normalise all bleach recovery (post bleach measurement) 
values by dividing by their corresponding control box time point value -> 
renormalize to zero by subtracting the initial value post bleach from all recovery 
values ->  calculate the diffusion coefficient by fitting this data to the equation 
for 1  dimensional diffusion:  gives the parameter D 
-> Finally the programme compared all the recovery values to a prebleach 
mean value and plotted the data.  From this the immobile fraction was also 
calculated as the difference between the asymptotic value of the recovery and 
the prebleach value.  NB: the crucial piece of data was the shape of the 
recovery curve -  from this the diffusion coefficient in pm2/s could be calculated.82
2.4.  Biochemistry
2.4.1.  Processing for analysis of PrPscand PrPc
Following lysis of a 162 cm2 flask in lysis buffer (see buffers below) nuclei are 
removed by centrifugation at 1000g, 4°C, for 5 minutes. Samples are then 
divided for PrPsc and PrPc analysis. 90 % of the post nuclear spin supernatant is 
taken for PrPsc analysis and 10% is taken for PrPc analysis.  100 pi 
approximately is available for PrPc which is methanol precipitated by addition of 
900pl (9x by volume) of methanol, -20 °C methanol, and the samples are 
themselves kept at -20°C for a minimum of 1   hour.  Precipitates are then 
pelleted by centrifugation at 1000g , 4°C, for 15 minutes and resuspended in 
100 pi of 1x sample buffer.
The other 90% of the post nuclear supernatant, for PrPsc analysis, is incubated 
for an hour at 37 °C with 30pg/ml of Proteinase K. The protease activity is then 
blocked by addition of PMSF (phenyl methyl sulfonyl fluoride) to 1mM on ice for 
20 minutes. Samples are then centrifuged at 365, OOOg for 15 minutes at 4 
degrees C in a Beckman ultracentrifuge using a TLA, 120.1  rotor.  Supernatant 
is removed and pellets are solubilised in 30pl of 1x sample buffer and stored at - 
20°C.
2.4.2.  BCA assay for total protein quantification
In order to determine total protein concentration for normalisation prior to 
loading of western blots the Bicinchoninic acid protein assay (BCA assay; 
Pierce) was employed.  Dilutions of a standard were made in the range of 0 to 
250pg/ml from a 2mg/ml BSA (bovine serum albumin) stock. All samples for 
analysis were diluted in 40x sample buffer, the same diluent used for the BSA 
standard dilutions. The advantage of this assay was that it was fully compatible 
with the detergents in the samples.  The assay was completed according to 
manufacturer’s instructions.  Reading from the 96 well plate were taken using 
the MRX micro plate reader, absorbance set at 562nm. The programme 
estimated the sample concentrations from the dilution series of standards.83
2.4.3.  Preparation of samples with N-glycanase
N-glycanase (N-glycanase : Glyko) was used according to manufacturer’s 
specifications. Briefly, pellets from PrPc  and PrPsc analysis as described above 
(either methanol precipitated for PrPc or ultracentrifuged for PrPsc), were 
resuspended in the N-glycanase 1x buffer, boiled for 2 minutes and cooled. The 
SDS (0.5%) was diluted out by addition of NP-40 to a final concentration of 2% 
NP-40, and 5pl of N-glycanase added to a sample which had been 
resuspended in 100pl of buffer for the PrPc pellets and 2.5 pi added to a sample 
which had been resuspended in 30 pi of buffer for the PrPsc pellets.
Samples were incubated overnight at 37degrees. Control samples were taken 
through the same procedure but no N-glycanase was added.  4x sample buffer 
was made up and added to produce a final concentration of 1.5x sample buffer 
in each sample.
2.4.4.  Western blotting
Western blotting  was undertaken, according to standard procedure (Sambrook 
et a l, 1989). Samples were electrophoresed at  200V for 50 minutes using 
Novex pre-cast tris-glycine 12% polyacrylamide gels (Invitrogen), prior to 
blotting onto nitrocellulose membranes (Schlecher and Schuel). Following 
transfer for 1.5 hours at 150mA , membranes were rinsed western washing 
buffer (see below) of Tris buffered saline with 0.1% Tween, and blocked for 14 
minutes in 3% non-fat powdered milk (Nestle). Membranes were then incubated 
with antibody overnight. Antibodies were diluted (see below) to the required 
concentrations in block.  Blots were rinsed once and then washed 4 times for 5 
minutes in TBST (Tris-buffered saline Tween). They were then incubated at 
room temperature for 1  h with horseradish peroxidase conjugated rabbit anti 
mouse antibody (DAKO rabbit anti mouse HRP antibody) at a 1:5000 dilution. 
Proteins were prepared for chemi-luminescent  visualisation using an  Enhance 
Chemiluminesence kit (Amersham, ECL kit). Images were then either 
developed using Kodak film (Kodak xls film) or the Fujifilm Luminescent Image 
Analyser (LAS 2000).84
The standard processing of a 162 cm2  flask of SMB cells for PrPsc analysis 
affords 3 western blot results.  In contrast 10% of that same material, taken for 
PrPc analysis, will afford enough sample to run 10 blots of equal intensity to that 
from the prion western signal described. (An example is shown in results 
Chapter 3 , Fig3.2 of the standard blot and the control samples from the Fig3.6 
as a more formal example). The approximate ratio from the above observations, 
is 1:30. i.e. roughly 3.3 % of PrP species are prion in an SMB sample.
2.4.4.1.  Quantification of western blots
Following blot preparation with ECL, blots were immediately taken with the 
Fujifilm Luminescent Image Analyser (LAS 2000). Images were then analysed 
in Image Gauge v3.1.  Average, background corrected, intensities of dilutions 
were compared to give a rough indication that measurement was being taken in 
the linear range.  The final intensity value was calculated as the weighted 
average intensity of the dilutions for each sample condition.
2.4.5.  Immunoprecipitation
Samples were lysed as normal. For the key experiments 2 black caps were 
taken for each condition. Lysates were incubated with a 1:100 dilution of rabbit 
anti-GFP (Clontech) or a control rabbit anti-Rb (Retinoblastoma) (Brockes lab 
antibody) for 1.5 hours at room temperature.
60pl of  Magnetic beads conjugated to secondary antibody (Dynal biotech M- 
280 sheep anti rabbit conjugated magnetic beads), were then added (stock 
dilution at 6-7 x108 beads/ml) to 1ml of lysate and rotated in an Eppendorf tube 
overnight. NB:  Beads to be used for Immunoprecipitation were washed in TBS 
and resuspended in lysis buffer before use  Following overnight incubation, 
beads were washed using TNT 4x and resuspended, using the magnetic 
particle separator (Dynal biotech) to remove supernatants. A final wash in TBS 
was then undertaken. For PrPc analysis, 10 % of the TBS resuspension beads 
were taken and removed to 1x sample buffer and boiled for 3 minutes. 
Supernatants were run on western blots.85
For PrPsc analysis, the remaining portion of the TBS beads was taken.
Samples were resuspended thoroughly in lysis buffer (back to the 1ml volume 
post lysis per 162 cm2flask) and Proteinase K added.  The samples were mixed 
thoroughly every 10 minutes during this period.  Beads were removed and the 
supernatants processed for PrPsc as described above.  Pellets were 
resuspended and samples pooled: the processed sample from 2 x 162 cm2  
flasks were run on each western blot lane.
Background controls were also taken by resuspension of  antibody in 1ml lysis 
buffer at normal concentration, and then taking it through the same processes 
as described above for cell lystates.
2.4.6.  Immunoflourescence studies
2.4.6.1.  Fixation protocols
Cells were washed 2x in PBS and fixed using 3% PFA (paraformaldehyde), for 
5 minutes
Cells were then washed in PBS 2x, washed once in block ( 10% goats serum in 
PBS ), and then blocked for 15 minutes. Antibodies diluted in block were added 
for 1   hour, cells were washed in PBS (4x5 minutes ) and incubated with 
secondary antibody (diluted in block at 1:100) for 1   hour and subsequently, 
rinsed once and washed 4x5 minutes in PBS.
For permeabilisation protocols, post fixation, 0.1% Triton was added to block 
and PBS for washing.
Antibodies used in this thesis for immunofluorescence, and their respective 
concentrations/dilutions of use are enumerated below.86
2.5.  Reagents
2.5.1.  Antibodies
2.5.1.1.  For western blotting
The following antibodies were used for western blotting 
6H4 (0.5pg/ml)  (Prionics AG),  3F4 (kindly provided by Chris Birkett, I.A.H. 
Compton, and anti GFP monoclonal antibody(mixture of two monoclonal 
antibodies) (Roche: mouse anti GFP), 0.2 pg/ml.
2.5.1.2.  For immunocytochemistry 
Primary antibodies:
6H4 (Prionics Ch)) was employed at 1:100 dilution (from 5mg/ml stock)
Brdu (Brockes laboratory) employed at 1:60 (from 3.4mg/ml stock)
GFP polyclonal was used (Clontech) at 1:100
Secondary antibodies:
FITC or TRITC conjugated goat anti mouse (DAKO), antibodies were used at a 
dilution of 1:100 (10pg/ml final concentration).  TRITC conjugated swine anti 
rabbit (DAKO) was used at 1:100 dilution.
2.5.2.  Solutions and Buffers
2.5.2.1.  General purpose
Tris-EDTA
10mM Tris-HCI, pH 8.0 
1mM EDTA
LB broth
10g bacto-tryptone 
5g bacto yeast extract 
10g NaCI
1   litre ddH20 (deionised)87
2.5.2.2.  Cell culture
Lysis buffer (regular use)
10mM Tris-HCI, pH8.0 
100mM NaCI 
10mM EDTA
0.5% NP40 (Nonidet P40)
0.5% sodium deoxycholate
For experiments where protease inhibition is required 
Addition of 1  tablet of complete protease inhibitor cocktail mini (Roche), 
including Pancrease extract, Pronase, Thermolysin, Chymotrypsin and Papain 
was added to 7ml buffer and dissolved prior to use.
2.5.2.3.  Preparation for and generation of Western blot
N-glycanase buffer 1x complete 
50m M 2-beta mercapto ethanol 
0.5 % SDS
5x  supplied N-glycanase kit buffer solution 
in ddhhO
Phenyl methyl sulphonyl fluoride (PMSF)
200mM PMSF diluted in methanol
Proteinase K 
1  mg/ml diluted in water
2x sample buffer 
100mM Tris-HCI, pH 6.8 
4% SDS (ordinary SDS)
0.2% bromophenol blue 
20 % glycerol88
Transfer buffer, pH8.3 
50mM Tris 
40mM glycine
0.08% SDS (electrophoresis grade)
20% methanol
2.5.2.4.  Western blotting procedure
Western blot washing buffer (TBS-Tween (TBST)): 
50mM Tris-HCI 
100mM NaCI 
0.1% Tween 20
2.5.2.5.  Immunoprecipitation
Washing buffer TNT:
50mM  Tris  8.0 
200mM NaCI 
2% NP40 
2% Tween
TBS
50mM Tris-HCI, pH8.0 
200mMNaCIChapter 3  The Role of Glycoform
Infection90
3.1.  Introduction
Cell lines capable of maintaining infection provide a means for the study of the 
nexus between the molecular mechanisms underlying prion disease and the 
cellular context in which they operate.  This chapter briefly explicates the 
SMB/PS system and explores one strategy for asking clear questions about the 
importance of glycosylation for the process of infection.
The critical cell line employed in this thesis, Scrapie Mouse Brain Cell (SMB), 
was derived from the cultured mouse brain of an animal which was  infected 
with the Chandler strain of Scrapie (Clarke and Haig 1970; Haig and Clarke 
1971). The outstanding property of these cells is their ability to stably maintain 
infectivity, roughly one LDsoper 100 cells, over multiple passage; cells stably 
maintain the production of PrPscfrom endogenous PrPc expression. In order to 
produce an infected/uninfected cell line pair, SMB cells were cured with the 
sulphated glycan, Pentosan Sulphate, yielding a cell line, nominated ‘PS’.  PS 
cells contain no PrPsc, as assayed by  western blotting, and no infectious titre, 
as assayed by inoculation of mice (Birkett, Hennion et al. 2001).  The 
mechanism of Pentosan Sulphate action remains unclear, but suggestions have 
included binding to PrPsc,  binding to PrPc  to prohibit substrate conversion 
(Gabizon, Meiner et al. 1993) and stimulation of PrPc endocytosis  (Shyng, 
Lehmann et al. 1995).
One central question that has not been addressed in Prion disease is the 
relevance to infection of the glycan residues of PrPsc and PrPc.  PrPc can be 
glycoyslated at two potential sites, and in the SMB system the glycoform 
species of PrPc which are represented include un-, mono- and diglycosylated 
forms of the protein. The overall pattern of glycosylation is termed the glycoform 
profile.  In an organism there may be some variation of PrPc glycoform profile 
between cell types and  brain areas (DeArmond, Sanchez et al. 1997).91
Figure 3.1.  Analysis of TSE strain glycoform profiles passaged in mice
The profiles are defined by the ratio between high, H, (diglycosylated) and low, L, (mono and un
glycosylated) glycoforms of PrPsc.  79A is closest to the glycoform profile of
SMB cells which display little diglycosylated PrPsc
(From a slide of Robert Sommerville : pers comm, to Jeremy Brockes)
Different strains of  Scrapie demonstrates a wide variety of glycoform profiles 
(see Fig 3.1)  and in most cases these profiles are maintained on passage to a 
new host of the same species. It has been suggested that the glycoform profile 
of the Prion associated with a particular strain is indicative of the strain type and 
in particular this has been used as evidence for the existence of a causal 
relationship between BSE and vCJD (Collinge, Sidle et al. 1996; Hill,
Desbruslais et al. 1997).  An open question remains in the Prion field as to how 
glycoform profiles of PrPsc are stably maintained on passage to a new 
organism.  A sub question which this chapter focuses on is whether glycoform 
profiles of PrPsc are causally relevant to the process of infection or just 
epiphenomena in this regard.
Cell culture models have been employed in the study of strain and glycoform 
profile and PS cells have been shown to support  infection by 22F, 139A, and 
79A strains of Scrapie (Birkett, Hennion et al. 2001). Culture models have also 
been used to address the relevance of PrPc glycosylation by creating constructs92
which lack the glycosylation sites.  It has been argued that deletion of one of the 
glycosylation sites leads to aberrant trafficking and conversion (DeArmond, 
Sanchez et al. 1997) although later studies employing different mutations of the 
glycosylation sites (N180Q and N196Q)  did not lead to aberrant trafficking and 
the mutant PrP supported conversion (Korth, Kaneko et al. 2000). These data 
support the conclusion that an unglycosylated PrPc can act as a substrate for 
effective conversion in culture, and that multiple strains can be supported in 
culture.
In this chapter, the PS/SMB system is assessed as a means for investigating 
some of the issues associated with glycoforms. The main tool used has been 
tunicamcyin, a reagent for blocking N-linked glycosylation in vivo, and its 
suitability as a reagent for studies of Prion glycosylation has been assessed in 
the context of this system. In particular, this chapter makes use of tunicamycin 
to ask whether the glycoform profile of an infectious source is causally related to 
the glycoform profile of newly formed Prion, which is established following 
infection.
3.2.  SMB and PS:  Assay for infectivity
Biochemical assay for infectivity relies upon the differential properties of PrPsc 
and PrPc:  the abnormal isoform, in contrast to its normal counterpart,  is both 
resistant to limited proteolysis and insoluble in non-denaturing detergents. 
Following lysis in detergent buffer, samples to be processed for PrPc are 
methanol precipitated whilst those for PrPsc analysis are treated with Proteinase 
K and ultracentrifuged. Samples taken through this procedure for PrPsc analysis 
are indicated in figure 3.2 and elsewhere in this thesis by the ‘+PK’ marked 
lanes.  An example below (see fig3.2) illustrates the detection of the PrP 
isoforms following the standard biochemical procedure and assay on a western 
blot using the 6H4 antibody which is able to recognise PrPsc following partial 
denaturation.  Proteinase K completely digests PrPc  (PS, + PK lane).  In 
contrast, PrPsc undergoes only partial proteolysis and is cleaved in its N- 
terminus, leaving  a 149 amino acid  protease resistant species nominated 
PrP27-30 because it runs at a lower molecular weight than PrPc (SMB, +PK93
lane). PrPsc species of PrP represent less than 4% of the total PrP population in 
an SMB sample (see Materials and Methods 2.4.4).
The glycoform profile of PrPsc can be seen to differ from PrPc.  In particular 
PrPsc displays virtually no diglycosylated species and an abundance of mono 
and unglycosylated forms. In contrast, the majority species of PrPc appears to 
be the diglycosylated form and the unglycosylated species is a minority form. 
This relationship between glycoforms is not a general feature of all systems but 
varies, dependent on strain property and cell type (see Fig. 3.1).
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Figure 3.2.  Processing  of  SMB  and  PS  cells  for  detection  of  Prion  and  normal 
isoforms
Cells are lysed in a buffered detergent and processed for PrP8 0  or PrPc as described in 
Materials and Methods. PrP®0  assay, which is usually undertaken on 90% of the sample 
compared to 10% taken for PrPc analysis, involves treatment with Proteinase K  which 
completely digests  PrPc.  In PS cells, where only PrPc is present, treatment with Proteinase K 
completely digests all PrP (PS, +PK). In contrast, SMB cells contain both normal and prion 
isoforms and protease digests PrPc completely and digests PrPscto leave a protease resistant 
core (SMB, +PK).  N-linked Glycosylation of PrPc varies in extent, and a mixture of di, mono and 
un glycosylated forms are found within the cell.  In the SMB/PS cell system PrPc is most 
abundantly di glycosylated, with the unglycosylated species representing the minority form. 
PrP80, by contrast, shows little of the diglycosylated form and a mixture of mono-glycosylated 
and unglycosylated species. PrP8 0  represents less than 4% of the PrP species in SMB cells (see 
Materials and Methods 2.4.4). The relatively low abundance may be a particular feature of this 
cell line.
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3.3.  PrP localisation
Immunocytochemistry with 6H4 demonstrate that the majority of PrPc is found 
on the cell surface (Fig 3.3). There are few clear differences between PS and 
SMB cells except for a slightly more pronounced peri-nuclear PrP population in 
SMB.
In order to ascertain whether PrPscwas present on the plasma membrane, SMB 
cells were surface biotinylated (see Materials and Methods).  Lysates were 
incubated with streptavidin beads overnight to pull down biotinylated species, 
washed and resuspended. 10% of the sample was taken for PrPc analysis, pull 
down material removed from the beads, by boiling in sample buffer, and run on 
western blots (Fig 3.4 -PK lanes). For the PrPsc analysis the remainder of the 
sample was PK digested, and supernatants (once beads were removed) were 
proceseed for PrPsc as normal and the final resuspended pellets run on western 
blots (Fig3.4 +PK lanes). Control unbiotinylated samples were also taken 
through the streptavidin pull downs. The results in Figure 3.4 indicate that PrPc 
can be pulled down by this process efficiently (-PK Biotin PrPc lane). The lack 
of PrPsc (Biotin PrPsc lane) found after surface biotinylation indicates that there 
is little PrPscon the surface.
(An estimate places it at less than 10 % although this is a very rough estimate 
based on the relative efficiency of PrPc pull down and the expected signal of the 
PrPsc input without pull down).95
SMB
SMB  Control
6H4 Triton
SMB
Control
6H4
Triton
PS
6H4
PS
6H4
Triton
PS
Control
Triton
PS
Control
Figure 3.3.  Immunocytochemistry of PS and SMB cells
Cells were fixed with 3% PFA and stained with monoclonal antibody 6H4 at 1:100 dilutions with 
or without Triton permeabilisation (see Materials and Methods). Alternatively cells were stained 
with a control primary antibody (Brdu) at the same concentration prior to addition of secondary. 
In the top two sets of panels staining of SMB cells is indicated, (scale bar = 20 microns). Note 
that Triton permabilistion of SMB cells reveals an increased perinuclear accumulation of PrP 
species.  (Greater than 5 fields for each condition was observed and the experiment was 
reproduced).96
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Figure 3.4.  Surface biotinylation of SMB cells
SMB cells were biotinylated (Biotin lanes) following the protocol described in Materials and 
Methods, in parallel with controls (-CNT lanes). Following quenching of the reaction, cells were 
lysed and incubated with streptavidin beads. Material removed from the beads for PrPc analysis 
(see Materials and Methods) was run on the right half of the western blot. ‘Biotin PrPc lane 
indicates the result of this pull down for the biotinylated sample and ‘-CNT PrPc indicates the 
control un-biotinylated sample. +CNT is a 6H4 positive brain homogenate control which was run 
as a western blotting reference only. The left half of this figure indicates the results of the pull 
down of the biotinylated material processed for PrPsc analysis in the ‘Biotin PrP8 0  lane (see 
Materials and Methods)  and the ‘-CNT PrPsc’ lane represents a non-biotinylated control taken 
through the same process (-CNT PrP8 0 ). Note that efficient pull down of PrPcis achieved via 
surface biotinylation but not PrP80. This result was reproducible.
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3.4.  Glycosylation of PrPsc and PrPc
In vivo manipulation of glycoform profile in PrPc and consequently PrPsc, can be 
achieved by blocking  N-linked glycosylation using Tunicamycin an inhibitor of 
N-acetyl glucosamine transferases.  PrPc turnover is in the order of 3-6 hours 
(Borchelt, Scott et al. 1990) and therefore after a short period of blocking N- 
linked glycosylation, only unglycosylated PrPc should be present in cells treated 
with an effective concentration of tunicamycin. PrPc is the substrate for PrPsc 
and therefore any new PrPsc formed in the situation where all the cellular PrPc is 
unglycosylated, will itself be unglycosylated.
The effects of 1   pg/ml of tunicamycin treatment on SMB cells for 48 hours were 
compared with an in vitro stripping of oligosaccharides using N-glycanase (fig 
3.5). The lanes indicated as  -PK’  represent  samples processed for PrPc 
which were either treated with tunicamycin in culture (T and T-ctl the control)  or 
treated with N-glycanase post lysis  (N and N-ctl the respective control). Use of 
tunicamycin in culture or use of N-glycanase in vitro, have the same effect on 
PrPc glycoform profile which is to collapse it to an unglycosylated species.  The 
treatment also collapses the PrPsc to a largely unglycosylated form (see Fig 3.5 
‘+PK’ lanes).  It is noteworthy that other lower molecular weight bands are 
apparent for PrPc (-PK, T or N lanes) indicating the existence of proteolytic 
fragments. These are not apparent, as discussed below, for PrPsc.
This experiment indicates that tunicamycin is a valid means of manipulating 
glycoform profile of PrPsc without the need for denaturation of the proteins which 
is required by the in vitro procedure using N-glycanase.  This means that 
proteins can be used for further experiment following deglycosylation, in their 
native conformations.
One suggestion of interest might be that the PrPsc glycoform profile does not 
truly represent a mixture of the mono and unglycosylated species. This could be 
of significance if it turned out for example, that one species in particular was 
more active in the conversion process. The hypothesis might be considered 
therefore that the apparent lower molecular weight band of PrPsc which is98
described normally as unglycosylated is actually a cleaved product of a mono­
glycosylated species. However, the experiment of Fig 3.5 indicates that 
treatment to remove oligosaccharides does not collapse the glycoform profile of 
PrPsc to a molecular weight below that of the putative unglycosylated PrPsc.  By 
contrast PrPc following treatment reveals bands that run below the putative 
unglycosylated weight, which are likely to have been shorter glycosylated 
fragments of protein, prior to deglycosylation.
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Figure 3.5.  Manipulation of PrP8Cand PrP° glycoform species in SMB cells
In order to assess the glycoform profile, oligosaccharides were removed in two ways: either by 
inhibition of biosynthesis or by enzymatic digestion. SMB cells were treated for 48 hours in 
tunicamycin (1  pg/ml) prior to assay for PrPscand PrPc, (lanes marked T for treated and T-ctl for 
control untreated samples). Alternatively,  N-glycanase was employed following lysis (lanes 
marked N or N-ctl for control untreated) as described in Materials and Methods.  The left half of 
the gel represents the effects of these treatments on PrPc(-PK lanes) whilst the right half 
represents the effects on PrPsc(+PK lanes). Note that the effect of pre incubation with 
tunicamycin or post treatment with N-glycanase has the main outcome of collapsing the 
glycoform profile to the unglycosylated form, although there are further bands which result 
below the expected weight indicating that shorter fragments of PrPc exist.  By contrast, multiple 
fragments of PrP^are not revealed following removal of oligosaccharides.99
3.5.  Relative contribution of glycoform species to in vivo conversion
The unglycosylated form of PrPc represents less than 5% of total PrPc (Fig 3.7 
C), and yet the unglycosylated form of PrPsc represents 35% of the total PrPsc 
(Fig 3.7 D). The non equivalence in glycoform stoichiometries suggests the 
hypothesis that unglycosylated PrPc might be a preferential substrate for 
conversion to the prion form.  One prediction that might be inferred from this 
hypothesis is that increasing the abundance of the unglycosylated form of PrPc 
protein, whilst keeping total quantity a constant (relative to a normal sample of 
PrPc), should lead to an increase in quantity of PrPsc formed. Therefore, to test 
this prediction cells were treated in tunicamycin (1  pg/ml) for 48 hours and 
compared to control samples. The aim of this manipulation was to increase the 
relative quantity of unglycosylated PrPc. Dilutions of samples were run in order 
to quantify within the linear range (see Materials and Methods).  Cell viability 
varied between experiments which made comparison of experiments difficult 
and the data is therefore indicative rather than quantitatively conclusive 
because total protein was affected. The general trend of a reduction in total 
PrPscfollowing the tunicamcyin treatment was however reproducible.  In the 
experiment indicated in Fig 3.6,  total PrPc in Tunicamycin treated samples 
decreased in abundance by 40% compared to controls (Fig3.6 -PK  and 
quantified in  Fig7A) and PrPsc in the treated samples decreased by 66% 
compared to controls (Fig6 +PK and Fig 7B).  The decrease in total PrPc was 
not anticipated and makes it difficult to assess the validity of the hypothesis that 
was stated above i.e. that increasing the relative abundance of the 
unglycosylated species of PrPc, keeping total PrPc constant compared to normal 
samples, would lead to an increase in total PrPsc.
Another reason for undertaking this experiment was to assess the use of 
tunicamycin as a means of increasing the levels of PrPsc (a prediction that was 
described above) which would be a potentially useful tool for infection studies. 
Overall a reduction in PrPsc is found with use of  tunicamcyin and therefore it 
does not represent a useful tool for increasing total levels of infectious material.100
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Figure 3.6.  SMB cells treated with tunicamycin
SMB cells were treated with tunicamycin (1 |jg/ml) for 48 hours prior to cell lysis. Treated and 
control samples were normalized for total protein content using the BCA assay, prior to analysis 
by western blot and total signal in a lane was quantified using image gauge and the average 
values for total protein calculated -  see Fig 3.7A and B. (For measurement of ratios of 
glycoform species in Fig 3.7 C and D, the glycoform bands visible in the control samples were 
individually quantified). Dilutions of treated and control samples were run in order to assess the 
efficacy of quantification by reference to a linear range. Panel A indicates the results for PrPc  
treated  with tunicamycin (dilutions 1,2,3) or controls (C1, C2, C3). Panel B represents the 
results for PrP8 0  processed from the same sample. The effect of prolonged inhibition of N-linked 
glycosylation is to reduce PrPc to an entirely unglycosylated form and as a result PrP** is also 
reduced to an unglycosylated form.101
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Figure 3.7.  Quantification  of total  PrPc  (A) and  total  PrP8 C  (B)  following  tunicamycin 
treatment and quantification of normal glycoform profile of PrPc  (C) and PrPsc (D) in SMB 
cells.
A and B  Total protein in the lanes of the gel represented in Fig3.6 were quantified using image 
gauge (see Materials and Methods). Total abundances are expressed as a percentage of 
control, untreated, samples. Note that PrP3 0  Abundance is decreased to 40 % of the level of the 
control following 48 hours of tunicamycin treatment, in contrast to PrPc which is 60 % of the 
level of the control.
C and D The control samples from Fig3.6 were utilized as a means of assessing the ratios 
between glycoforms species of PrP^and PrPcin SMB cells. Individual glycoform species of the 
control sample were quantified using image guage. Results are indicated as a percentage of the 
total of PrP^or PrPc in the sample. Note that Un-glycosylated PrPc represents 4% of the total 
PrPc in comparison to unglycosylated PrP5 * which represents 36% of total PrP5 5 0 .102
3.5.1.  Glycosylation as a determinant of Prion infection
It remains to be determined how glycosylation contributes to the process of 
prion conversion.  One hypothesis might be that perturbation of the initial 
conditions of infection, in the PrPsc template, might lead to a subsequent 
perturbation of products of the conversion process.
Although only a schema the equation below can be taken as a useful way for 
thinking about the process of conversion.
prpsc +  PrPc  PrPs c  + PrPs c
The intial conditions are represented on the left handside. The starting condition 
after tunicamycin treatment of an SMB cell is one where the prion template is in 
an unglycosylated form, in contrast to the normal glycoforms of PrPscin an SMB 
cell. Therefore the question was asked of what would happen to new PrPsc 
formed in SMB cells if tunicamycin was washed out at the end of 48 hours of 
treatment. To this end, cells were treated in tunicamycin for 48 hours and then 
cells were washed and normal media replaced.
Figure 3.8 B demonstrates that it takes 96 hours for the full PrPc glycoform 
profile to return following removal of tunicamycin and 96 hours for PrPsc to 
recapture its full profile (Fig3.8A). This experiment is indicative of the result that 
from an unglycosylated PrPsc template (the condition at the time when 
tunicamycin is washed out) one is able to regain the full glycosylated PrPsc 
profile after 96 hours. One hypothesis stated earlier was that a perturbation in 
the PrPsc glycoform profile of a cell will leads to perturbation of the profile of 
newly formed Prion by the cell.  The experiment above, following the effects on 
PrPsc after tunicmaycin treamtment and wash out, indicates that this hypothesis 
is not valid.103
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Figure 3.8.  Washout of tunicamycin from SMB cells
SMB cell cultures were treated in tunicamycin for 48 hours (Tunicamycin was added at -48 
hours), and tunicamycin then removed by replacing the medium (Wash out begins at 0 hours). 
Cells were lysed at,  0, 48, 96 hours after removal of tunicmaycin or after 1   passage (PI).
Cell lysed at -48 hours are untreated SMB cells which represent controls.  Samples in gel A 
(+PK) represent PrP^and in gel B represent PrPc (-PK). Note that PrPsc returns to its full 
glycoform profile after 96 hours despite the presence of a converting template at 0 hours which 
is largely unglycosylated.104
In order to further clarify the finding that unglycosylated PrPsc can act as a 
template for the conversion of all PrPc glycoform species, an experiment was 
carried out which added two elements to the experiment described in Fig3.8. 
Firstly, a fully unglycosylated PrPsc template was produced to rule out 
contribution from other PrPsc glycoforms and secondly, the starting PrPc 
glycoform profile was a full profile. The process of cell infection was achieved by 
use of dead cell freeze-thaw lysates as inoculums (Korth, Kaneko et al. 2000). 
To produce the inoculums (see Fig 3.9), SMB and PS cells were treated with 
Tunicamycin (10pg/ml) for 64 hours in parallel with controls (see fig 3.9). 
Inoculums were then formed by PBS lysis followed by freeze thawing and 
shearing (see methods). Roughly a 1/3 of each sample was diluted in lysis 
buffer and processed as normal for PrPsc and PrPc.  The remnant of the two 
inoculums were used as an infectious source on fresh plates of PS cells (see 
schema for the experiment Figure 3.9).
Western blots of the four innocula prepared and used for the infections can be 
seen in Figure 3.10;  The four inoculums were SMB cells treated or untreated 
with tunicamycin and PS cells treated or untreated with tunicamycin which were 
all taken through the freeze thaw lysis process. The effect of prolonged 
tunicamycin treatment is to produce an unglycosylated PrPsc(Fig 3.10  +PK : 
SMB-TM lane) in contrast to a control sample.  PS cells treated for this period 
(Figure3.10 +PK : PS-TM lane) do not produce a protease resistant band.
As illustrated in the schema of fig3.9 these inoculums were then used as 
sources of infection on separate PS cell cultures which were expanded over the 
following weeks. It was noted that the addition of the tunicamycin treated 
inoculums, whether PS or SMB in origin, caused a marked decrease in cell 
viability compared to cultures to which the non-tunicamycin inoculums were 
added.  After assay for PrPsc (Fig 3.11  +PK lanes) it was apparent that a full 
glycoform profile for PrPsc  was produced from the unglycosylated template as 
illustrated in the SMB-Tm lane although the abundance of the PrPsc was greatly 
reduced.  Addition of inoculums PS and PS-Tm (Fig3.10) did not lead to 
formation of PrPsc.105
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Add each of innoculums to uninfected PS cells
PS cells
Culture post addition of innoculums for 2 weeks
Assay for PrPsc/c 
(see Fig 3.11)
Figure 3.9.  Schema of process of infection with manipulated Prion glycoforms
SMB and PS cells were cultured in the presence of 10 pg/ml Tunicamycin
for 64 hours. No tunicamycin was added to control SMB and PS cells during this period.
Dead cell freeze-thaw lysates were then produced by PBS lysis, followed by 4 freeze thaw 
cycles in liquid nitrogen and shearing with a syringe (Bosque and Prusiner 2000). A proportion 
of the material from each inoculum produced was analyzed for PrPsc/ PrPc. The remnant was 
normalized for total protein and added to PS cells, and left for 3 days before media were 
changed. Cells were then cultured for a further two weeks and assayed for PrPsc/ PrPc.106
Figure 3.10.  Inoculums used for infection
SMB and PS cells were treated with tunicamycin for 64 hours, in parallel with sham treated 
controls. A proportion of the samples were taken and diluted in lysis buffer (2x strength) and 
were processed for PrP^and PrPc  Note that panel B, SMB-TM condition, indicates that no 
detectable monoglycosylated PrP is present.
+PK
-PK
-41
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Figure 3.11.  Analysis of PS cells after infection with cell derived inoculums
After 2 weeks of culture, the 4 samples of PS cells that had been infected with different cell 
preparations (inoculums) were normalized for total protein and assayed for PrP8 0  and PrPc in 
parallel with an SMB cell culture (Cnt). SMB-Tm and SMB represent the PS cultures infected 
with the tunicamycin and sham treated SMB derived inoculums. PS-Tm and PS represent the 
PS cultures infected with the tunicamycin and sham treated PS derived inoculums. Note that 
although less abundant, a full glycoform profile is regained after infection with an entirely 
unglycosylated template as illustrated in the +PK : SMB-Tm lane.107
3.6.  Discussion
Immunocytochemistry confirms the common finding that PrPc is expressed on 
the cell surface in both SMB and PS cells. There are few differences observed 
with or without permeabilisation protocols on these cells, although it is 
noteworthy that peri-nuclear material is more visible in the SMB cells than PS 
which may be a function of cellular stress.  A key problem in the Prion field has 
been the lack of a robust  Prion specific antibody, and the 6H4 used for this 
immunocytochemistry is thought to have very low affinity for PrPsc and perhaps 
it is not surprising that post membrane compartments like endosomes or 
lysosomes, which have been indicated as one possible sink for PrPsc, do not 
show up differentially between the infected and non-infected cell types. In order 
to confirm the presence of PrPscon the surface, which has been demonstrated 
for other cellular systems (Shyng, Moulder et al. 1995; Vey, Pilkuhn et al. 1996), 
biotinylation was carried out. The result indicates that PrPc is found to be 
abundantly accessible to surface biotinylation  and in contrast PrPsc  is not. It is 
difficult to calculate the total abundance of surface and non surface forms from 
other studies, but it is a critical piece of information because the surface is one 
of the putative sub-cellular sites which has been suggested for prion 
conversion.  A more quantitative approach would be useful for future 
experiments. One other  possible manipulation that would enable triangulation 
of previous studies and the present study would be separation of plasma 
membrane compartments in order to assess the quantity of PrPsc present by 
another means.  The result, in this thesis, may also be a feature of  the SMB 
cell line for other reasons. It may be that PrPsc is not accessible to surface 
biotinylation because the cell compartments at the surface are invaginated to a 
greater extent than in other cell systems and structural differences of this kind 
might limit access of reagents such as biotin. It would therefore also be worth 
using other cell lines as further controls.
PrPsc in SMB cells is comprised of unglycosylated and mono-glycosylated 
species and lacks diglycosylated forms in contrast to its substrate PrPc, which 
displays abundant diglycosylated species and a minority unglycosylated108
species. In order to rule out the hypothesis that putative unglycosylated species 
of PrPsc are actually mono glycosylated fragments of the full molecule,  N- 
glycanase was used to collapse the glycoform profile to a completely 
unglycosylated form.  Removal of the carbohydrate residues did not lead to an 
overall shift of the PrPsc profile as the hypothesis would have predicted.
The relative abundance of unglycosylated PrPsc and PrPc might suggest the 
hypothesis that unglycosylated PrPc is a more efficacious substrate for 
conversion.  One means of testing this hypothesis was to ask whether a bias 
towards the unglycosylated form would therefore produce more PrPsc.  The 
effect of treating cells with tunicamycin for 48 hours was to reduce total PrPc 
which makes it difficult to assess this hypothesis. Irrespective of this point, a 
clear effect of treatment with tunicmaycin in general was to reduce total cellular 
PrPsc and therefore this manipulation does not represent a useful tool for 
increasing Prion abundance in the SMB cultures.
After treatment of SMB cells with tunicamycin for a period of 48 hours PrPc 
(Fig3.8B) was reduced to an entirely unglycosylated form and PrPsconly 
demonstrated a small amount of the mono-glycosylated species (Fig3.8A). 
When tunicamycin was removed, PrPc came back to its full glycoform profile 
very slowly, in 96 hours, despite its relatively fast turn over. One reason for this 
might be that the cells have suffered considerable stress as a result of a 
treatment which disrupts glycosylation in general and activates documented cell 
stress pathways such as the unfolded protein response(Niwa, Sidrauski et al. 
1999). Nevertheless, at the point where tunicamycin is removed and PrPc 
glycosylation begins to return to normal, PrPscis largely unglycosylated. The 
fact that PrPsc returns to its full profile after the 96 hours, in line with PrPc, 
indicates that the largely unglycosylated form is able to convert other glycoform 
species of PrPc in order to re-establish the profile.
Two caveats with this experiment are that the cells are in a poor state by the 
end of the process and, more importantly that there is some visible mono­
glycosylated PrPsc.109
The final experiment of this chapter addressed the question of the informational 
requirements in an inoculum for propagation of glycoform profile. In order to 
address concerns about cell viability and presence of unwanted glycoform 
species the experiment was undertaken with samples prepared from freeze- 
thaw lysates of cells which had been previously manipulated with tunicamycin. 
Using a source of Prion which is entirely unglycosylated as an inoculum returns 
a glycoform profile which is the same as infection with a full glycoform Prion 
template.
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Figure 3.12.  Schema of two hypotheses for glycoform maintenance
This experiment indicates that informational requirements for the transfer and 
maintenance of glycoform profile do not reside in the glycoform species 
themselves.  In its most limited form the hypothesis can be stated with 
reference to a strict matching hypothesis and a non-strict matching hypothesis 
(Fig 3.12). On the strict matching hypothesis unglycosylated template PrPsc 
converts PrPc only in its unglycosylated form and mono-glycosylated PrPsc only 
converts PrPc of monoglycosylated form and so on....  The explanation for why 
there is no diglycosylated form when a new infection is initiated, would then be 
that there is not an accompanying diglycosylated species in the inoculum. 
Glycoform profiles would partly be explained, on this hypothesis, by the110
presence or absence of particular glycoform species from an initial inoculum. A 
full explanation of  the transfer and maintanence of glycoform profile  would also 
require some explanation of the relative abundance of species present.  The 
strict matching hypothesis may seem trivial as a hypothesis which has been 
disproved by this experiment, but it is useful in dissecting questions and models 
that address how glycoform profiles might be maintained following Prion 
infection.  A key question that is highlighted by this work is whether or not the 
other glycotypes of PrPsc can be seen to have any converting activity and 
whether the glycotypes differ in their efficiency of converting activity.
Work in culture has also suggested the importance of the PrPc side of the 
equation in setting up of glycoform profile of Prion (Vorberg and Priola 2002). In 
particular it has argued that PrPc profile varies between compartments in a cell 
and that where PrPsc is converted in a cell determines the glycoform profile 
because this is where substrate of a particular sort is available.  However, 
differences in the glycoform profile cannot be solely explained on the basis of 
the cells where Prion infection is occurring. Some information must be carried 
by the infecting Prion that will influence the eventual glycoform profile which is 
established in the new infection. The compartmentalisation model would 
suggest that the information which is carried by the infectious source will 
determine the site of conversion for Prion.
When the glycoform profile of a strain is referred to it refers to the resulting 
western blot of a brain homogenate, and not individual cell populations -  in this 
sense it represents an aggregate of what might be different profiles of distinct 
cell populations in that brain. This is one possible weakness of using cell culture 
models for study of glycoform profile.  Nevertheless, it must be the case that 
some information that will lead to glycoform profile in a newly infected host, 
must be  stored in the PrPsc molecule of an inoculum, as discussed, and this 
work investigates one hypothesis regarding that information. The work suggests 
that the glycotypes of the prion template (e.g. of the inoculum) are not 
themselves the key source of the information required for re-establishment and 
maintanence of the glycoform profile in the newly infected host.I l l
Chapter 4 Cell lines expressing PrP 
fluorescent fusion 
proteins112
4.1.  Introduction
One major obstacle to progress in the prion field has been the absence of an 
antibody that is specific for PrPscand therefore an absence of clear means for 
the elucidation of the sub cellular behaviour of Prion.
This chapter focuses on the characterisation of fusion proteins between PrP 
and a fluorescent reporter, Green Fluorescent Protein (GFP). It explores 
whether fusion constructs could be used to report appropriately to reveal 
differences in localisation between infected and uninfect contexts. There are 
two potential ways in which the fusion protein when expressed in infected and 
uninfected contexts might report on differences in localisation. In the first mode 
the fusion protein is hypothesised to report directly on differences in localisation 
because the c-terminal portion is converted to and therefore trafficked as 
PrPsc(i.e. GFP-PrPc becomes GFP-PrPsc in the infected context).  In a second, 
indirect mode, differences in localisation are hypothesised to occur in virtue of 
differences in trafficking of PrPc between infected and uninfected contexts. 
Expression of fusion proteins in different contexts was investigated by 
microscopy for this purpose.  The second issue explored is whether or not, in 
the context of an intact fluorescent fusion protein, PrPc is converted to PrPsc  - a 
prerequisite for the fusion to act as a direct marker for Prion.
Previously GFP has been produced in fusion with PrP to assess the dynamics 
of PrP endocytosis  and trafficking (Lee, Magalhaes et al. 2001; Magalhaes, 
Silva et al. 2002; Hachiya, Watanabe et al. 2004) to assess the effects of 
mutation on accumulation and trafficking (Gu, Verghese et al. 2003). 
and recently, a transgenic mouse expressing GFP in fusion with PrP has been 
reported (Barmada, Piccardo et al. 2004). However, there are no published 
reports to date which assess the behaviour of PrP fluorescent fusion constructs 
in an infectious context. It has been reported that attempts to elicit conversion of 
PrPc to PrPsc in a fusion protein in which the GFP is inserted near to the GPI 
anchor have been unsuccessful (pers comm,  at  D. Harris group poster at 
Keystone Conference 2002).  This thesis therefore follows an alternative 
approach of inserting the GFP molecule close to the  N-terminus, in between113
the signal peptide and the rest of PrP (Lee, Magalhaes et al. 2001).  The N- 
terminus has been shown to be an unstructured domain from NMR studies 
(Zahn, Liu et al. 2000) which is distinct from the part of PrP (broadly: residues 
90-230) oridinarily implicated in the PrPsc transition. It is therefore hoped that it 
is a reasonable place to insert a protein like GFP, with the expectation that the 
GFP will both fold appropriately and not interfere with any PrP folding necessary 
for Prion formation.
In summary, this chapter addresses the critical question of whether PrPc 
conversion to PrPsc occurs in the context of the fusion with GFP. It also acts as 
a description of cell types expressing PrP-GFP fusion constructs which can be 
used to study general trafficking and dynamic issues relating to PrPc. These 
observations of fusion behaviour are critical for further work that will explore the 
dynamics of PrP in the context of the plasma membrane and intercellular 
exchange.
4.2.  Construction of fluorescent fusion proteins
Fluorescent constructs were designed which placed PrP in fusion with Green 
Fluorescent protein (GFP). In order to ensure appropriate trafficking along the 
secretory pathway, the cDNA coding for the signal peptide of PrP, residues 1- 
22, was placed N-terminal to the EGFP construct in the Clontech EGFP-C3 
vector backbone by PCR (see Chapter 2: Materials and Methods). The 
remaining C-terminal portion of PrP, the cDNA coding for residues 23 onwards, 
was placed in the cloning site of EGFP-C3 and in frame with the EGFP 
sequence.  The construct formed by this method is denoted gfp-prp for the 
cDNA and GFP-PrP for the fusion protein itself (see fig4.1B).  The fusion 
protein derived from mutagenesis of GFP-PrP was expected to react with the 
6H4 antibody and to be distinguished by weight -  previously, fusion proteins 
with similar design have been attributed the weight of around 57Kda on 
expression (Lee, Magalhaes et al. 2001). In order to assay for conversion of 
PrPc in the context of an intact fusion protein to PrPsc by the usual biochemical 
procedures (i.e. to assay for whether a proportion of GFP-PrPc has become 
GFP-PrPsc) it is necessary to introduce a digestion step using Proteinase K.114
This would therefore cleave the GFP from the putative PrPsc portion of the 
fusion, and when run on a western blot the putative PrPsc portion of the fusion 
would run in the same weight range, and be obfuscated by, the endogenous 
PrPsc.  (Note that this was not expected for western blotting where Proteinase K 
is not introduced because the full fusion weight is higher than endogenous PrP 
as described above). Therefore a modification was made to GFP-PrP to 
introduce an epitope which would be specific for the antibody 3F4(Telling, 
Tremblay et al. 1997).
The residues 108 and 111 of mouse PrP correspond to 109 and 112 of hamster 
PrP, and mutation of the Leucine and Valine residues to a Methionine at these 
positions produces a 3F4 epitope.  Therefore these mutations were introduced 
by site directed mutagenesis to generate a fusion protein denoted F4-GFP-PrP 
which could be recognised by the antibody 3F4 (see Fig 4.1C).
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Figure 4.1.  Construction of GFP-PrP fluorescent fusion proteins
CHO represents the carbohydrate residues, S S the disulphide bond and GPI, the position of 
the GPI addition sequence. A) Schema for the nascent PrP polypeptide. The sequence 
indicated in red from amino acid 1-22 comprises the signal peptide and cleavage before residue 
23 occurs on transit into the ER.  B) EGFP was effectively inserted between the signal peptide 
and the rest of the PrP molecule (see Materials and Methods).  C) The construct described in
B)  had a specific hamster epitope added by site directed mutagenesis at sites 108 and 111 
effecting the changes in amino acid sequence of L108M and V111M.115
4.3.  Transient expression of constructs
To ensure that the constructs were transcribed and translated appropriately 
they were expressed transiently in the PS/SMB cell system (see Materials and 
Methods) and the localisation of the fusion proteins was assessed. The ideal 
aim of using the two constructs at this stage was to establish that the F4-GFP- 
PrP functioned appropriately so that it could replace the GFP-PrP construct 
from which it was derived in later studies.  The hypothesis was described earlier 
that there might be some difference between trafficking of PrP in infected and 
uninfected contexts, and for this reason constructs were expressed in both PS 
and SMB cells. As a further control of interest, a vector coding for the same 
EGFP protein with a GPI anchor addition sequence was obtained and 
expressed in the SMB and PS cells (see Materials and Methods).
The GFP-PrP fusion protein localises largely to the plasma membrane with 
some indication of perinuclear accumulation, possibly in the golgi apparatus 
There is little obvious difference between expression in infected contexts(SMB) 
or uninfected contexts (PS) (see top two panels Fig4.2). The cell localisation of 
GFP-PrP and F4-GFP-PrP (figure 4.2) fusion proteins is identical and therefore 
trafficking is not perturbed by introduction of the 3F4 epitope.
The GFP-GPI fusion (Fig4.2 bottom two panels), is a GFP protein with a GPI 
anchor which has been engineered by addition of a GPI anchor signal (see 
Materials and Mehods) as well as a signal sequence for import to the ER.
Under normal circumstances, expression of underivatised GFP is cytoplasmic, 
and the protein is not secreted. The localisation pattern of GFP-GPI  seen in 
Fig4.2  is the same as that of the other PrP fusions: plasma membrane and 
perinuclear localisation, indicating the sufficiency of the GPI anchor and a signal 
sequence for this localisation pattern.116
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Figure 4.2.  Transient expression of constructs in PS and SMB cells
GFP-PrP, F4-GFP-PrP and GFP-GPI were expressed in the SMB/PS cell system (see Materials 
and Methods). Panels on the left represent expression of constructs in PS cells and those on 
the right in SMB cells.  The scale bar indicates 20 microns. Note that the basic localisation of all 
the fusion proteins is plasma membrane with some evidence of perinuclear staining.  There is 
no clear difference fou'nd between localisation of a particular fusion protein in SMB or PS cells. 
There is no difference in localisation of GFP-PrP fusion protein or F4-GFP-PrP fusion protein in 
the cells, indicating that the mutations introduced to form the latter protein do not alter 
trafficking. The GPI anchored GFP protein (GFP-GPI) also appears to have the same 
localisation.  These experiments were reproduced independently. In each case multiple fields 
(n >=6) were observed for each condition. No signal was observed in untransfected cells.117
4.4.  Biochemistry of transiently expressed fluorescent fusion proteins
Fusion proteins were transiently expressed in PS cells which were subsequently 
processed for PrPc and western blotted with an anti GFP antibody or 6H4 (see 
Fig 4.3 and Materials and Methods).  Gfp-prp was expressed in PS cells which 
were  processed for PrPcand run in 3 fold dilutions (Fig 4.3 lanes GFP-PrP 
1,2,3). In parallel a cytoplasmic GFP was also expressed (Fig4.3 lane cyt- 
GFP). As a further comparator untransfected PS cells were processed for PrPc 
(Fig 4.3 lane PrP). The blot with an anti GFP monoclonal antibody (Fig4.3 left 
panel) indicates the fusion protein running at a weight above 45Kda.  There 
appear to be two distinct bands, as seen in the lower dilutions) of the fusion 
construct, which may correspond to different glycosylated forms (lane GFP- 
PrP1 and 2).  Cytoplasmic GFP is found at two weights, the majority band just 
above 30 kda.  Also of note is the presence of some GFP in the fusion 
constructs, at the same weight as the lower weight band from the cytoplasmic 
GFP sample. It is unclear why this signal was not seen in the more 
concentrated sample (Fig4.3 GFP-PrP 3 anti GFP blot).
The 6H4 blot indicates both the GFP-PrP fusion at the appropriate weight of 
between 50 and 60 Kda, and also endogenous PrP running at weights below 45 
Kda. It is noteworthy that the fusion is highly expressed, at more than two times 
the level of endogenous PrP. It is also apparent that the extent of PrP in the 
fusion lanes (Fig4.3 lanes GFP-PrP 1,2,3 6H4 blot)  runs beyond the 
endogenous weights, possibly indicating degradation products of the fusion.
The f4-gfp-prp construct was transiently transfected into SMB cells and 
processed for PrPc (Fig4.4 GFP-PrP lanes). A positive control for the efficacy of 
the 3F4 antibody was included (lanes marked +Cnt) in the form of a 
recombinant hamster PrP protein. A negative control, cytoplasmic GFP 
expressed in SMB cells, was also run to assess the specificity of  the 3F4 
antibody for the engineered hamster epitope. The fusion protein F4-GFP-PrP 
appears to run at the same weight as the unmutated fusion from which it is 
derived above 45Kda and probably between 50 and 60 Kda (antiGFP blot lane118
F4-GFP-PrP),  and two species are distinguishable. Some GFP appears to be 
found at a lower weight, indicating proteolysis of the fusion.  The 3F4 blot 
indicates that the mutant fusion is picked up efficiently by the antibody and that 
the negative control is not (Fig4.4 3F4 blot:  F4-GFP-PrP and PrP lanes 
respectively). A note of caution applies to the result which reveals that the 
endogenous PrP is expressed at a lower level than the fusion (compare Fig 4.4 
6H4 blot: F4-GFP-PrP and PrP lanes), and may not blot with 3F4  to some 
extent as a result of quantitative difference in loading. Therefore this is not a 
stringent test of 3F4 specificity but highly indicative. It is noteworthy, 
nevertheless, that the 3F4 blot reveals such a clear signal in the F4-GFP-PrP 
lane at weights below the fusion protein. This indicates that much of the 
material is not endogenous, and is derived from the fusion protein itself. This 
issue is discussed in detail below.119
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Figure 4.3.  Transient expression of GFP-PrP fusion protein
Constructs were transiently transfected into PS cells (see Materials and Methods) 
and processed for PrPc.  GFP-PrP 1, 2 and 3 represent three dilutions of the same sample from 
cell transfected with the gfp-prp construct. The lane marked PrP represents an untransfected 
sample and cyt-GFP indicates PS cells transfected with a cytoplasmic GFP.
The left half of the gel is blotted for GFP and the right half for PrP with 6H4. Blotting with 6H4 
reveals endogenous PrP at the normal weights but clearly picks up the higher weight PrP which 
is part of the fusion protein. Note that at the weight of the fusion protein, between 50 and 60 
Kda, a doublet can be seen on the GFP blot possibly indicating different extents of 
glycosylation.
Blot with  antiGFP  3F4  6H4
Figure 4.4.  Transient expression of F4-GFP-PrP fusion protein
The lanes marked F4-GFP-PrP indicate SMB cells which were transiently transfected with the 
3F4 epitope tagged fusion protein and processed for PrPc.
+Cnt denotes a recombinant hamster PrP control, containing both 3F4 and 6H4 epitopes,and 
cyt-GFP represents an SMB sample which was transfected with a cytoplasmic GFP. The cyt- 
GFP sample also acts as a control for endogenous PrPc.  Gels were blotted with an anti-GFP 
polyclonal antibody, 3F4 or 6H4.  Note that in all cases the fusion construct can be seen to run 
at the appropriate weight, above the 45Kda marker.  The 3F4 antibody blot reveals no signal in 
the ‘cyt-GFP’ lane because endogenous PrP does not contain a 3F4 epitope. However, material 
at the endogenous PrPc weight is found in the gel blotted with 3F4, indicating that this material 
is not endogenous PrPc but is derived from from the fusion construct.120
4.5.  Creation of Stable Transfectants
Stable Transfectants are a necessary endpoint for this thesis because the 
intended study of the infectious process requires long term analysis in culture 
and therefore stable expression.
The approach of bulk selection was taken for two principle reasons. Firstly,
SMB cells are not clonally derived and therefore there may be a range of 
important phenomena to be observed in a mixed cell population.  Secondly, 
repeated attempts to clone SMB and PS cells in the laboratory have proven 
unsuccessful in the past (Brockes, Kanu and Landy data unpublished). Cells will 
not grow at clonal density and do not survive at very low, densities.  Attempts to 
affect a more transformed phenotypes have previously been undertaken in the 
laboratory: large T antigen was transfected into SMB cells resulting in a more 
transformed phenotype but a loss of infectivity (Brockes and Kanu data 
unpublished). Survival and consequent cell growth is not ameliorated 
significantly by the usual manipulation of conditioning media (data not shown) or 
growth on feeder laylers (Brockes and Kanu unpublished data).
Therefore PS cells were transiently transfected with GFP-PrP and F4-GFP-PrP 
and selected for neomycin resistance, conferred by the expression of neomycin 
resistance gene, part of the vector backbone for the fusion constructs.
Initial attempts to select cells led to cell death and poor percentages of 
fluorescent cells, however a protocol using bulk selection (pers comm. Telling 
group keystone symposium -  see Materials and Methods) led to the production 
of cell lines which were 95-100 % fluorescent.
Fig 4.5 represents micrographs of cell lines produced by transfection of PS cells 
followed by bulk selection (left panels). The fusions expressed in each case are 
indicated on the right.  These cell lines were then used to create infected 
counterparts by the procedure employed in chapter 3 of culturing with infectious 
freeze-thawed cell lysates (see Materials and Methods). The uninfected stable 
cell line expressing the GFP-PrP fusion is denoted GFP-PrPst,  the cell lines 
expressing F4-GFP-PrP  is denoted F4-GFP-PrPst.  The suffix 'Inf is added to 
indicate the infectious partner  e.g. F4-GFP-PrPstlnf represent the infected cell121
line expressing F4-GFP-PrP protein. Cells in both cell lines expressed the 
constructs at detectable levels and showed the same localisation of fusion 
protein to the plasma membrane with some perinuclear fluorescent 
accumulation. Again, as with the transient transfectants, it the F4-GFP-PrP is 
localised in all cases in the same way as its non mutated counterpart GFP-PrP. 
There are no clear differences between the expression in the infected cell lines 
and their uninfected partners for either of the fusion constructs.
In order to ascertain whether the fusion construct was appropriately tethered by 
the GPI anchor to the plasma membrane, phosphatidylinositol-specific 
phospholipase C  (PIPLC) was employed.  F4-GFP-PrPst and F4-GFP-PrPstlnf 
cells were grown on glass cover slips coated with laminin and treated for 1h 
with PIPLC in parallel with controls (see Materials and Methods). Micrographs 
were then taken of the cells at 63 x magnification, which revealed that the 
results of PIPLC treatment was to remove the majority of the plasma membrane 
fusion protein (Fig4.6). The remnant of perinuclear material is more pronounced 
after treatment and this may be because some internalisation of material has 
occurred or because material obscuring the interior fluorescence has been 
removed.
It may be that some fusion protein in the cells is denatured in the process of 
trafficking or conversion, and  fluorescence may be extinguished by the low pH 
of certain cellular compartments like the lysosome. For this reason antibody 
staining was undertaken on fixed cells in the hope that any alternative pattern to 
GFP signal alone might be revealed.  Surface staining did not reveal anything 
unusual (data not shown) and therefore a permeabilisation protocol was 
employed (see Materials and Methods).  Infected and uninfected stable cells 
lines (and stlnf cells) were stained with 6H4, anti GFP polyclonal antibody, and 
a Brdu control antibody (fig 4.7 A F4-GFP-PrPst and 4.7 B F4-GFP-PrPstlnf 
cells). The primary antibody used is indicated on the right of the relevant panel 
and in each case the GFP signal is illustrated on the left in green.  In summary, 
there are no differences in localisation revealed by ordinary GFP and antibody 
staining.122
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Figure 4.5.  Micrographs of stable transfectants
Cells were transfected with either the gfp-prp or the f4-gfp-prp constructs (indicated on the right 
of the panels above) and bulk selected for neomycin resistance (see Materials and Methods). 
The resulting populations were almost entirely fluorescent cells (see below). The cells were then 
infected with freeze-thaw lysates of  SMB cells, with the result of two pairs of infected/uninfected 
cell lines expressing the fusion constructs (see Materials and Methods). Micrographs of live 
cells were taken at 63x magnification in order to avoid fixation artefacts. The distribution of 
constructs reflects that of PrP in general: most of the material is found on the plasma 
membrane, with some perinuclear PrP accumulation. No clear differences were visible between 
infected and non-infected cells. Observations were made in n>=5 fields for each condition, and 
the experiment was reproduced. The F4-GFP-PrP cells (uninfected and infected) have also 
been used for multiple further experiments in time-lapse and no differences observed between 
them).123
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Figure 4.6.  PIPLC treatment of cell pairs expressing F4-GFP-PrP
The stable infected and uninfected cell lines expressing F4-GFP-PrP (F4-GFP-PrPst and F4- 
GFP-PrPstlnf) were grown to confluence on the glass cover slips coated in laminin, in order to 
maximise their adhesion to the dish following treatments. Cells were either kept on ice at 4 
degrees for 1   hour in L-15 medium or kept on ice for 1   hour in L-15 medium supplemental with 2 
units/ml of PIPLC (see Materials and Methods).  The results of treatment of both infected an 
uninfected cells is shown in the micrographs above (fig4.6) at 63x magnification.  Note that the 
majority of PrP is removed by PIPLC treatment for 1   hour indicating the GPI anchorage of the 
fusion at the plasma membrane. This result was reproducible.124
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Figure 4.7.  Micrographs of fixed F4-GFP-PrPst uninfected cells 
stained with antibodies to PrP or GFP
Cells were fixed in PFA and permeabilised with 0.1% Triton (see Materials and Methods).
They were then stained with antibodies 6H4 (1/100 dilution), anti GFP (1/200 dilution) or 
a control monoclonal antibody to Brdu, diluted to the same final concentration.  A TRITC 
conjugated secondary to mouse or rabbit was added depending on the use of a monoclonal or 
polyclonal primary antibody.  Micrographs at 63x magnification were taken in FITC Channels, to 
view GFP, indicated in green, and TRITC channels to view the secondary antibody, indicated in 
red.  Note that the antibodies did not reveal a clear difference in staining pattern to live cells as 
might have been expected. Also, antibody staining does not appear to reveal any clear 
differences over GFP fusion localisation seen in the FITC channel.125
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Figure 4.8.  Micrographs of fixed F4-GFP-PrPstlnf, infected cells stained with 
antibodies to PrP or GFP
Cells were fixed in PFA and permeabilised with 0.1% Triton (see Materials and Methods).
They were then stained with antibodies 6H4 (1/100 dilution), anti GFP (1/200 dilution) or 
a control monoclonal antibody to Brdu, diluted to the same final concentration.  A TRITC 
conjugated secondary to mouse or rabbit was added depending on the use of a monoclonal or 
polyclonal primary antibody.  Micrographs at 63x magnification were taken in FITC Channels, to 
view GFP, indicated in green, and TRITC channels to view the secondary antibody, indicated in 
red.  Note that the antibodies did not reveal a clear difference in staining pattern to live cells 
(see Fig 4.5) or to GFP signal in the FITC channel.126
4.6.  Conversion of PrPc  in fusion to PrPsc
One of the original aims in pursuing an approach of creating fusion proteins 
between PrP and GFP is the possibility of creating a reporter for PrPsc: a 
difference in localisation in an infectious context may have been indicative 
of/attributable to the prion form. Although evidence from the 
immunofluorescence studies so far indicates no clear difference in localisation 
of the fusion proteins between infected and uninfected contexts, a key question 
that remains to be answered is whether or not the PrP portion of the fusion 
protein is converted to PrPsc.  It is also important to ascertain whether a 
converted PrP species is still in fusion with the GFP reporter molecule following 
its conversion.
F4-GFP-PrP fusion was expressed in SMB cells transiently for 3days (see 
Materials and Methods) and cultures were assayed for PrPsc.  Fig 4.9 illustrates 
the sample blotted with 3F4 or 6H4 in lanes marked F4-GFP-PrP.
+Cnt refers to a recombinant hamster PrP loaded as a positive control for the 
efficacy of 3F4 and SMB refers to SMB cultures which were processed in 
parallel as controls for endogenous Prion (these cells are also transfected with 
a cytoplasmic GFP as a control for effects of transfection reagent on Prion). The 
endogenous Prion is not picked up by the 3F4 antibody (SMB lane: 3F4 blot) 
and therefore the signal in the F4-GFP-PrP lane indicates Prion that is from the 
fusion because it containes the 3F4 epitope. It appears that PrP from the fusion 
construct is therefore converted after transient expression.
The same process was repeated for the infected stable cell line F4-GFP- 
PrPstlnf which was analysed for PrPscand PrPc and western blotted using 3F4 
and 6H4 antibodies (Fig 4.10 lanes Infected F4-GFP-PrP).  Uninfected cells 
(F4-GFP-PrPst) were also processed in order to ensure that GFP in fusion, did 
not confer protease resistance to normal PrP (Uninfected F4-GFP-PrP lane).
As a further control, HMH8 cells were infected and assayed in parallel (infected 
HMH8 lanes). These cells are stable expressors of a chimerical Hamster,
Mouse Hamster construct which also includes the 3F4 epitope and has127
previously been shown not to undergo conversion (see Materials and Methods). 
The gels marked +PK are westerns of samples which have been processed for 
PrPsc, and those marked -PK are samples processed for PrPc. The HMH 
chimera is not converted in these conditions (+PK, 3F4 blot: infected HMH8 
lane). Of note is the key result that, as with the transient expression, the PrP 
portion of the fusion protein is converted in stable transfectants (+PK, 3F4 blot: 
infected F4-GFP-PrP lane).
This result initially seems to suggest the successful conversion to prion of the 
F4-GFP-PrP fusion, but the PrPc biochemistry of the fusion proteins discussed 
(Fig 4.10 -  PK blot) begs the question of whether this conversion occurs before 
or after a cleavage event occurring in the cells. Specifically, signal should not be 
present below the weight of the full fusion (Fig 4.10 -pk panel, 3f4 blot, infected 
and uninfected F4-GFP-PrP lanes).  The presence of this signal indicates that 
both in the infected and uninfected cell lines, PrP is being cleaved from the GFP 
in the fusion. It is also clear that this is occurring prior to residue 108 of PrP 
because the 3F4 epitope remains intact. Furthermore, comparison of the 
similarity in weight of this cleaved product and HMH8 PrPc (-PK blot, 3f4, 
infected HMH8 lane) also indicates the proximity of the cleavage to the junction 
between the GFP and C-terminal portion of the fusion.
A key question is why cleavage of the fusion protein is occurring and three 
basic hypotheses were tested (Fig 4.11). In order to assess the hypothesis that 
the cleavage is a specific property of the F4-GFP-PrP fusion or more general, a 
comparative analysis of F4-GFP-PrP and the non mutated GFP-PrP fusion was 
undertaken. The constructs were expressed transiently in PS cell prior to 
analysis for PrPc and blotted with 3F4, 6H4, or an antiGFP antibody (see 
Materials and Methods).  Comparing the fusion constructs it can be seen that 
the mutant (3F4 blot, lane: -   F4-GFP-PRP ) is being cleaved as discussed 
previously. The material below the weight of the fusion is not attributable to 
endogenous signal in this gel. This approach cannot be used for fusion protein 
without  the 3F4 epitope to answer the same question. However, when blotting 
with an anti GFP antibody (see GFP blot: lanes F4-GFP-PrP) GFP is being 
seen at around the weight of cytoplasmic GFP and therefore this is a further128
indication of cleavage from the fusion because GFP has been liberated. The 
normal fusion protein also demonstrates liberated GFP material (GFP blot lane: 
GFP-PrP).  Therefore it appears that cleavage is not a direct result of the 
introduction of the 3F4 epitope.
In order to further assess whether there was a specific issue with the linker in 
the design of the fusion proteins a CFP-PrP fusion (produced by Nenna Kanu) 
was included by way of comparison.  This represents a direct fusion between 
the end of the GFP molecule and the c-terminus of PrP, in contrast to the 
fusions described above which include a short linker sequence. The anti-GFP 
polyclonal antibody employed for western blots also recognised CFP. A 
comparison of CFP-PrP lanes in the GFP blot with the other fusions (see GFP 
blot: CFP-PrP lane vs GFP-PrP or F4-GFP-PrP lanes) also indicates cleavage 
given the liberation of CFP from the full fusion.
The  possibility that the cleavage is an artefact introduced by protease release 
and action following cell lysis was tested. The normal lysis buffer employed in 
studies assaying for PrPsc does not include protease inhibitor cocktails in order 
to avoid interference with protease digestion involved in the  PrPsc  biochemical 
assay.  Therefore conditions of lysis including protease inhibitor (see Materials 
and Methods)  were compared with those omitting it and this is indicated by the 
+ or -  signs above each lane. The experiment demonstrates no clear difference 
between lysis conditions which included protease inhibition and those which did 
not (see Fig 4.11: compare + and -  lanes for fusion expressing cells).  In 
general approximately 50 percent of the material appears to be in the full fusion 
form and the remnant is cleaved. The proteolysis appears not to be particular to 
the mutant form of the fusion protein and more generally is not dependent on 
the specific linker of this design of fusion. Proteolysis is also unlikely to be an 
artefact introduced during the lysis of the cells.A —
Figure 4.9.  Transient expression of F4-GFP-PrP in SMB cells
In order to assay for conversion of the fusion protein to Prion recourse was made to the specific 
3F4 epitope in order to distinguish Prion from the fusion against endogenous prion background. 
F4-GFP-PrP  lane represents material transiently transfected into SMB cells and then 
processed for  PrPsc(see Materials and Methods). Lanes marked + Cnt represent hamster 
recombinant PrPc loaded as a positive control for 3F4 antibody efficacy. SMB, represents an 
SMB sample (transfected witha cytoplasmic GFP) processed for PrP8 0.  Gels were blotted with 
3F4 or 6H4 as indicated above. Note that endogenous PrP8 0  is not picked up by the 3F4 
antibody as seen in the SMB lane on the 3F4 blotted gel. This implies that material in the F4- 
GFP-PrP lane in the 3F4 blot,  is Prion from the fusion construct.130
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Figure 4.10.  Conversion to Prion isoform of PrP° in fusion protein expressed in  stable 
transfectants
Infected and uninfected F4-GFP-PrPst cells were processed for PrPscand PrPc.
Infected HMH8 cells, which express a chimeric hamster, mouse PrP,  and a control SMB 
sample, were taken through the same procedure.  The +PK gel and -PK gels represent blots for 
PrPscand PrPc respectively.  Note that the infected cells expressing the fusion F4-GFP-PrP 
fusion, yield prion with the 3F4 epitope (+PK,  3F4 blot :infected F4-GFP-PrP lane). The -PK 
blot for PrPc indicates that the fusion undergoes some cleavage because 3F4 positive material 
is seen at the endogenous weight below the full fusion weight (-PK, 3F4 blot: lane F4-GFP-PrP). 
This result was reproducible.131
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Figure 4.11.  Cleavage of the fusion protein
PS cells were transiently transfected with either the f4-gfp-prp, with  gfp-prp  or with a cfp-gfp 
(see Materials and Methods). Cells were processed for PrPc either in the presence of protease 
inhibitors or without (indicated by +/- protease inhibitors).  Control samples included PS cells 
(PS lanes) or PS cells transfected with a cytoplasmic GFP (cyt-GFP lanes).  Samples were 
loaded and blotted with 3F4, 6H4 or anti GFP antibodies.  The GFP blot is critical because it 
indicates that GFP is liberated from the fusion in all the transfected samples. Also note that the 
CFP-PrP fusion, designed with a different linker undergoes this proteolysis. The inclusion of 
protease inhibitors (+lanes) does not abrogate proteolysis.132
4.6.1.  Immunoprecipitation experiments
It has been established that cleavage of fusion protein occurs and for this 
reason, although it has been shown above that the PrP portion of the fusion is 
converted to PrPsc, it cannot be confirmed whether there is any PrPsc in fusion 
with GFP.  In order to assess the question of whether material existed in the cell 
which contained PrPsc in fusion with GFP it was therefore necessary to carry out 
immunoprecipitation of fusion protein by the GFP part of the molecule and then 
to assay for PrPsc after this step.  A schema for the process of immuno 
precipitation is shown in fig4.12.  (see Materials and Methods also). Briefly two 
162 cm2 flasks were taken for each analysis. They were lysed and were 
incubated with an anti GFP polyclonal antibody at a dilution of 1:100.  This 
dilution was previously ascertained as providing a maximum efficiency for IP of 
the fusion, at approximately 25 % of input GFP (data not shown). Lysates were 
then incubated with magnetic beads coupled to secondary antibody (see 
Materials and Methods), and beads were then washed and resuspended. 10% 
was taken for PrPc analysis and processed by resuspension in sample buffer to 
remove protein from the beads. Supernatants were run on western blots.  The 
remainder of the bead resuspension was taken for PrPsc analysis, resuspended 
in lysis buffer and digested with Proteinase K.  The beads were removed 
following this step and supernatants  processed for PrPsc as usual  (see 
Materials and Methods).  It was hoped that protease digestion would cleave 
protein from the beads (see schema 4.12B).
The entire process was repeated with the polyclonal antibody to mouse Rb 
protein as a control for non specific immunoprecipitation.
An illustration of samples taken through this process is seen in fig4.13.
Samples SC1,2 3, refer to 10 fold dilutions of PrPsc from F4-GFP-PrPstlnf cells, 
which were the source for the IP. The highest concentration represents a sixth 
of the input to the IP.  Material Processed for PrPscfollowing the IP is indicated 
in lane 1a. The control condition where IP is undertaken with an Rb antibody is 
indicated in lane 1b. Note that no PrPscis seen at the expected weight, although133
antibody is seen to be removed from the bead following digestion, which runs 
just below the weight of the fusion protein. Lanes 3 and 4 indicate controls for 
this antibody background and are dilutions of antibody in lysis buffer which have 
been taken through PrPsc analysis in parallel with the other samples.  IP of the 
fusion protein through its GFP component is successful as seen in lane 2a and 
is specific when compared with IP using the control antibody (lane 2b).
The lowest dilution of control sample (lane Sc3) represents approximately 1/600 
of the input total PrPsc available in the sample processed for PrPsc in this IP.
The experiment was repeated with the non mutant fusion, using GFP-PrPstlnf 
cells, and the same result obtained (data not shown).  When the beads that had 
been taken through the PrPsc analysis were boiled in sample buffer, large 
amounts of antibody were found and a mess of species at around 100 kda but 
no material was seen at weights below 45kda (the rough weight at which this 
antibody background is in evidence).  This experiment therefore illustrates that 
GFP is not present in fusion with PrPsc in these cell lines.134
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Figure 4.12.  Schema for Immuno precipitation of fusion protein from infected cells
A: Infected cell, F4-GFP-PrPstlnf, were lysed and samples are incubated with an anti GFP 
polyclonal antibody (or a control antibody to Rb protein) for 1.5 hours and then, following 
addition of magnetic beads conjugated to secondary antibody, were incubated overnight at 4°C. 
Samples for PrPc analysis were then washed and PrPc  removed by boiling in sample buffer. 
Samples for PrPsc analysis were digested with Proteinase K and supernatants taken through the 
standard PrPsc analysis.  Samples were blotted with 6H4 antibody. B: Diagram indicating the 
proposed cleavage of putative PrP^from the fusion after pull down by the GFP part of the 
fusion protein.m
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Figure 4.13.  Immunoprecipitation of fusion protein from infected stable transfectants
Immuno precipitations were carried out as described above (see schema 4.12) with either an 
anti GFP antibody or a control antibody (anti Rb) and samples were western blotted with the 
6H4 antibody.  Material pulled down with the anti GFP antibody and processed for PrPsc, is 
represented in lane 1a. Material pulled down with the control antibody and processed for PrPsc, 
is represented in lane 1b. Material pulled down with the anti GFP antibody and processed for 
PrP°, is represented in lane 2a and with the control antibody in 2b.
Lanes 3 and 4 represent GFP or control antibody diluted to the same concentration in lysis 
buffer and taken through the normal PrPsc analysis used on SMB cells.
SC1.2 and 3 represent 10 fold dilutions of the F4-GFP-PrP infected cells processed for PrPsc. 
Two exposures of the gels are indicated.  Note that PrPc in fusion is efficiently 
immunoprecipitated (lane 2a) but not PrPsc(lane 1a). This result was reproducible.136
4.7.  Discussion
In this chapter the basic properties of fusions between GFP and PrP were 
assessed. In particular the question was addressed of whether conversion of 
PrPc to PrPsc occurs in the context of the full fusion protein.
The normal fusion and mutant derived fusion were compared for differences in 
localisation or other behaviours and none were found, indicating that the F4- 
GFP-PrP fusion protein is a useful tool for distinguishing PrP species from the 
fusion rather than endogenous sources. This was true for both transient 
expression and stable expression  and applied to expression in infected and in 
uninfected contexts.
One key procedure was the use of bulk selection rather than cloning to produce 
stable transfectants. It would probably have been preferable to compare many 
different clonally selected lines but this has not been historically possible and it 
was not possible under various conditions attempted for this work.
One feature of this work was to establish the pattern of localisation of fusion 
proteins between PrP and GFP and these fusion proteins have much the same 
pattern as endogenous PrP (see chapter 3). The use of PIPLC treatment to 
clear fluorescent fusion protein from the cell surface indicated that it was 
appropriately attached by a GPI anchor to the plasma membrane.  One 
experiment that has not been attempted might involve the use of PIPLC to clear 
material from the surface and then, as mentioned above, watch the evolution of 
fluorescent protein. Along these lines, it should be emphasised that the 
conditions assayed here are conditions of stable equilibrium and that 
differences in dynamics of trafficking are not assessed.
There seemed to be no obvious differences in localisation of fusion protein 
between infected and uninfected contexts. The most obvious possibility to be 
considered given the evidence presented in this chapter, is that these fusions 
do not report on the localisation of PrPsc, because the PrPsc is not found in 
fusion with GFP. Either a cleavage event occurred prior to conversion or post137
conversion. Alternatively, it may be that  PrPsc  is found in fusion with GFP,  but 
that there are no clear differences in trafficking between PrPsc and PrPc. The 
lack of an antibody to PrPsc makes it difficult to clearly assess the evidence for 
or against positions taken on the localisation of PrPsc as distinct form PrPc. 
Another possibility remains which is that the relative abundances of PrPsc and 
PrPc make it hard to practically distinguish any fine differences. Ordinarily PrPsc 
represents much less than 10% (and in the range of 3-5 percent) of the total 
PrP population in these cells.  It may be then that differences in localisation 
would be hard to see against this majority background. Hypotheses were tested 
which assessed whether differences in localisation might be obscured by 
problems with the reporter protein, GFP. It is conceivable that denaturation 
occurs or that fluorescence is quenched in some cellular compartments for 
example. In order to try and rule this hypothesis out, antibody staining was 
employed with a permeabilisation protocol, and did not reveal any obvious 
differences in pattern of localisation from that indicated by the fusion proteins in 
live cells.
One of the vexing issues of this thesis has been the exploration of the finding 
that significant proteolysis of the fusion protein appears to take place. 
Experiments were described which assessed whether this proteolysis might be 
either an artefact or specific to the linker in the fusion construct. However this 
does not appear to be the case.  An alternative design of fusion, placing of GFP 
closer to the PrP c-terminus, is not desirable because it is likely to cause 
disruption of folding.
The immunoprecipitation was designed to assess whether, although  cleavage 
occurs, there might still be a proportion of PrPsc in fusion with GFP. However, 
although GFP in fusion with PrPc could be immunoprecipitated, GFP in fusion 
with PrPsc could not.  Given the large amounts of PrPsc that appear to be 
derived directly from the fusion, as assayed by the 3F4 epitope, and given the 
lack of any immunoprecipitated GFP-PrPsc, it is a reasonable indication that 
conversion occurs after a cleavage event.  It is also possible, although less 
likely, that the conversion does occur in the context of the intact fusion and that 
the cleavage event occurs immediately following this.138
The hypothesis that I would suggest is that proteolysis is separating PrP prior to 
or shortly after conversion.  A key experiment would be to try and inhibit the 
proteolysis and then assay for conversion again by immunoprecipitation.
It may be that the proteolysis is specific at a given sequence in which case the 
fusion could be re-engineered to remove it (Yao, Ren et al. 2003).It may be that 
a more general shredding (Parkin, Watt et al. 2004) is occurring and that 
specific inhibitors might act to prohibit those molecules responsible for this. It 
would remain to be seen whether these interventions would themselves prohibit 
proper trafficking of PrP and its conversion to PrPsc.
One final consideration would be that the GFP protein in fusion is simply an 
obstacle to conversion wherever it is placed and irrespective of whether it is 
cleaved. It may interfere with the necessary seeding or folding needed for 
conversion of the Prion portion of the molecule.  This hypothesis could be 
tested through the in vitro conversion assay on recombinant fusion protein.
In summary, GFP-PrP fusion proteins were expressed in cells and found to 
localise much as endogenous PrP. Although conversion of material from the 
fusion protein occurs, as assayed through an engineered specific 3F4 epitope, 
there is no PrPscin fusion with GFP, as assayed by Immunoprecipitation. The 
indication is that at some point, prior to or post conversion, the GFP and PrP c- 
terminal to it, are separated by proteolysis.139
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5.1.  Introduction
The last chapter argued that the GFP-PrP fusion constructs might not be 
adequate in their present form to report on PrPsc localisation. It is important to 
emphasise that this does not obviate their use, even in present form.  Although 
they might not be direct reporters of differences between infected and 
uninfected cells which are attributable to Prion, there may be other critical 
differences between these cell conditions which are reflected in PrPc behaviour. 
For example it might be that trafficking of PrPc differs between infected and 
uinfected contexts. It is also possible that a mode of transfer of infectivity 
between cells, for example a putative vesicular release, might transfer PrPc 
along with PrPsc and therefore make the GFP-PrP fusion protein a useful 
reporter for such a process.
One further issue relating to the proteolysis of the fusion proteins that will be 
raised at this point in the thesis, is that questions can be asked about the object 
of visualisation in any observations of fluorescent signal. It would seem possible 
that signal could be attributed either to the intact fusion or to GFP that has been 
released from the fusion following proteolysis. One point in response to this 
difficulty is particularly relevant for those studies below which include 
visualisation or measurement of the fusion in the context of the membrane.  The 
design of the fusion entails the fact that anchorage to the membrane is through 
the PrP portion of the fusion by GPI anchorage (see Chapter 4). Therefore, 
fluorescent signal which is membrane localised is likely to be attributable to 
intact GFP in fusion with PrP.
The molecular explanation for Prion conversion will need to be validated and 
elaborated upon in a cellular context.  A number of central questions remain in 
that context for which only tentative answers have been posed. The first of 
these, considered in this thesis, is how a cell becomes infected. Two distinct 
questions which can be asked along this theme are how an infected cell 
propagates its infectivity to cause infection in a neighbouring uninfected cell and 
how sporadic or genetic Prion disease are initiatiated in a cell?141
The question of inter-cellular infection is addressed in this chapter through the 
development of a time-lapse approach. The work described below attempts to 
employ time-lapse microscopy to investigate events that may be relevant to the 
process of inter-cellular infection. In particular, the central remit of the project 
given at the beginning of the Ph.d., was to create a system which might permit 
observation of these events over a time period of 48 hours, encompassing the 
period over which a cell becomes infected in co-culture (Kanu, Imokawa et al. 
2002). Microscopy of this time frame, at this resolution, has not been 
undertaken before and therefore the technical aspects, as much as any result, 
are crucial to an understanding of whether it can be a useful technique for future 
use.
The second question, about initiation of conversion in a cell without intervention 
of an external Prion source, was discussed in a number of sections in the 
Introduction, and of particular note was the recent debate on the relevance of 
ERAD to the potential formation of protease resistant and self propagating 
species(Ma and Lindquist 2002; Drisaldi, Stewart et al. 2003). This chapter 
investigates the extension of general claims in this area to the SMB/PS cell 
system.
Finally, a question that remains is the role of membrane dynamics in Prion 
conversion. This work was undertaken relatively late in the project and 
represents a starting point for consideration of the questions it poses.
It has been suggested that the membrane is a potential locus for conversion of 
Prion in a cell and that PrP may reside in distinct domains i.e. inside or outside 
of rafts, inside or outside of caveolae like domains and inside or outside of 
clathrin coated pits(see Introduction). If PrP is localised to a differential extent in 
an infected context to a domain which behaves like caveolae, perhaps this 
could be tested via investigation of populations with different diffusion 
coefficients. For example the protein caveolin-1 one has been found to be 
relatively immobile in studies of diffusion (Kenworthy, Nichols et al. 2004). 
Alternatively, distinct populations may also exist in an uninfected context and 
this might indicate something interesting about PrP dynamics that becomes 
highly relevant after infection.142
There are also general reasons why an understanding of the diffusion of PrP 
species in the context of the plasma membrane could be crucial. Prion 
conversion is a dynamic process which is poorly understood, and changes in 
diffusion, even if fairly small, could potentially have a significant impact on this 
process. It may be possible to answer a number of basic questions about PrP 
dynamics through the technique of Fluorescence Recovery After 
Photobleaching (FRAP) which bleaches a selected area in a cell and observes 
recovery by diffusion of fluorescent protein back into the bleached area 
(Lippincott-Schwartz, Snapp et al. 2001). One of the most basic questions that 
can be addressed as a first step is to ask whether the diffusion of PrP is 
comparable with diffusion of other reported GPI anchored proteins (Kenworthy, 
Nichols et al. 2004).  A second step is to ask whether differences can be 
observed in this diffusion of PrP between infected and uninfected contexts and 
an approach is formulated below to answer this question.
5.2.  The time-lapse approach and Proteasomal inhibition
The role of proteasomal degradation in Prion disease remains contentious as 
discussed in the Introduction.  It is an important issue to clarify because 
potentially it could explain the de novo cellular formation of Prion and provide a 
potential explanation for the link between Prion and cell toxicity. It would be 
interesting to extend these observations and the debate to the SMB/PS system 
and particularly to do so in light of the observations on fusion protein in the cell 
lines that have been created and described in Chapter 4.
This is the first demonstration of the use of time-lapse in this thesis and 
therefore some description of its role would be appropriate at this point. 
Time-lapse microscopy was an important remit of this project and it has proved 
to be difficult. The time-lapse system was developed over a 3-4 year period 
(rather than importing one from a company) and is therefore a bespoke system 
which addresses particular technical needs. This system was developed in 
parallel and shared with newt regeneration researchers who needed to assay143
multiple position time-lapses, at lower resolution, over an extended period of 48 
hours. Although it was possible to undertake the time-lapse for the latter 
purpose, there were a number of obstacles that have still not been surmounted 
at the higher resolution necessary for a GPI anchored membrane protein.
A number of issues in the use of the time-lapse system which have been 
addressed, entirely or in part, as they have arisen during the thesis include:
1)  bleaching
2)  cell survival
3)  resolution / quality
4)  focus drift
In order to ameliorate survival a heated chamber was produced which includes 
the possible use of CO2 media.  It took considerable time to enable this chamber 
to maintain temperature at the desired level, and this has now been achieved. 
Resolution and quality of image have been a major obstacle for viewing PrP 
fusion protein. One issue that plagued the time-lapse was that of condensation 
forming on the apparatus. This was removed by a bespoke designed heated lid. 
In general a 40x oil lens has been necessary to get an image that could 
potentially report on any movements of fusion protein, but many other lenses 
including a high resolution 20x lens, and 40 dry lens have been tried and tested. 
The main issue which has prohibited the remit from being completed has been 
focus drift. Focus drift is particularly bad for membrane localised proteins and 
has proven not to be such an issue for cytosolic proteins or bright field time- 
lapse, for two reasons: focus drift is much worse with an oil immersion lens, and 
has a more deleterious effect on image quality in the case of membrane 
observation than for general cell distribution, such as cytoplasmic expression. 
Many variations were attempted to ameliorate these problems and the complete 
list of elements employed is described in Materials and Methods.  An example 
of typical focus drift and refocus was found with the experiment described below 
which assayed for proteasomal changes. Although not discussed in this 
chapter, a new time-lapse was purchased by the Department at the end of the 
period of completion of experimental work and, given the development in144
microscopy over the period of 5 years, it offers a considerable improvement in 
resolution of image. However, it is still being adapted for the use of time-lapse 
of living cells, and the time-lapses obtained do not add anything at this point to 
the data discussed below.
The study of the proteasome serves as a good starting point to introduce actual 
investigation using time-lapse into this thesis.
To assay for efficacy of the proteasome inhibitor used - MG132 (Ma and 
Lindquist 2002),  a control indicator cell line was created which made use of the 
proteasome sensor vector from Clontech (see Materials and Methods). This 
vector encodes for a destabilised green fluorescent protein (Zs green) which 
has a c-terminal fusion with a degradation motif for removal by the 26S 
proteasome.  There is therefore no need for ubiquitination in order to target it to 
the proteasome.  The ZSGREEN protein, when expressed in a normal cell, is 
degraded and not visible, under conditions of normal proteasomal activity. 
However, effective inhibition of the proteasome should lead to an abrogation of 
protein degradation and consequently green fluorescence should accumulate. 
Cells were transfected with zsgreen plasmid and bulk selected for 10 days.
MG 132 (to 50pM) was added to cells and time-lapse is taken over 15 hours. 
Cells have already been in inhibitor for 1   hour in the first frame (Fig5.1C). 
Although the majority of cells effectively degrade all the ZSGREEN, a small 
percentage of cells do not seem to degrade ZSGREEN entirely. This is useful 
for the purposes of time-lapse in order to set up the focus of an otherwise blank 
field. Therefore a field was chosen where two cells which did not degrade 
ZSGREEN could be visualised from the start of the time-lapse process. By 7.5 
hours fluorescence is beginning to appear in other cells and therefore the 
proteasome inhibitor has probably taken effect by this time. After 15 hours a 
substantial increase in fluorescence is seen. It would therefore be tentatively 
concluded that proteasomal inhibition has been relatively effective prior to 7.5 
hours post addition of MG 132.
F4-GFP-PrPst cells (the control sample) were plated onto glass bottom dishes 
and time lapse analysis was performed over a 15 hour period, at 40x 
magnification with an oil lens.  Fig, 5.1 A described 3 frames taken at 1hour, 7.5145
hours and 15 hours into the time-lapse.  Areas of interest from these panels are 
repeated at full scale in Fig5.2 A.  They were compared to a time-lapse of the 
same cells with 50pM of MG 132, a proteasome inhibitor (Fig5.1B).  Again, an 
area of interest is taken and compared to the controls in Fig5.2 B.  It can be 
seen that after 15 hours, accumulation of fluorescent material has occurred in 
the cell to which MG 132 has been added and that his process has started by 
7.5 hours to some extent.  This is more clearly seen in fig5.2B after 15 hours 
when fluorescence appears to be largely confined to the peri-nuclear region. 
This finding parallels accumulation of PrP observed previously following 
proteasomal inhibition (Ma and Lindquist 2001).
It was therefore interesting to assess whether or not claims surrounding the 
nature of PrP species formed after inhibition could be substantiated in the PS 
system. In order to assess the effects of proteasomal inhibition on formation of 
PrPsc like species (see Materials and Methods), PS cells were treated with 
Proteasome inhibitor, 50 pM MG132, for either 3hours or 24 hours and 
processed for PrPc and PrPsc. The biochemical analysis (Fig 5.3) indicates that 
there are no obvious changes to PrPc as a result of inhibition (Fig 5.3 -PK : 
lanes PS 3h MG 132  and  PS 24 h MG 132 compared to SMB and PS control 
lanes). Although Prion is seen to be present in the control sample (Fig 5.3 +PK 
:SMB lane) there are no Prion like species observed in PS cell samples treated 
with proteasomal inhibitor for either 3h (+PK : PS 3h MG132) or for 24 hours 
(+PK : PS 24h MG132 ).
The tentative conclusion is that species which are similar to the Prion observed 
in SMB cells as assayed by the normal procedures in this laboratory, are not 
produced by inhibition of the proteasome, even though some apparent 
differences in localisation may be observed following treatment.146
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Figure 5.1.  Effects of proteasomal inhibition on F4-GFP-PrPst cells
A) F4-GFP-PrPst cells were plated onto glass bottom dishes and time-lapse taken over a 15 
hour period. Panel A represent 3 frames taken from this time-lapse at 1hour, 7.5hours and 
15hours. The scale bar represents 30microns.  B) Panel B is a time-lapse over the same period 
of F4-GFP-PrPst cells but MG132, to 50pM, was added at t=0 hours. C) Panel C represents 
cells expressing the ZSGreen proteasome sensor vector from clontech (see Materials and 
Methods). Proteasome inhibitor MG132 was added at t=0 hours to 50pM.
Time-lapse first frame is indicated at t= 1hour as a result of difficulty in maintenence of initial 
focus following addition of inhibitor in 5.1 B. The proteasome inhibitor seems to be effective in 
inhibiting the proteasome and this has started by 7.5 hours (panel C, 7.5h). The effects of 
proteasomal inhibition on localization of the fusion protein seems to be an accumulation at a 
perinuclear location (panel B 15h).  Also see corresponding movies 5.1 A, B and C for further 
illustration.Figure 5.2.  Effects of proteasomal inhibition on F4-GFP-PrPst cells in detail
The panels A and B represent enlarged areas of interest from panels A (control F4-GFP-PrPst 
cells) and B (cells treated with inhibitor) from figure 5.1.  The scale bar again represents 30 
microns.  The key panel is seen at 15 hours after addition of inhibitor (5.2 B: 15hours). A 
marked accumulation of fluorescent protein is visible around the nucleus and to some extent 
spread throughout the cytoplasm (see movies 5.1 A and 5.1 B for further illustration).148
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Figure 5.3.  Effect of Proteasomal inhibition on PS cells
In order to assess the effects of proteasomal inhibition (see Materials and Methods), cells were 
treated with Proteasome inhibitor, 50 pM MG 132, for either 3hours or 24 hours (PS 3h MG 132 
and PS24h MG132 lanes).  Cells were processed for PrPsc(+PK blot) and PrP° (-PK blot) with 
SMB cells (SMB lane) and untreated PS cells (PS lane) as controls.  Blots were undertaken with 
the antibody 6H4.  There were no clear effects of treatment with inhibitor on PrPc.  Note that 
treatment with inhibitor for 3h (+PK :PS 3h MG 132) or 24hours  (+PK: PS 24h MG 132)  did not 
produce protease resistant species.149
5.3.  Investigations of Prion protein transfer between cells by time-lapse 
microscopy
One of the questions that underlined the remit of the project is how an infected 
cell manages to transfer infectivity to its neighbour. A number of hypotheses for 
this were discussed in the introduction to this thesis but there is no clear 
understanding of a mechanism for transfer and many different alternatives have 
been suggested including release of vesicular material from cells (Schatzl, 
Laszlo et al. 1997; Fevrier, Vilette et al. 2004) and a cell contact based 
mechanism that does not require transfer of any material per se (Kanu,
Imokawa et al. 2002).
The possibility exists that several mechanisms operate to transfer infectivity and 
that identification of any of these mechanisms would offer potential routes for 
blocking progression of disease. Time lapse microscopy studies were carried 
out using the system described in Materials and Methods with a speculative 
view to seeing some event over a reasonable time period that could be pursued 
later in more detail as a potential candidate for transfer.  In general the 
observations were made of cell lines expressing the fusion proteins at 
confluence or not at confluence, and sometimes alone or juxtaposed to 
alternatively coloured cells to try and increase the ability to visualise any 
transfer against the background fluorescence.  A frame from an sample time 
lapse is shown in Fig 5.4 of the F4-GFP-PrPstlnf cell line in co-culture with a 
cell line which was created by transfecting  PS cells with Dsredll, a fluorescent 
red coral protein (see Materials and Methods).  This time-lapse was taken over 
a period of 5 hours and although no transfer of green fluorescent fusion protein 
is evident it can be seen that material has issued from the cytoplasmically 
marked cells. In some way, this offers a positive control for the ability at least to 
visualise material released from cells.
A further example of a time-lapse in the same configuration is provided in Fig 
5.5, in which the infectivity status of the two cell types has been swapped. Here 
the green fluorescent cells are uninfected (F4-GFP-PrP cells) and the DsRed 
expressing cells are the infected PS counter part of the cell line described150
above.  Again it can be seen that material is released from the DsRed 
expressing cells, as illustrated in Fig 5.5A.  The material can be seen to move 
away from the source cell and out of the frame of interest as illustrated in panel 
B of the same figure over a 6 hour period. Co-localisation with vesicles 
containing green fluorescent material is possible given the yellow colour of 
vesicles seen (a superposition of the red and green colours) although it cannot 
be ruled out that this co localisation is actually only the red colour of the 
released material set against a background of green.  The general conclusion 
of these movies, and other movies considering the infected, uninfected pairing, 
and status of the cells as confluent or mobile, has illustrated the same lack of 
any obvious result i.e. no release of fusion protein is clearly evident. In general 
it has been my conclusion that the time lapses are of too poor a resolution to 
enable this kind of study. Attempts to time-lapse membrane proteins at 40x 
resolution using oil lenses, over periods of 24 hours or more have not been 
reported in the literature. It may be that the next generation of microscopes will 
enable such studies to continue apace given the background in technical 
expertise that the laboratory has acquired in this area.
One possibility that remained was to try and view co-localisation by contrasting 
different colours of fusion protein. To this end a red fluorescent fusion protein 
was formed by analogy with the previous design, placing DsRed in fusion with 
PrP.  However, this fusion, in contrast to the GFP-PrP fusion, was poorly 
expressed, and produced an intracellular localisation pattern (figure 5.6). 
Although this may be interesting for further study in itself, it does not aid in the 
time-lapse process.
One clear result of the work undertaken, apart from the technical improvements 
to the time-lapse set up, was the conclusion that cytoplasmically localised 
fluorescent protein does seem to be released from cells.  Although not in the 
original remit of the project, this was pursued by making cell line pairs of 
cytoplasmic green fluorescent infected and uninfected cells to complement the 
DsRed infected/uninfected pair (see Materials and Methods).151
The first question that was addressed was whether the release was specific to 
the DsRed protein. Fig5.7A  shows a frame 9 hours into  a time-lapse taken 
over a period of 24 hours. Images were acquired every 15 minutes.  It is easier 
to undertake time-lapse over this period with these cells because a non-oil, 20 x 
lens, could be used and a slight change in focus does not lead to a complete 
loss of image as with membrane protein observation. It can be seen, even in 
this one frame, that there is abundant material of red and green colour that has 
been released by these cells and therefore the phenomenon of release does 
not appear to be restricted to the Dsred protein. In general the release of this 
material did not depend on whether one or other of the cell lines are infected. It 
is not clear how this material is being released and time-lapses with shorter 
interval would be helpful in this respect and worthwhile future experiments. 
However, one area of interest is taken and depicted in fig5.7B.  This is the same 
movie as in figure A but 13 hours in. In the first set of panels, a green 
fluorescent cell can be seen to contact and extend a process into a cell 
expressing Dsred (both cell lines are uninfected in this particular case) and then 
to retract after 30 minutes.  The result is the release of what appears to be a red 
vesicle from the contacted cell and this is highlighted in an identical set of 
panels below for clarity. It is very difficult to spot events like these and it would 
be very helpful to run these movies in multiple positions at short time intervals 
between exposures.
This work on cytoplasmically marked cells was undertaken relatively close to 
the end of the experimental period of the PhD, and had the focus of observing 
transfer. However, this system does offer the possibility of observing more 
general cellular behaviour that could be relevant to infection. Cell tracking was 
attempted using the tracking facility in the programme Volocity (Improvisions) 
but at this resolution these cells are too frenetic and in contact too often to 
enable the software to separate them. Considerable effort was made to identify 
alternative software that could enable this analysis but the present algorithms 
employed by most commericially available applications are not suited to these 
data sets and are not capable of individuating the cells. It would have been 
interesting to ask questions about the speed and directionality of cells which are 
infected and uninfected. Such differences could affect the way in which infection152
progresses in an organism for example.  Attempts were made to make manual 
measurements of cell behaviour along these lines but proved too time-intensive 
(It would take weeks of manual analysis for relatively small sample numbers).153
Figure 5.4.  Release of cytoplasmic material from uninfected cells expressing DsRed
The panel above (Fig 5.4) is a frame taken from a time-lapse over 5 hours of Infected cells (F4- 
GFP-PrPstlnf) expressing the fusion construct, in co-culture with PS cells expressing a 
cytoplasmic DsRed.  The scale bar indicates 30 microns.  The quality of these time-lapse 
images often makes it difficult to assess the exchange of membrane species, however, clear 
release of Dsred containing material can be seen as indicated by the arrow.  Each time-lapse 
was repeated in this configuration within 4 permutations available, confluent fusion protein 
expressing cells (infected or uninfected ) with cytoplasmic marker cells (infected or uninfected). 
Repeats of movies were also made of non-confluent cells expressing fusion protein (infected or 
uninfected) in juxtaposition to marker cells (uninfected only).  Release of cytoplasmic material 
from the DsRed expressing cells was common in all cases but no clear transfer of fusion protein 
could be identified, (see movie 5.4 for further illustration).T im e hours
Figure 5.5.  Release of cytoplasmic DsRed from Infected PS cells expressing DsRed
A) The panel above (Fig 5.5A) is the first frame of a time-lapse over 6 hours of uninfected cells 
(F4-GFP-PrPst cells) expressing the fusion protein F4-GFP-PrP, in co-culture with infected 
cells expressing a cytoplasmic DsRed protein.  The scale bar indicates 30 microns.
The frame from the time-lapse shown indicates that there is release of material from the DsRed 
expressing cells (Fig 5.5 A).
B) The main area of interest where exchange is occurring was followed over 6 hours (Fig 5.5 B). 
Note that material can be seen moving away from the Dsred expressing cell in the frame (see 
movie 5.5 for further illustration).155
Figure 5.6.  Expression of a fusion construct between DsRedll and PrP in PS cells
A construct was made which paralleled the design of GFP fusion with PrP, but placed DsRed in 
fusion with PrP. Expression of this construct was intended to highlight exchange of any fusion 
protein by visualising co localisation -  it was hoped that this would enhance the poor quality of 
the time-lapse data.  However, expression of this construct did not yield a normal localisation for 
PrP and generally either did not express well or was localised to the cytoplasmic spots or 
perinuclear regions of cells.156
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Figure 5.7.  Time-lapse of cells expressing cytoplasmic fluorescent proteins.
In order to further investigate the exchange of cytoplasmic material between cells, stable 
transfectants were produced which expressed DsRed and GFP. From these, uninfected and 
infected counterparts were produced (see Materials and Methods).  Figure 5.7. illustrates 
uninfected cells expressing DsRed or GFP. Each of the possible configurations explored was 
repeated (i.e. green uninfected vs red uninfected, green infected vs red uninfected, green 
uninfected vs red infected) except for the case of infected green vs infected red.
Panel A represents a frame 9 hours into a 24 hour time-lapse. It is clear from this panel that 
cytoplasmic material has been released by some means from both GFP and DsRed expressing 
cells.  Two areas where material can be seen are highlighted (see movie 5.7 A for further 
illustration). Panel B represents an area of interest from the time-lapse, at three time points (t=0 
represents a point 13 hours into the same time-lapse).  A GFP expressing cell makes contact 
with, and appears to extend a process into, a DsRed expressing neighbour,  subsequent to 
which a DsRed containing vesicle appears to be released from the cell.  Bii) represent the same 
panels but highlight the area in question for ease of reference (see movie 5.7B for further 
illustration).157
5.4.  Diffusion of Prion protein in the plasma membrane: An analysis by 
FRAP (Fluorescence Recovery After Photobleaching)
The question of how Prion species diffuse in the plane of the membrane 
remains uninvestigated, and it is unknown whether diffusion differs between 
infected and uninfected contexts. The question was addressed initially by 
means of a Fluorescence recovery after photo bleaching protocol employed on 
a Biorad confocal (see Materials and Methods).  A typical experiment is 
depicted in figure 5.8.  The laser is zoomed onto a bleach strip and multiple 
scans taken at 100 percent power, in order to remove fluorescence from that 
strip which is 3 micrometeres in diameter and extends across the cell. The laser 
intensity is then reduced to a minimum to capture images (at 4% power) and 
measurements taken from an area of interest encompassing the bleach strip. A 
further area of interest encompasses the whole cell and is used as a control for 
the purposes of normalisation (see Materials and Methods and figure 5.8 A). 
Following bleaching, fluorescence recovery into the bleach strip is measured 
over an extended time period, and can be seen to have largely returned after 
160 seconds (figure 5.8 B).  In order to calculate the diffusion coefficients an 
approach was taken of effectively solving, numerically, an equation for diffusion 
by curve fitting to the data (Ellenberg, Siggia et al. 1997).  The approximate 
diffusion equation is
l(t)  = IM fl-fw 2 (w2 + 4.pi.D.ty1  )m)
Where l(t) describes intensity in the bleach strip at time t post bleach, l(°°) 
represents the assymptotic value of fluorescence intensity, w represents the 
width of the bleach strip and D represents the parameter of greatest interest for 
the purposes of this chapter that is the diffusion coefficient. A nonlinear 
regression fit of simulated curves to the data are made estimating the 
parameter D.  A programme was written in Matlab to enable both the 
normalisation and the non linear regression of the data as described (see 
Materials and Methods and Appendix).158
A typical graph of the results using the Biorad system is shown in figure 5.8C. 
The data itself represents intensity data for recovery into the bleach strip. This 
data has been normalised to the control AOI (accounting for any general 
bleaching or mild focus drift) and then further normalized for presentation 
purposes (see Materials and Methods). The circles represent this actual data 
and the line through it represents the best fit curve.
Typical values for a GPI anchored protein (Kenworthy, Nichols et al. 2004) have 
been described at around 0.5 pm2/s but it is generally accepted that some 
variation occurs between setups, and therefore diffusion coefficients should be 
treated with caution when quoted as absolute values without reference to an 
experimental setup.  The setup in this case (the biorad confocal) which was 
used initially was not suitable to FRAP. In particular there was no temperature 
controlled environment for living cells, and the temperature fluctuation led to 
focus drift that invalidated much of the experimental data. It was also found that 
the diffusion coefficient (for n= 12) was 0.072pm2/s for the F4-PrP-GFP fusion 
construct expressed transiently in PS cells. This figure, even given the 
cautionary note on differences between systems seems too low and given the 
technical difficulty with the system another set up was sought.
Permission to use a Zeiss LSM 510, ideally suited to FRAP, with a temperature 
control unit was given close to the end of the project. Therefore the n values are 
small. However, a similar protocol was carried out to that described above (see 
Materials and Methods).  The quality of the data appeared to be significantly 
better.  Figure 5.9 illustrates a typical data set taken from one experiment. 0 
seconds is the time post bleaching. The data has been normalised as described 
above, but further normalised by comparing to the prebleach intensity (see 
Materials and Methods). In effect these normalisations correct for change in 
overall intensity of fluorescence in the cell (change which does occur because 
some bleaching takes place from normal confocal scanning at low intensities). 
From this a typical calculation of the immobile fraction can be made. Recovery 
is often not complete (i.e. not to the level of the prebleach value), and this is 
because a percentage of the molecules bleached are immobile. Therefore when 
diffusion occurs to equilibrium there is an overall decrease in intensity to the 
extent of this fraction.  4 FRAP experiments were carried out on uninfected cells159
expressing the fusion construct ,F4-GFP-PrPst cells, (see figure 5.10 A) and 5 
infected cells, F4-GfP-PrPstlnf cells, (see figure 5.1 OB). The data were 
analysed as described above and the diffusion coefficients for each are 
displayed in the corresponding  table below (table 5.1 ). The mean value (n=4) 
for the diffusion coefficient of the fusion protein in the uninfected cells was 0.31 
pm2/s and was 0.39 pm2/s in the infected cell context (n=5).  The mean mobile 
fraction was 90.6% for uninfected cells and 89.9 % for the infected cell samples. 
These figures are in line with previously reported figures for diffusion in the 
context of the plasma membrane for GPI anchored proteins(Kenworthy, Nichols 
et al. 2004). It is unclear whether there is a significant difference between 
diffusion in the infected and uninfected contexts.  A sample closer to n=20, 
would permit a simple t test to determine this.  It would be unclear why diffusion 
was faster, as this data would indicate, in the case of the infected cells but it 
could be important and clarification of this result would be worthwhile. Given the 
small sample it is also somewhat speculative to infer anything from the high 
standard deviation of the infected cell diffusion coefficients (see table 5.1 
infected cell (I) experiments). However, there are quite large differences (50% 
roughly) between diffusion coefficients for different experiments on infected 
cultures and perhaps this reflects the possibility of two populations of cells, with 
two corresponding diffusion coefficients.  Either way, this experiment has 
validated the technical aspects of the FRAP necessary to test the simple 
hypothesis that there are significant differences between diffusion coefficients in 
infected and uninfected contexts. More experiments would clearly be required 
and use of the fusion proteins and cell lines established in Chapter 4 would be 
appropriate for this experimental approach.160
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Figure 5.8.  Illustrative diagramme of technique for fluorescence recovery after photo 
bleaching
A typical experiment is illustrated from a FRAP. A) illustrates the control area of interest and the 
bleach box (3microns). Bleaching is obtained by zoom of the laser and repeat scanning of the 
bleach box, subsequently measurements are taken after bleach from both boxes to enable later 
normalisation of bleach box data (see Materials and Methods). B illustrates a time course for the 
example experiment. Note that by 160 seconds most of the recovery towards an asymptote has 
taken place. The first frame is a prebleach frame. Following this 15 bleach zooms were 
undertaken to create the bleach strip on the biorad confocal at full laser intensity.  Note that 
there is some general bleaching caused by low level scanning during the experiment but 
normalisation using the control box should account for this in the calculation of the diffusion 
coefficient. C) Illustration of bleach strip data which has been normalised. The shape of the 
curve is critical in determining the diffusion co-efficient.  The co-efficient is calculated by non­
linear regression fit to the approximate equation for diffusion (In this case it is 0.038pm2 /s ).
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Figure 5.9.  Experimental result from FRAP using a Zeiss LSM 510
The set up used for the first set of FRAP experiments did not produce expected results, and 
particularly was not adapted to live cell work. Therefore, a set up was found with environmental 
control which was specifically used for qualitative FRAP but could be used for the simulations 
carried out here. The figure above illustrates the data collected from one experiment. The blue 
line represents actual data taken and the red line the predicted curve from parameters 
calculated to the data. The data point at -5 s  represent the prebleach value intensity value. All 
values displayed are expressed as a percentage of this value (and have also been corrected 
using the control region).  The mobile fraction is indicated on this graph, assuming the end point 
represent a point on the asymptote.
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50Figure 5.10.  Results of FRAP experiments on uninfected (panels in A) and infected F4- 
GFP-PrP cells (panels in B).
The blue line represents actual data points and the red line the exponential predicted from 
parameters calculated from the data.  The mean diffusion coefficients for uninfected cell are 
0.310 pm2 /s (std 0.022) and for infected cells is 0.391 pm2 /s (std 0.113). Note that the sample 
sizes are too small to test significance for the difference in these samples. It is of particular note 
that the variance within the infected sample appears to be greater -  this may be indicative of 
two populations of cells but will require greater N numbers to test for signficiance.163
Table5.1.  Diffusion coefficients associated with experimental results depicted in 
Figure 5.10
Uninfected cell (U) 
Diffusion Coefficients 
pm2 /s
Infected Cell (I) 
Diffusion Coefficients 
pm2/s
Experiments
1 0.31  (U1) 0.48  (11)
2 0.32 (U2) 0.45  (12)
3 0.33 (U3) 0.279 (13)
4 0.28 (U4) 0.50  (14)
5 0.26  (15)
Mean 0.31 0.39
Standard Deviation 0.022 0.113164
5.5.  Discussion
The main focus of this chapter has been on issues that might relate to the 
dynamics of PrP.  These have fallen broadly into two groups, firstly those 
relating to transfer of material between cells, and secondly, those relating to 
diffusion of PrP within the membrane.  The approach which has underlined the 
study of intercellular transfer has been based on the development of a time- 
lapse system in parallel to regeneration researchers who are also pursuing a 
time-lapse approach, although at lower resolution.  The approach has proven 
difficult and in particular the problem of focus drift has been difficult to address. 
There a number of questions that need to be asked in the field which will require 
a temporal richness/continuity of information that cannot be easily provided 
without reference to a dynamic picture.  Particularly it is worth noting that time- 
lapse is not supposed to be a surrogate for cytochemical staining under 
different conditions. Its final aim is quite straightforwardly to individuate distinct 
objects through time and to follow those objects moment to moment in their 
behaviour.  It will then be possible to capture information that would otherwise 
be missing -  for example the brief contact event over 45 minutes depicted in 
Figure 5.7 B,  that leads to release of a vesicle.  One question that could be 
asked was what the rationale was for attempting such long time periods -  why 
not make short movies of trafficking events?  The answer is that the question of 
Prion transfer, or transfer of infectivity, seems to occur over an extended period 
between cells in culture, and indeed also when material is added to cells (Kanu, 
Imokawa et al. 2002). One interpretation of this fact is that the events necessary 
for effective transfer are occurring sporadically, and therefore a long time period 
will be necessary to visualise them.  This is an assumption which has not been 
validated and therefore it would be worth repeating experiments for shorter time 
periods, although probably if this is the case it would be better done on a 
confocal microscope which would permit a much higher resolution of image in 
general.
The first experiment of this chapter looked at the effects of proteasomal 
inhibition in the PS/SMB system. The inhibitor chosen was taken because it was 
one of the inhibitors used by two laboratories which have made differing claims165
about results following proteasomal inhibition.  One laboratory (Ma and 
Lindquist 2002) has claimed that ERAD occurs normally in cells and that 
proteasomal inhibition leads to improper ERAD and a resultant cytoplasmic 
accumulation of PrP following retro translocation from the ER, and subsequently 
the formation of a protease resistant, self propagating, species. The other 
laboratory (Drisaldi, Stewart et al. 2003) claims essentially that ERAD is not 
occurring in this case, that the species observed were never transported across 
the ER, and that the results regarding the self-perpetuating nature of the 
species are artefactual for other reasons. It would be interesting to investigate 
the nature of the accumulated speices. The particular experiment which this 
author had in mind was to produce the claimed protease resistant species by 
proteasomal inhibition and to follow on with the question of whether these 
species produced were infectious by using the freeze-thaw cell lysate 
preparation method described above to produce inoculums of proteasomal 
inhibitor treated cells. However, the biochemical results (Figure 5.3 ) 
demonstrated that as assayed by our normal procedure for Prion detection, 
there was no protease resistant material to be found, either after 3 hours or 24 
hours of treatment.  This is surprising in some ways since the microscopy 
(Figure: 5.1  and 5.2) indicated that an accumulation of PrP was expected after 
15 hours to a significant level, given that this behaviour was seen in the fusion 
protein. This accumulation was also seen in the previous studies using 
inhibitors (Ma and Lindquist 2001).  It was seen that the inhibitor was efficacious 
in inhibiting proteasome function prior to 7.5 hours after addition and given that 
it would take time for accumulation of fluorescence to be visualized at this point, 
inhibition had probably been effective considerably earlier.  Although it was not 
possible to time-lapse over a further extended period, it would be interesting to 
try and keep cells alive beyond the 24 hour treatment point, because it may be 
that this is not enough time to for the accumulating species to start a conversion 
process. Aggregation seemed to occur around a perinuclear region and it 
seems possible that this is the Golgi apparatus and not the cytoplasm. This 
accumulation may also reflect a build up of material through blocking of normal 
trafficking as a stress response of the cell.  Nevertheless, in this system no 
protease resistant material was found and therefore given the unlikely relevance 
to Prion infection it was not pursued further.166
The question of transfer of infectivity was difficult to answer for the reasons 
described. No clear evidence was seen of any transfer of fusion protein 
between cells, in any movies. Even at low confluency where the green 
backround did not make it hard to pick out any potential exchange release of 
fusion protein material was not in evidence.  However, some evidence was 
seen of release and possible transfer of cytoplasmic material. The studies 
undertaken here showed that this phenomenon is not particular to DsRed 
expressing cells, and that it appear to be a process that occurs independently of 
whether cells are infected or uninfected.  These observations are somewhat 
speculative because it is possible that the putatively released material is part of 
a cellular structure, like a filopodium. It is unclear how general these 
observations are with respect to other cell lines, and also what their relevance 
might be to Prion infection.
It would have been useful to compare two membrane fusions of different colour 
in juxtapostion, in order to assess any direct exchange between neighbouring 
cells. This work would best be done by reference to a Cyan and Yellow 
fluorescent protein system which is a more standard set used for two colour 
microscopy. It would also be better pursued with reference to a confocal set up 
which would enable higher resolution study of any co-localisation. There are no 
clear results from the work done here, but technical advances have been made. 
The result of being able to time-lapse over a roughly 24 hour period at a 
resolution required to visualise membrane localised protein has taken 
considerable effort and may be useful for future investigations in the future 
when the knowledge can be applied to development of the new higher 
resolution time-lapse system.
The issue of the dynamics of PrPc in the membrane, as assayed by reference to 
quantitative investigation of diffusion, has not been addressed in previous 
studies in the literature. Factors relevant to the process of infection of a cell, or 
even maintenance of infection, may only differ in their quantitative aspects when 
comparing infected and uninfected cells, and it is conceivable that a quantitative 
approach to define the relevant differences could be helpful. The work167
described here outlines the beginning of a project which could address how PrP 
diffuses in the plane of the plasma membrane. The initial results suggest that 
the protein is diffusing in much the same way as other GPI anchored proteins 
but as mentioned above, it would be important to include further comparators 
within the experimental system in future.  The key hypothesis here to test was 
whether there was a difference in diffusion coefficients between infected and 
uninfected contexts. It was found, with a very small sample number, that there 
is a difference, and that diffusion is faster in the case of the infected context.  It 
is unclear whether or not this difference is significant from a statistical point of 
view and these experiments might be repeated in future with greater n numbers. 
It is also of note that in the infected sample there seemed roughly half the cells 
with a 1x diffusion coefficient and the other with a 2x coefficient. This may be a 
feature of this specific set of data which is removed with higher n numbers but it 
may indicate that there are different populations of cells within an infected 
sample, and that the key variable defining the populations might be that some 
cells are infected and some are not. One issue is how this would be relevant to 
Prion conversion if the difference was to prove significant between infected and 
uninfected contexts.  Let us suppose that there was a significant difference, or 
the hypothesis that there are two populations in the infected sample was proved 
significant with greater n numbers.  There would then be a second question as 
to what is responsible for the difference. Is it a difference in general plasma 
membrane fluidity or a difference in compartmentalisation (e.g. to particular 
membrane domains) of the PrP fusion protein? This could be addressed by 
observing bleaching of dyes which specifically bind to the lipids in the plasma 
membrane, and comparing infected and uninfected cells in this regard.  A 
related question to be addressed, and perhaps the question which underlies all 
of these studies, would be whether or not this difference was an epi- 
phenomenon, not particularly relevant to infection but issuing from it, or whether 
it was causative or necessary in some aspect of infection.  To make this less 
abstract I would suggest an entirely speculative hypothesis that encompasses 
these latter two questions: that infection is preceded by a change in plasma 
membrane fluidity which is necessary for effective infection.  The question 
would then be to address how to model this effect and create perturbation in 
experimental systems to test the models.168
Chapter 6  Summary, discussion,
and future directions169
This discussion summarises the key results of the thesis and motivates future 
experiments, either straightforward follow ups or broader research directions.
Chapter 3 raised a key question about the use of antibody to identify Prion in an 
immunocytochemical context. There is no antibody currently available in the 
field which can act as a marker for Prion in this context and this was one part of 
the motivation for the work undertaken with fluorescent fusion proteins. It is 
discussed further below.
PrPsc was not found on the surface of SMB cells following surface biotinylation 
protocols.  Surface PrPsc has been identified on the surface of cells in other 
studies  (Shyng,  Moulder et al.  1995; Vey, Pilkuhn et al.  1996).  However, there 
was very little quantitative data available from these studies to indicate how 
much Prion, as a proportion of total cellular Prion, was found on the surface. 
There is also an issue issue of differences between this study and the mode of 
assay for Prion used in other studies.  In particular the process for detection of 
PrPsc used in this thesis is different in some respects than that employed in the 
other studies. In particular, protease digestion is 10 fold higher than in one 
study  (Shyng, Moulder et al.  1995) and detergent insolubility is also included as 
a criterion for PrPsc. This experiment could be repeated with another infected 
cell line as a control and with less stringent requirements for PrPsc analysis.
A central theme of Chapter 3 was the investigation of glycosylation in the 
context of infection.  A key question that motivated this work, a question which 
remains unanswered in the Prion field, is what the mechanism is for 
maintenance of the same glycoform profile in Prion of a newly infected host as 
in Prion of the infectious source. The key result of the chapter is that a 
completely unglycosylated template of PrPsc is able to act as a template for 
conversion of cellular PrPc to new PrPsc.  Fig 3.12  depicted a non-matching 
hypothesis and a matching hypothesis.  The matching hypothesis argued that 
the PrPsc template would  have to be of the same glycoform condition as the 
PrPc it was converting.  The explanation for why there is little or no170
diglycosylated PrPsc found in the SMB system would be, on the strict matching 
hypothesis, that there is no diglycosylated PrPsc available in the inoculum to 
convert the diglycosylated PrPc of the cells. This hypothesis was disproven 
because it was shown that unglycosylated PrPsc can act as a converting 
template for at least in the case of monoglycosylated PrPc, converting it to 
monoglycosylated PrPsc.
A further hypothesis, perhaps unlikely, but which has never been tested, is 
whether only unglycosylated  PrPsc has converting activity.  It has never been 
proven that glycosylated PrPsc species have any converting activity. Further 
experiments that might be attempted in SMB cells could involve separation of 
glycosylated PrPsc species from unglycosylated species.  It is not clear that this 
is possible (they may be structurally interconnected for example) but a potential 
procedure could be to make use of Lectins to separate glycosylated protein.
At steady state two main factors contribute to the quantity of Prion in the cell. 
Firstly, the rate of synthesis (rate of production per unit time) of Prion and 
secondly, the rate of degradation (rate of destruction per unit time) of Prion. 
There may be other contributions to the amount of Prion in a cell (e.g. transfer 
from another cell) and in reality cell division complicates the issue, but consider 
these two processes for simplicity.  The balance of synthesis and degradation 
will contribute ultimately to the quantity of Prion in a cell. This balance is also 
applicable to consideration of the relative abundance not just of the total amount 
of Prion but also of the particular  glycoform species of Prion and it may be that 
different net effects of synthesis and degradation obtain for each glycoform 
species of PrPsc. This basic framework would argue that a consideration of the 
relative rates of synthesis and degradation could explain the particular 
glycoform profile of a particular cell.  For example, if there is a relatively fast 
degradation of diglycosylated PrPsc, perhaps because it is less stable as a 
species, it may be that there is no ‘net’ production of diglycosylated PrPsc.
One prediction of this model would be that there are different rates of synthesis 
or degradation for each species and to test these hypotheses pulse chase 
protocols could be employed. If there were a means of completely blocking171
degradation of protein in cells (not just the proteasome) for a period this would 
also be a useful test but I am not aware of an experimental intervention that 
would permit this.
One final consideration is that de-glycosylation occurs in cells. There is no 
evidence for this in the context of the Prion field but this has not been 
independently tested.
In summary, the results in Chapter 3 indicated that carbohydrate additions to 
PrP do not carry the information required to transfer and maintain a glycoform 
profile, because using an infectious source as an inoculum which lacks these 
residues still leads to the maintenance of the original, full glycoform profile 
following infection.  It has been argued that synthesis and degradation of Prion 
may need to be considered more carefully to understand the heart of the 
glycoform maintenance problem.  However,  synthesis and degradation may not 
be steady state, for example when cells divide,  and synthesis may be coupled 
to degradation by a cellular mechanism. Therefore this research direction may 
prove to be highly complex even if essential to a thorough understanding of the 
phenomenon of the maintenance of glycoform profile.
There were two distinct ways in which a fusion protein between GFP and PrP, 
described in Chapter 4, could be a useful indicator of localisation.  It could be 
used as a direct indicator of PrPsc localisation i.e. if the PrP portion of the fusion 
is converted, or it could be used as an indirect indicator of infected contexts, if 
PrPc trafficking differs between infected and uninfected contexts.  The fusion 
protein, although appropriately trafficked along the secretory pathway and 
tethered by a GPI anchor to the plasma membrane, did not show any 
differences in localisation when expressed in infected or uninfected contexts.  A 
key question with respect to the process of direct reporting on PrPsc localisation, 
was whether or not the PrP fusion protein was
converted to PrPsc and remained in fusion with GFP. A 3F4 epitope was 
engineered into the fusion protein and it was used to biochemically identify 
PrPsc issuing from the fusion protein against the endogenous background.  Initial 
biochemical studies indicated that successful conversion was occurring.172
However, the observation that fusion protein also underwent substantial 
proteolysis raised the question of whether the conversion, assayed 
biochemically, represented an event happening after separation of the PrP from 
the GFP protein.  Studies were undertaken which demonstrated that neither the 
specific linker between the PrP and GFP in the fusion described here, nor the 
introduction of the mutant epitope, were responsible for this proteolysis. The 
hypothesis that protease action following lysis was responsible for the observed 
cleavage was also tested but not supported.
Despite proteolysis, biochemistry and microscopy indicated that there was still 
an abundance of intact fusion protein.  It therefore remained a possibility that 
intact fusion protein, which has not undergone the proteolysis, could include 
GFP in fusion with PrPsc. This was tested ultimately by immunoprecipitation 
experiments that isolated intact fusion protein, and these experiments 
demonstrated that in this fusion protein PrPscis not found in fusion with GFP. 
The most likely explanation for the series of observation is that a cleavage 
event is separating the PrP portion of the fusion prior to or just following 
conversion to PrPsc.
The first follow up experiment which might be attempted would be to carefully 
assess whether a C-terminal insertion of GFP in a 3F4 epitope mutated mouse 
PrP, undergoes the same proteolysis and whether the 3F4 portion undergoes 
conversion. Two suggestions that were made in chapter 4 were that the 
proteolysis was either directed and specific, or general.  In the former case, a 
motif at which proteolysis occurs might be identified by creating a series of 
deletion constructs. Alternatively, if general protease action is responsible in the 
cell, then an array of inhibitors could be tested to attempt to find whether a 
specific class of proteases (e.g. zinc metalloproteinases) is responsible for the 
action.  One possibility that remains, which was not discussed, is that PrP itself 
has some protease action.  However, there is no suggestion of this in the 
literature, and there is no bioinformatics to support such a claim.
If the problems with conversion and cleavage cannot be overcome there still 
remains a use for the fusion proteins described in this thesis.  Before173
considering the use to which they were put in the final results chapter, I would 
like to return to the issue of localisation. Two localisation effects were described 
above, direct and indirect. It might be that although conversion to Prion does not 
occur in the context of the fusion protein, indirect reporting on differences in 
PrPc trafficking could be interesting and informative.  However, differences were 
not seen between expression in infected or uninfected contexts. There are two 
possible reasons for this which could be explored.  Firstly, there may be 
differences, but these are not seen in the equilibrium condition where trafficking 
of PrP has settled to a steady state. Secondly, there may just be too much 
background to see this happening given the resolution of the present system. 
The first question could be addressed by reference to an inducible PrP-GFP 
fusion construct. This has been attempted in the laboratory and has proven 
technically very difficult but an approach with this intention may reveal 
differences in trafficking that cannot be observed ordinarily under conditions of 
equilibrium.
The final results Chapter considered uses for the fusion protein. Firstly, the 
debate over the effects of proteasomal inhibition were considered in the context 
of the PS system. Aggregation of F4-PrP-GFP was found over 15 hours, and 
initiated prior to 7.5 hours, post addition of proteasomal inhibitor. However, 
biochemical assay revealed no formation of protease resistant, PrPsc like 
species. This was observed for 24 hours of treatment, a period much longer 
than that of the original study which reported formation of Prion like species, 
using MG132, after 3 hours (Ma and Lindquist 2002). Again, following the 
discussion of the biotinylation result, there are noted differences in the assay 
procedure for Prion. In particular the study above did not employ the criterion of 
detergent insolubility and only employed the criterion of partial protease 
resistance.  Both of the studies undertaken attempted to address the question 
of whether ERAD could be observed by this manipulation of the proteasome. It 
would be interesting to test this hypothesis by making use of an antibody to the 
signal peptide for PrP in the context of the experiments described in the PS cell 
system.174
Time-lapse microscopy was undertaken to assess whether there was any 
visible exchange of fusion protein between cells in culture, and specifically 
whether there were any differences in this respect between infected and 
uninfected cells. No exchange of fusion protein was found in either infected or 
uninfected cell lines expressing the fusion constructs although cytoplasmic 
exchange was indicated. This exchange did not depend on the infectious status 
of cells as assayed by time-lapse of cytoplasmically marked infected and 
uninfected cell line pairs. It may be that vesicular or other release mechanisms 
are not  a feature of the PS/SMB system This has been indicated by studies 
taking conditioned media from SMB cells and using them to attempt to infect PS 
cells (Kanu, Imokawa et al. 2002). Alternatively it may be that a higher 
resolution approach is required in order to clearly assess whether this exchange 
is occurring.  It was described how time-lapse of a fusion protein over long 
periods is pushing the boundaries of what is technically feasible. However, if 
money were no object a multiphoton confocal set up, using lower bleach 
intensities, could be used with sophisticated software to provide a very high 
resolution, and overcome some of the focus issues.  The costs of such a 
dedicated system would be prohibitive however.  Alternatively, shorter time- 
lapse at high resolution might indicate transfer events which are frequent and 
short lived, although events occurring more sporadically would be missed.
One further experiment that has not been undertaken in this thesis, would be to 
observe the effects of juxtaposing cells which express different coloured 
membrane fusion proteins.  It is possible that exchange is occurring via cell 
contact directly between membranes, and not by vesicular release.  This would 
be more clearly observed with a PrP-CFP, PrP-YFP fusion pair if it were 
occurring. This would be a priority as an experiment to complete the time-lapse 
analysis.
Further use of the fusion constructs was made by FRAP analysis in a series of 
experiments which sought to set up a system to assess the diffusion of PrP 
species in the plasma membrane.  At present the diffusion of PrP has not been 
assessed in the literature. Experiments carried out on a second confocal (Zeiss 
LSM 510) demonstrated a robust system for this analysis and curves were fitted175
to the data collected in order to obtain the relevant parameter describing the 
diffusion coefficient. The samples are very small and perhaps not too much 
should be read into the results at this stage. However, it was found that in an 
infected context the diffusion coefficient was higher than that of PrP in an 
uninfected context.  It is unclear whether this result is significant and the first 
experiments that should be undertaken is to increase the n numbers to test this 
hypothesis conclusively.  It was also found that the variance was high in the 
infected sample. This may again reflect the small n number, or alternatively it 
may reflect the existence of distinct populations of cells within an infected 
sample. At present, it is not known how many infected cells there are in an SMB 
culture.  Until there is an antibody available to test for Prion 
immunocytochemically, it would be very difficult to assess the hypothesis that 
the two populations of cells, defined by different diffusion coefficients, 
correspond to an infected and an uninfected population of cells.
Extensions to research in the area of diffusion could involve attempts to identify 
distinct population of PrP in the same cell by diffusional criteria. For example, if 
a substantial population of PrP were in contact with transmembrane protein, two 
populations might be distinguishable with two distinct diffusion coefficients. 
Simulations could be carried out to test the limits in sensitivity of the modelling 
process employed here to assess what that proportion of bound populations 
would need to be, under a set of reasonable assumptions about the diffusion of 
such putative complexes.
If it does turn out that there is a significant difference between the infected and 
uninfected samples, it would be interesting to know why.  Is it a direct effect of 
infection?  Is it an effect which is particular to PrP between infected and 
uninfected contexts?  These questions could be addressed with reference to 
other fusion constructs (e.g. the GFP-GPI construct employed in chapter 4).
One final point that has not been considered is the contribution of dynamics, 
movement and collision, to conversion.  The picture that is often conjured up is 
a process of slow seeding or templated conversion -  often mirrored by long 
phases seen during in vitro analysis of Prion formation. However,  little is known 
about conversion in the context of membranes. The critical initial events may176
occur while the proteins are in motion and the chances of Prion meeting and 
converting PrPc might be determined by dynamics in the plane of the 
membrane.  This kind of dynamic effect has never been studied. It is only 
relatively recently that the tools to consider some of these questions with any 
robustness or accuracy have become available.  Further research would also 
permit manipulation of cell membrane fluidity and assessment of the effects this 
has on diffusion (i.e. whether it is causative of changes). Although speculative, it 
may be that general cell fluidity is responsible for differences in diffusion and 
that a cell falling within boundary conditions for this fluidity is necessary for 
some aspects of conversion.
This thesis has been a study in a specific cell culture system of a specific set of 
issues. One crucial question, stepping back from the work undertaken in this 
system, would be whether primary cultures of neurons might be a better model 
for Prion infection. There are no recorded instances of successful infection of 
primary neurons in culture.  Also of note, as described in the introduction, is the 
fact that only a limited number of cell lines demonstrate a propensity for 
infection, and an even smaller number, of which SMB is one, maintain stable 
infection.  For these reasons, primary cultures would be very difficult models to 
work with. However, infected neurons from transgenic mice expressing fusion 
constructs might be co-cultured with uninfected neurons, or co-cultures of other 
cell infected cells and primary neurons could be considered.
The lack of a Prion specific antibody, a reagent which can identify Prion clearly 
in an immunocytochemical context, represents a barrier to faster progress in the 
field of Prion cell biology. It is not clear why it has been so difficult to produce 
such a reagent and it may be prove to be in principle very difficult, although the 
lack of structural information on PrPsc makes it hard to assess this suggestion. 
One point that has not been emphasised, is that even if this reagent was 
discovered, the questions of Prion dynamics would still be pertinent for all the 
reasons described. The specific reagent would not address these dynamic 
issues although it would be an invaluable tool in addition to these studies 
because the variable under consideration here, of greatest interest, has been177
that of infectivity. It is a variable that at present cannot be independently 
determined on a cell by cell basis.
An attempt to identify mechanisms for transfer of infectivity was undertaken in 
this thesis i.e. how an infected cell is able to infect an uninfected cell.
These have been addressed in cell culture in the work described, but there are 
a number of issues which remain that have not been addressed in animal 
models and might be relevant to directed clinical interventions. Although it has 
been demonstrated that PrP expression in peripheral nerves is sufficient for 
transfer of Prion infection in mouse models (Race, Oldstone et al. 2000) the 
question of whether other cell types are also sufficient has also not been clearly 
addressed.  These issues could be modelled by reference to infection of PrP 
knockout in populations of cells with specific promoters. One potential candidate 
for such a study would be the Schwann cell population.  If the fusion proteins 
can be designed in future which can act as surrogate markers for PrPsc  (i.e. 
they can be used to create intact fusions between GFP and  PrPsc and these 
fusions display differences in localisation) then transgenic mice expressing 
these proteins would be of great value in study of Prion disease progression.
In summary, some of the issues investigated in this thesis have included, the 
question of how Prion glycoform profile is maintained,  the creation and 
potential conversion of PrP in the context of fusion with GFP,  and the potential 
use of such fusion proteins for observation of PrP behaviour. The investigation 
of these issues has required a technically demanding approach through time- 
lapse microscopy and has pushed the boundaries of technical know-how 
forward. It is hoped that this work will make some contribution to the future state 
of knowledge in Prion cell biology and potentially clinical outcomes, through 
defining and attempting to answer the questions posed and through advancing 
the required technical approaches which will be needed to address these 
questions.178
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%find_diff coefficient
%normalise data, fit curve by estimating paramers, plot data and fitted
%find mobile fraction
function [D] = tim_script(name);
[s,sh] = xlsfinfo(name); 
sheets = strvcat(sh) 
end
for ii=1 :length(sh)
data_in = xlsread(name, sheets(ii,:)) 
t=data_in(:,1).'; 
tedit = t(1:2:length(t)) 
bl= data_in(:,2).'; 
bl_edit = bl(1:2:length(t)) 
control= data_in(:,3).'; 
control_edit = control(1:2:length(t)) 
p = [tedit', bl_edit',control_edit']
L_final = length (tedit) 
end
t_recovery = tedit(4:L_final) 
bleach_recovery = bl_edit (4:L_final) 
control_recovery = control_edit(4:L_final)
L_new = length(t_recovery)
check = [t_recovery,,bleach_recovery',control_recovery'] 
end
bleach_recovery_norma1  = 100*(bleach_recovery./control_recovery) 
%bleach_recovery_normaled = bleach_recovery_norm1  * 100 
bleach_recovery_normal_zero =  bleach_recovery_norma1  - 
bleach_recovery_norma1 (1) 
t_recovery_zero = t_recovery - t_recovery(1) 
check2 = [t_recovery_zero'] 
check3 = [bleach_recovery_normal_zero']198
end
plot (t_recovery_zero, bleach_recovery_normal_zero) 
end
xd ata=t_reco  ve ry_ze ro 
ydata=bleach_recovery_normal_zero 
xO = [100,0.002]
x = lsqcurvefit(@my_stages, xO, xdata, ydata)
%my_stages : is function file with break down as below of the diffusion equation 
% w=3 for biorad set up and 1  for Ism setup 
w=1;
xsim = xdata ;
F1= (wA 2 + x(2).*4*pi*xsim);
F2= F1.A (-1);
F3= F2*wA 2;
F4= F3.A (1/2);
F5= 1- F4;
F6= F5.*x(1);
F = F6; 
ysim = F;
%mobile fraction calculation 
end
mpb = mean(bl_edit (1:3)) 
mpc = mean(control_edit(1:3)) 
start = mpc/mpb
assym = mean (ydata(L_new-4 : L_new)) 
final_assym = bleach_recovery_norma1(1) + assym 
correction = start *  final_assym
interval = t_recovery(2) - t_recovery(1)
interval2= 2*interval
t_new = [-interval, xdata]
ydata_new = bleach_recovery_norma1  * start
ydata_final = [100, ydata_new]199
%put the simulated data back to the same level 
xsim_final = [xsim]
ysim_finala = ysim + bleach_recovery_norma1(1) 
ysim_final = ysim_finala * start
%plot normalised versions of data and simulated 
plot (t_new,ydata_final,,b') 
hold on
plot (xsim_final, ysim_final,,r') 
xlabel('time post bleach(s)') 
ylabel('normalised intensity')
diffusion= x(2) 
mobile = correction